<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><front><journal-meta><journal-id journal-id-type="nlm-ta">An Bras Dermatol</journal-id><journal-id journal-id-type="iso-abbrev">An Bras Dermatol</journal-id><journal-id journal-id-type="pmc-domain-id">2132</journal-id><journal-id journal-id-type="pmc-domain">anaisbrasderm</journal-id><journal-id journal-id-type="publisher-id">abd</journal-id><journal-title-group><journal-title>Anais Brasileiros de Dermatologia</journal-title></journal-title-group><issn pub-type="ppub">0365-0596</issn><issn pub-type="epub">1806-4841</issn><publisher><publisher-name>Sociedade Brasileira de Dermatologia</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC6544036</article-id><article-id pub-id-type="pmcid-ver">PMC6544036.1</article-id><article-id pub-id-type="pmcaid">6544036</article-id><article-id pub-id-type="pmcaiid">6544036</article-id><article-id pub-id-type="pmid">31166402</article-id><article-id pub-id-type="doi">10.1590/abd1806-4841.2019940211</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Psoriasis</subject></subj-group></article-categories><title-group><article-title>Diagnostic and therapeutic guidelines for plaque psoriasis -
Brazilian Society of Dermatology<xref ref-type="fn" rid="fn1">*</xref></article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-7192-5161</contrib-id><name name-style="western"><surname>Arnone</surname><given-names initials="M">Marcelo</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="c1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-8671-6680</contrib-id><name name-style="western"><surname>Takahashi</surname><given-names initials="MDF">Maria Denise Fonseca</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-0407-538X</contrib-id><name name-style="western"><surname>de Carvalho</surname><given-names initials="AVE">Andr&#233; Vicente Esteves</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-8597-5207</contrib-id><name name-style="western"><surname>Bernardo</surname><given-names initials="WM">Wanderley Marques</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-3296-5232</contrib-id><name name-style="western"><surname>Bressan</surname><given-names initials="AL">Aline Lopes</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-7414-3395</contrib-id><name name-style="western"><surname>Ramos</surname><given-names initials="AMC">Andrea Machado Coelho</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-2550-1341</contrib-id><name name-style="western"><surname>Terena</surname><given-names initials="AC">Aripuan&#227; Cob&#233;rio</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-8157-7658</contrib-id><name name-style="western"><surname>Souza</surname><given-names initials="CDS">Cacilda da Silva</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-1303-5419</contrib-id><name name-style="western"><surname>Nunes</surname><given-names initials="DH">Daniel Holthausen</given-names></name><xref ref-type="aff" rid="aff8">8</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-6156-6097</contrib-id><name name-style="western"><surname>Bortoletto</surname><given-names initials="MCDC">Maria Cec&#237;lia de Carvalho</given-names></name><xref ref-type="aff" rid="aff9">9</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-8594-200X</contrib-id><name name-style="western"><surname>de Oliveira</surname><given-names initials="MDFSP">Maria de F&#225;tima Santos Paim</given-names></name><xref ref-type="aff" rid="aff10">10</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-7888-0154</contrib-id><name name-style="western"><surname>Neff&#225;</surname><given-names initials="JM">Jane Marcy</given-names></name><xref ref-type="aff" rid="aff11">11</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-7981-9398</contrib-id><name name-style="western"><surname>Fieri</surname><given-names initials="LC">Luciana Cristina</given-names></name><xref ref-type="aff" rid="aff12">12</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-4698-2009</contrib-id><name name-style="western"><surname>Azulay-Abulafia</surname><given-names initials="L">Luna</given-names></name><xref ref-type="aff" rid="aff13">13</xref><xref ref-type="aff" rid="aff14">14</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-1055-0597</contrib-id><name name-style="western"><surname>Felix</surname><given-names initials="PAO">Paulo Ant&#244;nio Oldani</given-names></name><xref ref-type="aff" rid="aff15">15</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-9170-932X</contrib-id><name name-style="western"><surname>Magalhaes</surname><given-names initials="RF">Renata Ferreira</given-names></name><xref ref-type="aff" rid="aff16">16</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-0165-3831</contrib-id><name name-style="western"><surname>Romiti</surname><given-names initials="R">Ricardo</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-7594-620X</contrib-id><name name-style="western"><surname>Jaime</surname><given-names initials="TJ">Tatiana Jerez</given-names></name><xref ref-type="aff" rid="aff17">17</xref></contrib></contrib-group><aff id="aff1">
<label>1</label> Department of Dermatology, Hospital das Cl&#237;nicas, School of
Medicine, Universidade de S&#227;o Paulo, S&#227;o Paulo (SP), Brazil.</aff><aff id="aff2">
<label>2</label> Center of Psoriasis and Psoriatic Arthritis, Service of
Rheumatology, Hospital Moinhos de Vento, Porto Alegre (RS), Brazil.</aff><aff id="aff3">
<label>3</label> Center of Development of Medical Education, School of Medicine,
Universidade de S&#227;o Paulo, S&#227;o Paulo (SP), Brazil.</aff><aff id="aff4">
<label>4</label> Service of Dermatology, Hospital Universit&#225;rio Pedro
Ernesto, Universidade do Estado do Rio de Janeiro, Rio de Janeiro (RJ),
Brazil.</aff><aff id="aff5">
<label>5</label> Service of Dermatology, Hospital das Cl&#237;nicas, Universidade
Federal de Minas Gerais, Belo Horizonte (MG), Brazil.</aff><aff id="aff6">
<label>6</label> Center of Reference in Phototherapy and Cutaneous Photobiology,
Belo Horizonte (MG), Brazil.</aff><aff id="aff7">
<label>7</label> Division of Dermatology, Department of Internal Medicine, Faculdade
de Medicina de Ribeir&#227;o Preto, Universidade de S&#227;o Paulo,
Ribeir&#227;o Preto (SP), Brazil.</aff><aff id="aff8">
<label>8</label> Service of Dermatology, Hospital Universit&#225;rio, Universidade
Federal de Santa Catarina, Florian&#243;polis (SC), Brazil.</aff><aff id="aff9">
<label>9</label> Outpatient Department of Dermatology, Faculdade de Medicina do ABC,
Santo Andr&#233; (SP), Brazil.</aff><aff id="aff10">
<label>10</label> DERMAPP - Dermatology Clinic, Salvador (BA), Brazil.</aff><aff id="aff11">
<label>11</label> Department of Medicine, Dermatology Clinic, Universidade Federal
Fluminense, Niter&#243;i (RJ), Brazil.</aff><aff id="aff12">
<label>12</label> Service of Dermatology, Universidade de Mogi das Cruzes, Mogi das
Cruzes (SP), Brazil.</aff><aff id="aff13">
<label>13</label> Faculty of Medical Sciences, Universidade do Estado do Rio de
Janeiro, Rio de Janeiro (RJ), Brazil.</aff><aff id="aff14">
<label>14</label> Institute of Dermatology Prof R. D. Azulay, Santa Casa de
Miseric&#243;rdia do Rio de Janeiro, Rio de Janeiro (RJ), Brazil.</aff><aff id="aff15">
<label>15</label> Service of Dermatology, Hospital Federal dos Servidores do Estado,
Rio de Janeiro (RJ), Brazil.</aff><aff id="aff16">
<label>16</label> Department of Internal Medicine, Faculdade de Ci&#234;ncias
M&#233;dicas, Universidade Estadual de Campinas, Campinas (SP), Brazil.</aff><aff id="aff17">
<label>17</label> Cl&#237;nica Jerez Dermatologia, Barueri (SP), Brazil.</aff><author-notes><corresp id="c1">Mailing address: Marcelo Arnone. E-mail:
<email>arnones@uol.com.br</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Mar-Apr</season><year>2019</year></pub-date><pub-date pub-type="ppub"><season>Mar-Apr</season><year>2019</year></pub-date><volume>94</volume><issue>2 Suppl 1</issue><issue-id pub-id-type="pmc-issue-id">335592</issue-id><fpage>76</fpage><lpage>107</lpage><history><date date-type="received"><day>14</day><month>12</month><year>2018</year></date><date date-type="accepted"><day>28</day><month>1</month><year>2019</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>03</month><year>2019</year></date></event><event event-type="pmc-live"><date><day>12</day><month>06</month><year>2019</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2019-06-13 00:17:42.230"><day>13</day><month>06</month><year>2019</year></date></event></pub-history><permissions><license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution Non-Commercial No Derivative License, which
permits unrestricted non-commercial use, distribution, and reproduction in
any medium provided the original work is properly cited and the work is not
changed in any way.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="abd-94-02-s1-0076.pdf"/><abstract><p>Psoriasis is a chronic inflammatory disease that affects 1.3% of the Brazilian
population. The most common clinical manifestations are erythematous, scaling
lesions that affect both genders and can occur on any anatomical site,
preferentially involving the knees, elbows, scalp and genitals. Besides the
impact on the quality of life, the systemic nature of the disease makes
psoriasis an independent risk factor for cardiovascular disease, especially in
young patients with severe disease. By an initiative of the Brazilian Society of
Dermatology, dermatologists with renowned clinical experience in the management
of psoriasis were invited to form a work group that, in a partnership with the
Brazilian Medical Association, dedicated themselves to create the Plaque
Psoriasis Diagnostic and Treatment Guidelines. The relevant issues for the
diagnosis (evaluation of severity and comorbidities) and treatment of plaque
psoriasis were defined. The issues generated a search strategy in the
Medline-PubMed database up to July 2018. Subsequently, the answers to the
questions of the recommendations were devised, and each reference selected
presented the respective level of recommendation and strength of scientific
evidence. The final recommendations for making up the final text were worded by
the coordinators.</p></abstract><kwd-group><kwd>Biological therapy</kwd><kwd>Comorbidity</kwd><kwd>Dermatology</kwd><kwd>Practice guidelines as topic</kwd><kwd>Psoriasis</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p>In an initiative of the Brazilian Society of Dermatology, dermatologists with proven
practical experience in the clinical management of psoriasis were invited to be part
of a work group which, in partnership with the Brazilian Medical Association, was
dedicated to develop the Plaque Psoriasis Diagnostic and Treatment Guidelines.
Relevant issues for the diagnosis (assessment of severity and comorbidities) and
treatment of Plaque Psoriasis were defined. These issues were structured with the
P.I.C.O. strategy (patient; intervention or indicators; comparison; outcome). Such
strategies used Medline-PubMed database up to July 2018. The articles selected in
the first search strategy were submitted to the critical evaluation of evidences
using the Jadad score. Subsequently, answers were drafted to the questions of the
Recommendations, with each reference selected demonstrating its respective degree of
recommendation and strength of scientific evidence. The final Recommendations were
drafted by the coordinators for the development of the final text. Details of the
methodology as well as the complete version of these guidelines can be accessed
through the link <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://diretrizes.amb.org.br/?s=psoriase">http://diretrizes.amb.org.br/?s=psoriase</ext-link>
<sup><xref rid="r1" ref-type="bibr">1</xref></sup></p><p>Grade of recommendation and strength of evidence</p><list list-type="alpha-upper"><list-item><p>Experimental and observational studies of best consistency.</p></list-item><list-item><p>Experimental and observational studies of lower consistency.</p></list-item><list-item><p>Case reports (uncontrolled studies).</p></list-item><list-item><p>Opinion lacking critical evaluation, based in consensus, physiological
studies or animal models.</p></list-item></list></sec><sec><title>OBJECTIVE</title><p>To establish the recommendations for the diagnosis (assessment of severity and
comorbidities) and the treatment of plaque psoriasis.</p></sec><sec><title>1. TOOLS OF SEVERITY ASSESSMENT</title><p>With the aim of evaluating the role of the assessment tools applied to psoriasis
patients, a Medline-PubMed database search was conducted, resulting in 984 studies,
of which 14 were selected to answer to the clinical question.<sup><xref rid="r2" ref-type="bibr">2</xref>-<xref rid="r15" ref-type="bibr">15</xref></sup></p><sec><title>What is the role of the assessment tools PASI, BSA, DLQI and PGA for the
assessment of severity and therapeutic response of plaque psoriasis?</title><sec><title>1.1 PASI</title><p>In the PASI (Psoriasis Area Severity Index) score, the evaluator should
observe the erythema, thickness, scaling, and the percentage of the area
affected of four regions (head/neck, trunk, lower and upper limbs) and
calculate the score, which varies from 0 to 72 (<bold>B</bold>).<sup><xref rid="r15" ref-type="bibr">15</xref></sup></p><p>In the evaluation of severity in plaque psoriasis patients, the PASI tool
demonstrated adequate content validity and internal consistency and moderate
intraobserver variation. Despite some limitations, PASI can be recommended
for the scientific evaluation of the severity of plaque psoriasis
<bold>(B)</bold>. <sup><xref rid="r16" ref-type="bibr">16</xref></sup></p></sec><sec><title>1.2 PGA</title><p>This tool [Physician&#180;s Global Assesment (PGA)] only evaluates the features of
the lesion, measuring the degree of erythema, scaling and thickness of
psoriasis lesions of the whole body, grading in a six-point scale, ranging
from 0 (no lesion) to 6 (severe); however, it does not provide information
on the extension of the disease <bold>(B)</bold>.<sup><xref rid="r15" ref-type="bibr">15</xref></sup> It demonstrated adequate content validity,
moderate interobserver variation and low intraobserver variation
<bold>(B)</bold>.<sup><xref rid="r16" ref-type="bibr">16</xref></sup></p></sec><sec><title>1.3 BSA</title><p>BSA (Body Surface Area) was defined as the percentage of body area, where 1%
corresponds to approximately the palm of the hand of the patient being
assessed (<bold>B</bold>).<sup><xref rid="r15" ref-type="bibr">15</xref></sup> It demonstrated little intraobserver variation,
however, an unacceptable interobserver variation for the evaluation of the
severity of disease. It is not adequate to define psoriasis severity because
it does not assess the intensity of the lesion (<bold>B</bold>).<sup><xref rid="r16" ref-type="bibr">16</xref></sup></p></sec><sec><title>1.4 DLQI</title><p>The Dermatology Life Quality Index (DLQI) measures the impact of the skin
disease in the quality of life of the patient in the last seven days. It
consists of 10 items, six dimensions and one overall summary score. Each
question has four alternative answers: &#8220;not at all&#8221;, &#8220;a little&#8221;, &#8220;a lot&#8221; or
&#8220;very much&#8221;, with scores of 0, 1, 2 and 3, respectively. The overall summary
score aggregates the score of each item and ranges between 0 (the best
score) and 30 (the worst score). (<bold>B</bold>).<sup><xref rid="r10" ref-type="bibr">10</xref></sup> In plaque psoriasis patients, the DLQI
tool demonstrated adequate content validity, construct validity, internal
consistency, replicability, acceptability and sensitivity in appropriately
detecting changes in the disease (<bold>B</bold>).<sup><xref rid="r4" ref-type="bibr">4</xref></sup> Due to its briefness and simplicity, it is
useful for the clinical practice (<bold>B</bold>).<sup><xref rid="r3" ref-type="bibr">3</xref></sup></p></sec><sec><title>1.5 NAPSI</title><p>NAPSI (Nail Psoriasis Severity Index) is used to evaluate the severity of
psoriasis in the nail bed and nail matrix. The nail plate is divided into
quadrants using an imaginary longitudinal and horizontal lines. The
involvement of the nail matrix and nail bed is assessed, and the score
ranges from 0 to 8 per nail. The tool is replicable and the analysis is
simplified (<bold>B</bold>).<sup><xref rid="r13" ref-type="bibr">13</xref></sup> Although it has a few limitations (<bold>B</bold>), the
scoring agreement among observers was considered between good to moderate
with NAPSI (<bold>B</bold>).<sup><xref rid="r2" ref-type="bibr">2</xref>,<xref rid="r9" ref-type="bibr">9</xref></sup></p></sec><sec><title>1.6 PGA X BSA (PGA multiplied by BSA)</title><p>The instrument PGA X BSA was calculated multiplying the PGA result by BSA.
When associated to BSA, a tool that evaluates the body surface area
involved, PGA showed moderate to high correlation with changes in PASI
(0.53-0.89) to detect disease severity (<bold>B</bold>).<sup><xref rid="r15" ref-type="bibr">15</xref></sup> Using PGA x BSA to
evaluate the clinical response and define minimal disease activity, the
author found a significant correlation with percentage changes in PASI
(0.915-0.943; P &lt;.001) and medium correlation compared to DLQI
(0.303-0.407; P &lt;.008), independent of the category of baseline PASI
score (12-19 or higher than 20) (<bold>B</bold>).<sup><xref rid="r5" ref-type="bibr">5</xref></sup></p></sec><sec><title>1.7 PASI <italic toggle="yes">versus</italic> DLQI</title><p>When the mean percentage of PASI improvement was compared to the mean
improvement with DLQI, the value of the correlation coefficient observed was
of 0.898 (p&lt;0.01), showing a high correlation between the indexes
(<italic toggle="yes">Spearman correlation coefficient</italic> = 0.87, where the
coefficient higher than 1 demonstrates total agreement)
(<bold>A</bold>).<sup><xref rid="r11" ref-type="bibr">11</xref></sup></p></sec><sec><title>1.8 PASI <italic toggle="yes">versus</italic> PGA</title><p>The two instruments, PASI and PGA, when used to evaluate the PASI 75
therapeutical response (75% or more reduction in the PASI score) e and PGA
zero (no lesion) or 1 (almost no lesion), showed high correlation with each
other (p&lt;0.01). PGA and PASI are redundant, and the use of either PASI or
PGA only is recommended (<bold>A</bold>).<sup><xref rid="r13" ref-type="bibr">13</xref></sup> There is a high correlation between those
two tools (<italic toggle="yes">Spearman correlation coefficient</italic> = 0.87), with
low intra-evaluator variation for PGA (and high variation for PASI. The
inter-evaluator variation was higher with PASI when compared to PGA
(<bold>B</bold>).<sup><xref rid="r7" ref-type="bibr">7</xref></sup></p></sec><sec><title>Recommendations:</title><p>The instrument PASI is recommended for the evaluation of the severity of the
disease and the therapeutical response. The reduction in the PASI score has
a good correlation with the clinical improvement seen by the physician and
with the improvement of the symptoms reported by the patients.</p><p>The instrument DLQI showed a high correlation with PASI in patients with
moderate to severe psoriasis, being a useful instrument for the clinical
practice due to its briefness and simplicity.</p><p>The instrument PGA, when associated to BSA, has a high correlation with the
instrument PASI, and is recommended for the evaluation of disease severity.
Differently to PASI, PGA has the advantage of not depending of the
experience of the evaluator (low intra-evaluator variation).</p><p>NAPSI is a simple tool that can be used to evaluate nail psoriasis. It has
good to moderate scoring agreement between observers.</p></sec></sec></sec><sec><title>2. PREVALENCE OF COMORBIDITIES</title><p>Psoriasis is a chronic inflammatory condition that has been associated to a number of
comorbidities. With the aim of determining the main comorbidities associated to
plaque psoriasis patients, a search was carried out in the Medline-PubMed database,
resulting in 873 studies, of which 73 were selected to answer the clinical
question.<sup><xref rid="r17" ref-type="bibr">17</xref>-<xref rid="r89" ref-type="bibr">89</xref></sup></p><sec><title>What are the main comorbidities associated to psoriasis?</title><sec><title>2.1 Depression</title><p>The prevalence of depression in psoriasis patients in the random effects
model is of 16% (CI 95%: 13.2-19.3; <xref ref-type="fig" rid="f1">Figure
1</xref>).</p><p>
<fig id="f1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Prevalence of depression in moderate to severe plaque psoriasis
patients</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="abd-94-02-s1-0076-g01.jpg"/></fig>
</p></sec><sec><title>2.2 Anxiety</title><p>The prevalence of anxiety disorder in psoriasis patients in the random
effects model is of 15.4% (CI 95%: 10.6-21.7; <xref ref-type="fig" rid="f2">Figure 2</xref>).</p><p>
<fig id="f2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Prevalence of anxiety in moderate to severe plaque psoriasis
patients</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="abd-94-02-s1-0076-g02.jpg"/></fig>
</p></sec><sec><title>2.3 Suicide attempt</title><p>The prevalence of suicide attempt in psoriasis patients in the random effects
model is of 2.9% (CI 95%: 1.4-5.9; <xref ref-type="fig" rid="f3">Figure
3</xref>).</p><p>
<fig id="f3" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Prevalence of suicide attempt in moderate to severe plaque
psoriasis patients</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="abd-94-02-s1-0076-g03.jpg"/></fig>
</p></sec><sec><title>2.4 Asthma or COPD</title><p>The prevalence of asthma or chronic obstructive pulmonary disease (COPD) in
psoriasis patients in the random effects model is of 2.7% (CI 95%: 1.3-5.5;
<xref ref-type="fig" rid="f4">Figure 4</xref>).</p><p>
<fig id="f4" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Prevalence of Asthma/COPD in moderate to severe plaque psoriasis
patients</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="abd-94-02-s1-0076-g04.jpg"/></fig>
</p></sec><sec><title>2.5 Chronic liver disease</title><p>The prevalence of chronic liver disease in psoriasis patients in the random
effects model is of 0.8% (CI 95%: 0.1-4.9; <xref ref-type="fig" rid="f5">Figure 5</xref>).</p><p>
<fig id="f5" orientation="portrait" position="float"><label>Figure 5</label><caption><p>Prevalence of chronic liver disease in moderate to severe plaque
psoriasis patients</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="abd-94-02-s1-0076-g05.jpg"/></fig>
</p></sec><sec><title>2.6 Nonalcoholic fatty liver disease</title><p>The prevalence of nonalcoholic fatty liver disease in psoriasis patients in
the random effects model is of 15.3% (CI 95%: 5.8-34.5; <xref ref-type="fig" rid="f6">Figure 6</xref>).</p><p>
<fig id="f6" orientation="portrait" position="float"><label>Figure 6</label><caption><p>Prevalence of non-alcoholic fatty liver disease in moderate to
severe plaque psoriasis patients</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="abd-94-02-s1-0076-g06.jpg"/></fig>
</p></sec><sec><title>2.7 Obesity</title><p>The prevalence of obesity in psoriasis patients in the random effects model
is of 25.6 (CI 95%: 22.7-28.7; <xref ref-type="fig" rid="f7">Figure
7</xref>).</p><p>
<fig id="f7" orientation="portrait" position="float"><label>Figure 7</label><caption><p>Prevalence of obesity in moderate to severe plaque psoriasis
patients</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="abd-94-02-s1-0076-g07.jpg"/></fig>
</p></sec><sec><title>2.8 Dyslipidemia</title><p>The prevalence of dyslipidemia in psoriasis patients in the random effects
model is of 20.4% (CI 95%:13.6-29.3; <xref ref-type="fig" rid="f8">Figure
8</xref>).</p><p>
<fig id="f8" orientation="portrait" position="float"><label>Figure 8</label><caption><p>Prevalence of dyslipidemia in moderate to severe plaque psoriasis
patients</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="abd-94-02-s1-0076-g08.jpg"/></fig>
</p></sec><sec><title>2.9 Systemic hypertension</title><p>The prevalence of systemic hypertension (SHT) in psoriasis patients in the
random effects model is of 26.9% (CI 95%: 21.5-33; <xref ref-type="fig" rid="f9">Figure 9</xref>).</p><p>
<fig id="f9" orientation="portrait" position="float"><label>Figure 9</label><caption><p>Prevalence of systemic hypertension in moderate to severe plaque
psoriasis patients</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="abd-94-02-s1-0076-g09.jpg"/></fig>
</p></sec><sec><title>2.10 <italic toggle="yes">Diabetes mellitus</italic></title><p>The prevalence of <italic toggle="yes">diabetes mellitus</italic> (DM) in psoriasis
patients in the random effects model is of 11.7% (CI 95%: 8.9-15.2; <xref ref-type="fig" rid="f10">Figure 10</xref>).</p><p>
<fig id="f10" orientation="portrait" position="float"><label>Figure 10</label><caption><p>Prevalence of diabetes mellitus in moderate to severe plaque
psoriasis patients</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="abd-94-02-s1-0076-g10.jpg"/></fig>
</p></sec><sec><title>2.11 Coronary insufficiency</title><p>The prevalence of ischemic cardiomyopathy or coronary insufficiency in
psoriasis patients in the random effects model is of 3.4% (CI 95%: 2.3-5%;
<xref ref-type="fig" rid="f11">Figure 11</xref>).</p><p>
<fig id="f11" orientation="portrait" position="float"><label>Figure 11</label><caption><p>Prevalence of coronary insufficiency in moderate to severe plaque
psoriasis patients</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="abd-94-02-s1-0076-g11.jpg"/></fig>
</p></sec><sec><title>2.12 Inflammatory bowel disease</title><p>The prevalence of inflammatory bowel disease in psoriasis patients in the
random effects model is of 0.9% (CI 95%: 0.6-1.3; <xref ref-type="fig" rid="f12">Figure 12</xref>).</p><p>
<fig id="f12" orientation="portrait" position="float"><label>Figure 12</label><caption><p>Prevalence of inflammatory bowel disease in moderate to severe
plaque psoriasis patients</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="abd-94-02-s1-0076-g12.jpg"/></fig>
</p></sec><sec><title>2.13 Migraine</title><p>The prevalence of migraine in psoriasis patients in the random effects model
is of 15.5% (CI 95%: 0.3-84.8; <xref ref-type="fig" rid="f13">Figure
13</xref>).</p><p>
<fig id="f13" orientation="portrait" position="float"><label>Figure 13</label><caption><p>Prevalence of migraine in moderate to severe plaque psoriasis
patients</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="abd-94-02-s1-0076-g13.jpg"/></fig>
</p></sec><sec><title>2.14 Other comorbidities</title><p>Other prevalent comorbidities in psoriasis patients were alexithymia; other
dermatological conditions such as seborrheic dermatitis, acne, rosacea;
pulmonary hypertension; and celiac disease (<xref rid="t1" ref-type="table">Table 1</xref>).</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Other comorbidities associated to psoriasis</p></caption><table frame="hsides" rules="groups" style="background-color:#edf5f4"><colgroup span="1"><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Study</th><th align="center" rowspan="1" colspan="1">N</th><th align="center" rowspan="1" colspan="1">Comorbidity</th><th align="center" rowspan="1" colspan="1">Prevalence (%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">2016_Sampogna</td><td align="center" rowspan="1" colspan="1">670</td><td align="center" rowspan="1" colspan="1">Alexithymia</td><td align="center" rowspan="1" colspan="1">24.8</td></tr><tr><td align="left" rowspan="1" colspan="1">2014_Vanaclocha</td><td align="center" rowspan="1" colspan="1">528</td><td align="center" rowspan="1" colspan="1">Seborrheicdermatitis</td><td align="center" rowspan="1" colspan="1">8</td></tr><tr><td align="left" rowspan="1" colspan="1">2017_Zander</td><td align="center" rowspan="1" colspan="1">2781</td><td align="center" rowspan="1" colspan="1">Rosacea</td><td align="center" rowspan="1" colspan="1">3.4</td></tr><tr><td align="left" rowspan="1" colspan="1">2017_Zander</td><td align="center" rowspan="1" colspan="1">2781</td><td align="center" rowspan="1" colspan="1">Acne</td><td align="center" rowspan="1" colspan="1">2.1</td></tr><tr><td align="left" rowspan="1" colspan="1">2017_Choi</td><td align="center" rowspan="1" colspan="1">13936</td><td align="center" rowspan="1" colspan="1">Pulmonaryhypertension</td><td align="center" rowspan="1" colspan="1">1.6</td></tr><tr><td align="left" rowspan="1" colspan="1">2008_Birkenfeld</td><td align="center" rowspan="1" colspan="1">12502</td><td align="center" rowspan="1" colspan="1">Celiac disease</td><td align="center" rowspan="1" colspan="1">0.29</td></tr></tbody></table></table-wrap></sec><sec><title>Recommendations:</title><p>Psychiatric comorbidities, such as depression and anxiety, and the diseases
associated to metabolic syndrome, such as obesity, nonalcoholic fatty liver
disease, diabetes, systemic hypertension and dyslipidemia stand out among
the possible comorbidities associated to psoriasis.</p></sec></sec></sec><sec><title>3. TOPICAL TREATMENT</title><p>The topical treatment modality is used in clinical practice for all patients with
plaque psoriasis, regardless of the severity of the disease. With the aim of
establishing the recommendations on the topical treatment of plaque psoriasis, a
search was carried out in the Medline-PubMed database, and 29 studies were selected
to answer the clinical questions.<sup><xref rid="r42" ref-type="bibr">42</xref>,<xref rid="r89" ref-type="bibr">89</xref>-<xref rid="r116" ref-type="bibr">116</xref></sup></p><sec><title>3.1. What is the efficacy and the risk of topical corticosteroids for the
treatment of psoriasis?</title><p>Twice-daily application of 0.05% clobetasol propionate spray or placebo for four
weeks, in placebo-controlled studies, showed improvement of psoriasis lesions
after four weeks [Number Needed to Treat (NNT=2)], with significant response in
the intervention group already on the first week of treatment (p&lt;0.001).
Local burning sensation was observed in similar rates to the placebo group. No
serious adverse event was reported89 <bold>(A)</bold>101 <bold>(A)</bold>.</p><p>In a study that evaluated clobetasol propionate lotion, cream or its vehicle, the
use of lotion and cream showed significant and similar improvement (p&lt;0.001).
There was a reduction of lesions in 55% of patients using clobetasol propionate
in both groups of active treatment (NNT=2) on the fourth week. Three patients of
each treatment group with the active ingredient reported telangiectases, and
four patients in the group using clobetasol cream reported mild to moderate skin
atrophy <bold>(A)</bold>.<sup><xref rid="r92" ref-type="bibr">92</xref></sup></p><p>The use of 0.05% clobetasol propionate foam for two weeks was more effective than
placebo (vehicle with no active ingredient), with improvement ranging from 47%
to 22% (placebo) of patients reaching PGA score 0 or 1 (p&lt;0.0001, NNT=3). The
most common adverse event was burning sensation on the area of application (5%
of the patients in the intervention group and 7% of the comparison group). There
were no severe side effects, <bold>(A)</bold>.<sup><xref rid="r97" ref-type="bibr">97</xref>,<xref rid="r108" ref-type="bibr">108</xref></sup></p><p>The use of betamethasone valerate (BMV) on one side of the body and placebo on
the other side, twice daily for 12 weeks lead to at least 50% improvement
against 24% in the placebo group (NNT= 4). Adverse events were limited, being
burning sensation and pruritus the most common <bold>(A)</bold>.<sup><xref rid="r114" ref-type="bibr">114</xref></sup> When the investigator&#8217;s
global assessment is used for completely clear or almost clear lesions, there is
a 64% reduction (p&lt;0.0001, NNT=2) for the use of clobetasol propionate foam
and 57% reduction (p&lt;0.0001, NNT=2) for the use of clobetasol propionate
solution when compared to their corresponding vehicles on the scalp. The
percentage of patients that reported adverse events was not significantly
different among the comparison groups <bold>(A)</bold>.<sup><xref rid="r96" ref-type="bibr">96</xref></sup></p><p>The safety and efficacy of 0.005% fluticasone propionate ointment for four weeks
was evaluated, in comparison with its vehicle. There was significantly more
improvement in the intervention group (p&lt;0.0001) measured by PGA 0/1 between
29.4% (NNT=4) and 36% (NNT=3). The adverse events were mild to moderate, the
most common being burning sensation and pruritus on the area of application,
which occurred in 6% of patients, both in the intervention and the comparison
group <bold>(A)</bold>.<sup><xref rid="r109" ref-type="bibr">109</xref></sup></p><p>In the comparison between 0.05% betamethasone propionate ointment, its ointment
vehicle and 0.05% diflorasone diacetate ointment, the group using betamethasone
showed a faster improvement, seen already on the first week of treatment, with
significant difference in relation to the group using diflorasone or to the
control group (p=0.01). The improvement seen was maintained on the third week.
The adverse events were minimal <bold>(A)</bold>.<sup><xref rid="r105" ref-type="bibr">105</xref></sup></p><sec><title>Recommendations:</title><p>In plaque psoriasis, the use of the topical corticosteroids clobetasol
propionate, betamethasone valerate and fluticasone propionate, proved to be
significantly effective in improving signs and symptoms of erythema,
scaling, thickness of the plaque and pruritus, besides the significant
improvement in the evaluation of the physician or the patient regarding
clearance of the lesions. The most frequent adverse events were burning
sensation and stinging on the area of application, both with the active
ingredient and the placebo, with no significant difference among the
comparison groups.</p></sec></sec><sec><title>3.2 What is the efficacy and risk of tar derivatives (coal tar and liquor
carbonis detergens - LCD) for the treatment of psoriasis?</title><p>The use of 2% dithranol ointment, for one minute, once daily, associated to UVB
phototherapy, resulted in significant clearance measured by the physician and
the patient after eight weeks, except for pruritus (p=0.004). The adverse event
reported during the study was skin irritation on the area of application
<bold>(A)</bold>.<sup><xref rid="r42" ref-type="bibr">42</xref></sup></p><sec><title>Recommendations:</title><p>Of the tar derivatives, only dithranol (associated to phototherapy) showed
significant efficacy in the improvement of erythema, scaling and thickness
of psoriasis plaques, not being effective for the improvement of pruritus.
The adverse event observed with dithranol was local skin irritation.</p><p>There are no evidences that allow for the recommendation of coal tar and
<italic toggle="yes">Liquor Carbonis Detergens</italic> for the treatment of Plaque
Psoriasis.</p></sec></sec><sec><title>3.3 What is the efficacy and risk of topical calcineurin inhibitors for the
treatment of psoriasis?</title><p>The use of 6% salicylic acid gel associated to 0.1% tacrolimus ointment twice
daily, on one side of the body, compared to 6% salicylic acid gel associated to
placebo on the other side, lead to an improvement in the pruritus, erythema and
scaling on weeks 1, 2 and 8 (p&lt;0.05), as well as a significant improvement in
the global assessment of the disease in week 8, except for the evaluation of
erythema <bold>(A)</bold>.<sup><xref rid="r90" ref-type="bibr">90</xref>,<xref rid="r90" ref-type="bibr">90</xref></sup> In a study that evaluated
twice-daily 0.005% calcipotriol ointment or once-daily 0.3% tacrolimus ointment
or placebo, there was no significant reduction in PASI with the use of topical
tacrolimus in relation to placebo (p=0.77) <bold>(A)</bold>.<sup><xref rid="r116" ref-type="bibr">116</xref></sup></p><sec><title>Recommendations:</title><p>Regarding the topical use of calcineurin inhibitors, tacrolimus does not show
significant improvement in PASI reduction. However, in an evaluation eight
weeks after starting the application, it proved to be effective for the
improvement of pruritus, erythema and scaling of psoriatic plaques. When
using the global assessment index from 0 to 5 points, there is no
significant improvement in the erythema with the use of tacrolimus. There is
no response evaluation after eight weeks of follow-up.</p></sec></sec><sec><title>3.4 What is the efficacy and the risk of vitamin D analogues for the
treatment of psoriasis?</title><p>Calcipotriol ointment at 0.05% significantly improved lesions compared to the
control group (p&lt;0.001) <bold>(A)</bold>, however, the active ingredient in a
cream, in the same concentration did not show improvement when compared to
placebo (p=0.12).<sup><xref rid="r112" ref-type="bibr">112</xref></sup></p><p>In the physician&#8217;s global assessment there is also a statistically significant
difference between treatments, favoring twice-daily 0.005% calcipotriol, since
the first week (p&lt;0.001), which was maintained after the eighth week of
treatment <bold>(A)</bold>.<sup><xref rid="r100" ref-type="bibr">100</xref></sup></p><p>The use of twice-daily 50&#181;g/mg calcipotriol ointment for four weeks on one
side of the body showed improvement in the efficacy evaluation with PASI at two
weeks (19.8%, p&lt;0.001, NNT=5), as well as at four weeks (23.2%, p&lt;0.001,
NNT=5) <bold>(A)</bold>.<sup><xref rid="r94" ref-type="bibr">94</xref></sup></p><p>In the investigator&#8217;s global assessment, 56%, 22% and 22% of patients using
twice-daily 50&#181;g/mg calcipotriol ointment for eight weeks showed moderate
or marked improvement or clearance, respectively (p&lt;0.004) <bold>(A)</bold>.
<sup><xref rid="r104" ref-type="bibr">104</xref></sup></p><p>When evaluating the use of 0.005% calcipotriol foam according to the PGA, between
7% (p=0.058, NNT=15) and 11% (p=0.016, NNT=9) of patients achieved PGA 0/1 for
the intervention group in the study. The adverse events were reported in 1 to 2
% of patients (irritation, erythema, or pruritus on the area of application)
<bold>(A)</bold>.<sup><xref rid="r95" ref-type="bibr">95</xref></sup></p><p>When compared to placebo, the use of 3 &#181;g/g calcitriol showed difference
between 11.9% (p=0.05, NNT=9) and 21% (p&lt;0.01, NNT=5) in the physician&#8217;s
global assessment. The adverse events reported were mild, and included
discomfort, pruritus or erythema <bold>(A)</bold>.<sup><xref rid="r107" ref-type="bibr">107</xref></sup></p><p>The efficacy evaluation of 15 &#181;g/g calcitriol according to the PASI score,
showed there was a significant difference of response of 81% favoring topical
treatment with calcitriol after two months of follow-up (NNT=2). Nonetheless, in
the control group, 83.3% did not show any changes in the lesions and 1.2% had
worsening <bold>(A)</bold>. <sup><xref rid="r111" ref-type="bibr">111</xref></sup></p><p>Regarding PGA, when 15&#181;g/g calcitriol was evaluated on one side of the
body and its vehicle on the other side, there was a significant difference
between the treatments on both sides of the body from the first week (p=0.0004),
which was maintained after the sixth week (p=0.002), favoring calcitriol use
(NNT=3) <bold>(A)</bold>.<sup><xref rid="r106" ref-type="bibr">106</xref></sup></p><sec><title>Recommendations:</title><p>Vitamin D analogues, 50 &#181;g/g calcipotriol ointment, 0.005%
calcipotriol foam and 6&#181;g/g calcitriol, were shown to be effective
for the topical treatment of plaque psoriasis in a period of 4 to 16 weeks
for the analysis of clinical features like erythema, scaling and plaque
thickness, and for PASI and the investigator&#8217;s or patient&#8217;s global
assessment. This class of drugs proved to be safe, since most side effects
are mild and related to reactions on the areas of application such as
erythema, pruritus and burning sensation.</p></sec></sec><sec><title>3.5 What is the advantage of using the combination betamethasone +
calcipotriol and the advantage in relation to topical corticosteroids for the
treatment of psoriasis?</title><p>The comparison between 50&#181;g/g calcipotriol associated to 0.5mg/g
betamethasone, or 50&#181;g/g calcipotriol alone, or 0.5mg/g betamethasone
alone, when the SUM score is used (it evaluates erythema, thickness and scaling
in the lesion), demonstrates that the mean percentage of score reduction in four
weeks is of 61% for the combination of drugs, 32% for calcipotriol alone and 41%
for betamethasone alone; on the sixth week, this reduction was of 58%, 45% and
56%, respectively <bold>(A)</bold>.<sup><xref rid="r115" ref-type="bibr">115</xref></sup></p><p>When the difference in PASI change (in percentage) between the combination of
drugs compared to betamethasone alone was evaluated, the result was 10.3% (CI95%
5.8% to 14.7%, p&lt;0.001, NNT=10). <bold>(A)</bold>.<sup><xref rid="r110" ref-type="bibr">110</xref></sup> If the mean PASI difference is evaluated in
points during the treatment, the result was -13.1 for the intervention group
(CI95% -16.9 to -9.3, p&lt;0.001) in one study <bold>(A)</bold> and -14.2 for
the intervention group (CI95% -17.6 to -10.8, p&lt;0.001) in another
<bold>(A)</bold> in up to eight weeks.<sup><xref rid="r93" ref-type="bibr">93</xref>,<xref rid="r102" ref-type="bibr">102</xref></sup> Side
effects were mild and comparable between the groups analyzed
<bold>(A)</bold>.<sup><xref rid="r93" ref-type="bibr">93</xref>,<xref rid="r102" ref-type="bibr">102</xref></sup></p><sec><title>Recommendations:</title><p>In plaque psoriasis lesions, the use of calcipotriol associated to topical
betamethasone shows statistically significant improvement in comparison to
the use of the topical corticosteroid alone, in a period of assessment of 4
to 8 weeks, regarding the evaluation with the PASI score.</p></sec></sec><sec><title>3.6. What is the advantage of the use of the combination of betamethasone +
calcipotriol and the advantage in relation to calcipotriol alone for the
treatment of psoriasis?</title><p>When 50&#181;g/g calcipotriol ointment, 50&#181;g/g calcipotriol cream,
50&#181;g/g calcipotriol associated to 0.5mg/g betamethasone dipropionate
ointment, the same association in gel and 25&#181;g/g calcipotriol associated
to 10mg/g hydrocortisone for up to 21 days were evaluated, there was a
statistically significant difference between the use of calcipotriol associated
to betamethasone compared to the use of calcipotriol alone, considering
erythema, scaling and thickness of psoriatic lesions <bold>(A)</bold>.<sup><xref rid="r112" ref-type="bibr">112</xref></sup></p><p>When evaluated with the SUM score, there is a statistically significant
difference in the three variables analyzed on the fourth and sixth weeks
(p&lt;0.001) favoring the use of the combination of drugs. The mean percentage
of reduction on the fourth week was of 61% for the use of the combination of
drugs, 32% for calcipotriol alone and 41% for betamethasone alone; on the sixth
week, this reduction was of 58%, 45% and 56% respectively
<bold>(A)</bold>.<sup><xref rid="r115" ref-type="bibr">115</xref></sup>
In the evaluation of the mean reduction in PASI, this was of 6.99 for the
intervention group and 5.04 for the comparison group <bold>(A)</bold>.<sup><xref rid="r113" ref-type="bibr">113</xref></sup> The evaluation of the PASI
reduction in eight weeks showed 73.3% reduction of the mean PASI percentage for
the compound twice daily, 68.2% for the combination for four weeks, followed by
calcipotriol alone for four more weeks and 64.1% for calcipotriol alone
<bold>(A)</bold>.<sup><xref rid="r103" ref-type="bibr">103</xref></sup> The
difference in the mean reduction of the thickness of the lesions at the end of
the treatment ranged from 16.3% (CI95% 11.5 to 21, p&lt;0.001 NNT=7)
<bold>(A)</bold> to 25.2% favoring the combination of drugs (CI95% 20.1 to
30.1, p&lt;0.001, NNT=4) (110) <bold>(A)</bold>.<sup><xref rid="r93" ref-type="bibr">93</xref></sup> In regards to the number of daily
applications, there was no difference between once-or twice-daily application in
efficacy measurements, being the combination calcipotriol/betamethasone always
superior in comparison to calcipotriol alone. The most common adverse events
were local and mild, with pruritus being the most frequent
<bold>(A)</bold>.<sup><xref rid="r98" ref-type="bibr">98</xref></sup></p><sec><title>Recommendations:</title><p>The use of calcipotriol associated to topical betamethasone demonstrates a
statistically significant improvement in relation to the use of topical
calcipotriol alone for plaque psoriasis lesions in the period of 2 to 8
weeks of evaluation.</p></sec></sec></sec><sec><title>4. PHOTOTHERAPY</title><p>With the aim of establishing the recommendations on the efficacy and safety of
phototherapy for plaque psoriasis, a search was carried out in the Medline-PubMed
database, resulting in 436 studies, with 09 selected to answer the clinical
questions.</p><sec><title>4.1 What is the efficacy and risk of phototherapy for the treatment of
psoriasis?</title><p>In the evaluation of the treatment of plaque psoriasis with the concurrent use of
narrowband ultraviolet B (NB-UVB) phototherapy and fumaric acid esters and the
use of fumaric acid esters alone, it was observed that the NB-UVB combined
treatment led to a higher median reduction in the PASI score in six weeks of
treatment, when compared to the use of fumaric acid alone (p=0.016), therefore,
with a higher positive impact in the quality of life (p=0.031) and less side
effects <bold>(A)</bold>.<sup><xref rid="r117" ref-type="bibr">117</xref></sup></p><p>In a study that compared NB-UVB phototherapy, the association of NB-UVB with
methotrexate and methotrexate alone, there was no difference in the concurrent
use of methotrexate (MTX) regarding clearance of lesions. The rates observed
were of 94.74% with NB-UVB and MTX, 92.11% with NB-UVB alone, and 89.19% of
those with only MTX, (p=0.674)) <bold>(A)</bold>.<sup><xref rid="r118" ref-type="bibr">118</xref></sup></p><p>The association of NB-UVB phototherapy and etanercept also showed better results
than therapy with etanercept only (best result showing a difference of patients
achieving PASI 90 of 39.5% (p=0.018, NNT=3)) <bold>(A)</bold>.<sup><xref rid="r119" ref-type="bibr">119</xref>,<xref rid="r120" ref-type="bibr">120</xref></sup> The association of phototherapy to adalimumab also
significantly accelerated and improved resolution of lesions, assessed by the
PASI adapted for half of the body, with a 33% reduction of the PASI in the sixth
week (NNT=3) <bold>(B)</bold>.<sup><xref rid="r121" ref-type="bibr">121</xref></sup></p><p>Adding calcipotriol to the NB-UVB phototherapy regime lead to a significant
improvement (p&lt;0.001) in week 12 when compared to NB-UVB alone or twice-daily
calcipotriol only <bold>(A)</bold>.<sup><xref rid="r122" ref-type="bibr">122</xref></sup> Only one study did not show difference between the
application of the topical active ingredient alone and the same application
associated to phototherapy <bold>(A)</bold>.<sup><xref rid="r123" ref-type="bibr">123</xref></sup></p><p>In patients with palmoplantar plaque psoriasis, the use of PUVA (psoralen +
ultraviolet A) phototherapy yielded better lesion resolution when evaluated
according to complete or partial improvement of lesions (&gt;50% improvement or
&lt;50% improvement). More people achieved complete response with PUVA (UVB
group: 30%; PUVA group: 42%; p&lt;0.001). More people achieved partial response
with PUVA and the absence of response was lower for PUVA (p&lt;0.001), however,
more adverse events were observed with PUVA, albeit mild (p=0.04)
<bold>(B)</bold>.<sup><xref rid="r124" ref-type="bibr">124</xref></sup></p><sec><title>Recommendations:</title><p>Phototherapy with PUVA or UVB, associated or not to other treatments such as
etanercept, adalimumab, methotrexate, fumaric acid esters and calcipotriol
ointment, accelerates the process of improvement of psoriasis, in
evaluations with 6 and 16 weeks of follow-up, with significant reduction in
PASI compared to these treatments alone.</p></sec></sec><sec><title>4.2 What are the advantages and disadvantages of NB-UVB in relation to
PUVA?</title><p>A study proved NB-UVB to be superior to PUVA for plaque psoriasis, with 75% of
achieving complete resolution in the NB-UVB versus 54% in the PUVA group. There
was no significant difference between the groups regarding time for remission,
neither in the number of adverse events <bold>(A)</bold>.<sup><xref rid="r125" ref-type="bibr">125</xref></sup> When comparing NB-UVB with
the use of UVA associated to trisoralen, there was a median PASI reduction in
32% favoring UVB phototherapy (p&lt;0.001, NNT=3) <bold>(A)</bold>. <sup><xref rid="r126" ref-type="bibr">126</xref></sup></p><p>A study showed that, in patients with skin phototype I to IV, PUVA was
significantly more effective than NB-UVB regarding response to resolution (84%
vs. 65%, p=0.02, NNT=6), but with more side effects and longer treatment time
for clearance of lesions <bold>(A)</bold>.<sup><xref rid="r127" ref-type="bibr">127</xref></sup> Another similar study showed that clearance of
psoriasis lesions was achieved in a significantly higher proportion of patients
treated with PUVA (84%) compared to those treated with NB-UVB (63%) (CI95%, 1.18
to 7.84, p=0.018, NNT=5), but at the expense of more side effects
<bold>(A)</bold>.<sup><xref rid="r128" ref-type="bibr">128</xref></sup> When
PASI median was evaluated, treatment with PUVA showed a significantly higher
reduction in PASI median than in the NB-UVB group (26.72%, CI 95%, p=0.005,
NNT=4) <bold>(A)</bold>.<sup><xref rid="r129" ref-type="bibr">129</xref></sup>
The index of resolution with NB-UVB was of 80% in patients pre-treated with
topical retinoids, compared to a 90% index in patients pre-treated with topical
retinoids that were submitted to NB-UVB, and an index of 100% in patients using
PUVA ant topical retinoids concomitantly <bold>(A)</bold>.<sup><xref rid="r129" ref-type="bibr">129</xref></sup> The association of
etretinate and PUVA lead to 100% of complete improvement in a study, while the
association of the medication with NB-UVB improved 80% of patients.<sup><xref rid="r130" ref-type="bibr">130</xref></sup> When the combined treatment
of phototherapy and acitretin was analyzed, psoriasis clearance was seen in
56.6% of patients treated with NB-UVB and in 63.3% of patients treated with PUVA
<bold>(A)</bold>.<sup><xref rid="r131" ref-type="bibr">131</xref></sup></p><p>In other studies, no difference in improvement as measured by PASI was observed
between the use of NB-UVB and PUVA in the treatment of plaque psoriasis,
<bold>(A)</bold>, but there seems to be a higher frequency of side effects
in patients using PUVA <bold>(A)</bold>.<sup><xref rid="r132" ref-type="bibr">132</xref>,<xref rid="r133" ref-type="bibr">133</xref></sup></p><p>Evaluating a 0 to 4 index similar to PGA for the treatment of palmoplantar
psoriasis, a higher percentage in the reduction of the index with PUVA (85.45%)
was observed, rather than with NB-UVB (61.08%-p=0.0001)
<bold>(A)</bold>.<sup><xref rid="r134" ref-type="bibr">134</xref></sup></p><sec><title>Recommendations:</title><p>In the efficacy comparison between NB-UVB and PUVA, most studies demonstrate
a higher efficacy of PUVA in relation to NB-UVB in the evaluation of up to 3
months of treatment, although there is evidence that NB-UVB can occasionally
be superior. The mean number of necessary treatments for clearance of the
lesions was also significantly lower in patients undergoing PUVA, compared
to patients undergoing UVB. The most frequent adverse events in all
treatments were mucocutaneous xerosis, erythema, pruritus and nausea, most
of the times mild, not interfering with the treatments.</p></sec></sec></sec><sec><title>5. CLASSIC SYSTEMIC TREATMENT</title><p>With the aim of establishing recommendations on the classic treatment for plaque
psoriasis (acitretin, methotrexate and cyclosporine), a search was carried out using
the Medline-PubMed database and the best scientific evidences were selected to
answer the clinical questions.</p><sec><title>5.1 What is the efficacy and risk of methotrexate in the systemic treatment
of psoriasis?</title><p>Patients diagnosed with plaque psoriasis (n=120) were treated with methotrexate
17.5mg SC once weekly or placebo injections in the first 16 weeks of the study
(phase 1). In the second phase of the study (weeks 16 to 52), all patients were
treated with methotrexate. In week 16, PASI 75 response was obtained in 37 (41%)
patients of the methotrexate group compared to three (10%) patients in the
placebo group (RR 3.93 CI95% 1.31-11.81; p=0.0026). The PGA response &#8216;clear&#8217; (0)
or &#8216;almost clear&#8217; (1) occurred in 25 (27%) patients treated with methotrexate in
the evaluation at 16 weeks compared to two (7%) patients receiving placebo; 16
(18%) versus no patient, respectively, showed PASI 90 response.
<bold>(A)</bold>.<sup><xref rid="r135" ref-type="bibr">135</xref></sup></p><p>A double-blind, randomized study evaluated the efficacy of 7.5 to 25mg of oral
methotrexate (110 patients), compared to adalimumab 80mg SC as induction and
maintenance with 40mg SC fortnightly (108 patients) and placebo (53 patients).
After 16 weeks of follow-up, 79.6% of patients treated with adalimumab reached
PASI 75, compared to 35.5% for the group of patients treated with methotrexate
(p&lt;0.001 vs. adalimumab) and 18.9% for the group treated with placebo
(p&lt;0.001 vs. adalimumab - NNT=2 and p&lt;0.05 vs. methotrexate - NNT=6).
There was a statistically significant improvement in the complete resolution of
lesions (PASI 100) in the patients treated with adalimumab (16.7%) in relation
to patients treated with methotrexate (7.3%) or in patients treated with placebo
(1.9%). Regarding adverse events, there was no statistically significant
difference between the groups for infections, moderate to severe adverse events
and adverse events related to the drugs. More adverse events lead to
discontinuation of the study in the methotrexate group, mainly due to the events
related to liver dysfunction. <bold>(A)</bold>.<sup><xref rid="r136" ref-type="bibr">136</xref>,<xref rid="r137" ref-type="bibr">137</xref></sup></p><sec><title>Recommendations:</title><p>In the treatment of moderate to severe psoriasis with methotrexate, there is
significant PASI reduction in relation to baseline at 2, 4 and 6 months of
evaluation when compared to placebo, with a number necessary to treat
varying from 3 to 6 patients. The most frequent adverse events are nausea,
vomiting and abnormalities in transaminases.</p></sec></sec><sec><title>5.2 What is the efficacy and risk of acitretin in the systemic treatment of
psoriasis?</title><p>A randomized, double-blind study evaluated the efficacy and safety of oral
acitretin in the treatment of moderate to severe plaque psoriasis, in three
treatment groups with different doses: 25mg, 35mg or 50mg/day. Clinical
improvement was observed in all groups with PASI 75 response at week 12. The
mean PASI dropped 76% in the 35mg group after 12 weeks of treatment, this
difference was statistically significant compared to the 25mg and 50mg groups
(p&lt;0.05). In the evaluation at 12 weeks of treatment, PASI 75 response was
achieved in 47%, 69% and 53% patients in the 25, 35 and 50mg/day acitretin
groups, respectively. Most adverse events were mucocutaneous, mild to moderate
and dose-dependent <bold>(A)</bold>.<sup><xref rid="r138" ref-type="bibr">138</xref></sup></p><p>In another study, patients with moderate to severe plaque psoriasis were
randomized to the following doses of acitretin: eight patients using 10mg to
25mg per day, or 16 patients using 50mg to 75mg per day. Patients treated with
acitretin doses of 50 to 75mg per day showed a significant therapeutical
response (p&lt;0.05) in the evaluation at eight weeks. More adverse events
occurred in patients receiving the dose of 25mg per day or more of acitretin,
but usually mild and with no need to discontinue the
treatment<bold>(A)</bold>.<sup><xref rid="r139" ref-type="bibr">139</xref></sup></p><sec><title>Recommendations:</title><p>In patients with moderate to severe plaque psoriasis, the use of doses of
acitretin of 35 to 75mg per day showed significant improvement, evaluated by
the PASI response. The most frequently observed adverse events are
cheilitis, scaling of palmoplantar regions and alopecia, however, the need
to discontinue the treatment was rare.</p></sec></sec><sec><title>5.3 What is the efficacy and risk of cyclosporine in the systemic treatment
of psoriasis?</title><p>Patients with moderate to severe plaque psoriasis in remission after treatment
with continuous cyclosporine during eight to 16 weeks were evaluated, with 162
receiving oral cyclosporine 5mg/ kg/day for two consecutive days on the weekend
and 81 patients receiving placebo, in the same dosing regimen. The primary end
point was a rate of clinical success in 24 weeks, as defined by the absence of
relapse or PASI 75 response (in comparison to the PASI precyclosporine
treatment). There was no statistically significant difference in the rates of
clinical success in the evaluation at 24 weeks between the comparison groups
(66.9% in the cyclosporine group versus 53.2% in the placebo group, p=0.072).
The time frame till the first relapse was significantly longer in the group
using cyclosporine (p=0.023). Cyclosporine was well tolerated, with no
differences regarding renal function and blood pressure among those receiving
the active drug or placebo <bold>(A)</bold>.<sup><xref rid="r140" ref-type="bibr">140</xref></sup></p><p>A study evaluated the efficacy and safety of cyclosporine for the treatment of
severe psoriasis (PASI &#8805; 18), in two different dosing regimens:
2.5mg/kg/day and 5mg/kg/day. The mean PASI score reduction at the end of the
induction phase was 69% in the 2.5mg/kg/ day group and 89% in the 5mg/kg/day
group (p=0.0001, NNT=5). Eighty-six percent of patients described some adverse
event during the treatment period (for up to 21 months), most of them mild to
moderate. The most frequent events were systemic hypertension,
hirsutism/hypertrichosis, headache, paresthesia, nausea, abdominal discomfort,
flu-like symptoms, fatigue, tremor, edema and renal abnormalities. The severe
adverse events reported were the development of malignancies in eight patients
(of those, four were skin cancers) and two patients had myocardial infarction
<bold>(A)</bold>.<sup><xref rid="r141" ref-type="bibr">141</xref></sup></p><p>In another study, the efficacy and safety of cyclosporine for the treatment of
moderate to severe plaque psoriasis was evaluated in two different dosing
regimens. One of the groups initially received cyclosporine 1.25mg/kg/day,
increasing to 2.5mg/kg/day or 5mg/kg/day in cases where there was no PASI
reduction of 10% in two weeks or 30% in six weeks. Another group for comparison
received cyclosporine 2.5mg/kg/day, increasing to 5mg/kg/day in the cases where
there was no PASI reduction of 10% in two weeks or 30% in six weeks. After 12
weeks of treatment, 18% of patients with the initial dose of 1.25mg/kg/day and
56% of patients with the initial dose of 2.5mg/kg/day showed a PASI 75 response.
The most frequent adverse events were gastrointestinal abnormalities and viral
infections <bold>(B)</bold>.<sup><xref rid="r142" ref-type="bibr">142</xref></sup></p><sec><title>Recommendations:</title><p>The use of cyclosporine in moderate to severe plaque psoriasis demonstrates
significant improvement evaluated by the PASI response, with the best
responses obtained with the dose of 5mg/ kg/day. The most important severe
adverse events were reported in long treatments (21 months), encompassing
malignancies and systemic hypertension. For those patients who showed an
adequate therapeutic response in up to 16 weeks, maintenance treatment with
administration of cyclosporine on weekends proved to safely and effectively
prolong maintenance of the therapeutic response.</p></sec></sec></sec><sec><title>6. TREATMENT WITH IMMUNOBIOLOGICS</title><p>With the aim of establishing the recommendations on the treatment of psoriasis with
immunobiologics, questions regarding indication, efficacy and safety of these
medications were structured. A search was carried out in Medline-PubMed database and
the best scientific evidences were selected to answer the clinical questions. This
search encompassed all immunobiologics approved in Brazil for the treatment of
plaque psoriasis: adalimumab, etanercept, infliximab, ustekinumab, secukinumab,
ixekizumab and guselkumab.</p><sec><title>6.1 In which conditions is the treatment with immunobiologics
indicated?</title><p>The indications for the use of immunobiologics in patients older than 18 years of
age, with moderate to severe plaque psoriasis, with PASI score above 10 to 12 or
involvement of more than 10% of body surface area are:</p><list list-type="bullet"><list-item><p>Patients that did not respond to the treatment or have contraindications
or intolerance to the adequate dose and course of at least one of the
systemic drugs or phototherapy <bold>(A)</bold>.<sup><xref rid="r6" ref-type="bibr">6</xref>,<xref rid="r12" ref-type="bibr">12</xref>,<xref rid="r136" ref-type="bibr">136</xref>,<xref rid="r137" ref-type="bibr">137</xref>,<xref rid="r143" ref-type="bibr">143</xref>-<xref rid="r173" ref-type="bibr">173</xref></sup></p></list-item><list-item><p>Less than 50% improvement in the baseline PASI or less than 75%
improvement in the baseline PASI associated to a significant impact of
the disease on the quality of life as measured by the DLQI (Dermatology
Life Quality Index) &gt;=10 is considered therapeutic failure.</p></list-item></list><p>Some groups of patients with moderate to severe plaque psoriasis were not studied
for the treatment with immunobiologics <bold>(A)</bold>.<sup><xref rid="r6" ref-type="bibr">6</xref>,<xref rid="r12" ref-type="bibr">12</xref>,<xref rid="r136" ref-type="bibr">136</xref>,<xref rid="r137" ref-type="bibr">137</xref>,<xref rid="r143" ref-type="bibr">143</xref>-<xref rid="r173" ref-type="bibr">173</xref></sup></p><list list-type="bullet"><list-item><p>Patients with infections associated to the use of antibiotics in the last
week prior to the beginning of the study;</p></list-item><list-item><p>Patients with other associated skin conditions, besides guttate,
erythrodermic or pustular psoriasis;</p></list-item><list-item><p>Patients with hematologic, renal and/or liver abnormalities;</p></list-item><list-item><p>Patients with history of cancer of any etiology in the last five
years;</p></list-item><list-item><p>Treatment with PUVA in the four previous weeks or topical steroids,
vitamin A or D analogues, dithranol or UVB phototherapy in the two
previous weeks; or use of any immunobiologic or anti-TNF antibody at any
time before the beginning of the study;</p></list-item><list-item><p>Patients who are pregnant or planning pregnancy.</p></list-item></list><sec><title>Recommendations:</title><p>The indications for the use of immunobiologic drugs in patients older than 18
years of age, with moderate to severe plaque psoriasis, with PASI score
above 10 or body surface area involvement higher than 10% are: the lack of
response to systemic treatment or phototherapy, contraindications or
intolerance to the adequate dose and course of at least one of the systemic
treatments.</p></sec></sec><sec><title>6.2 What is the efficacy and risk of etanercept for the treatment of
psoriasis?</title><sec><title>Recommendations:</title><p>The treatment with etanercept for moderate to severe plaque psoriasis, for
the period of 12 weeks, was effective and safe with the evaluation of the
PASI 75 response (<xref rid="t2" ref-type="table">Table 2</xref>). The
adverse events presented were mild to moderate, mainly of reactions on the
site of injection. The best responses occurred in patients using 50mg twice
weekly. PASI 75 response rates in 12 weeks in the different regimens ranged
from10-28% with the dose of 25 mg once weekly; 26-39% in the dose of 25mg
twice weekly; and 35-54%, in the dose of 50 mg twice weekly.<sup><xref rid="r144" ref-type="bibr">144</xref>,<xref rid="r149" ref-type="bibr">149</xref>,<xref rid="r151" ref-type="bibr">151</xref>,<xref rid="r152" ref-type="bibr">152</xref>,<xref rid="r155" ref-type="bibr">155</xref>,<xref rid="r158" ref-type="bibr">158</xref>,<xref rid="r162" ref-type="bibr">162</xref>,<xref rid="r167" ref-type="bibr">167</xref></sup></p><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Evaluation of etanercept expressed by the benefit estimated in
percentage</p></caption><table frame="hsides" rules="groups" style="background-color:#edf5f4"><colgroup span="1"><col width="12%" span="1"/><col width="12%" span="1"/><col width="12%" span="1"/><col width="12%" span="1"/><col width="12%" span="1"/><col width="12%" span="1"/><col width="12%" span="1"/><col width="12%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Author</th><th align="center" rowspan="1" colspan="1">Dose (mg/week)</th><th align="center" rowspan="1" colspan="1">Time of follow-up</th><th align="center" rowspan="1" colspan="1">PASI 50 (%)</th><th align="center" rowspan="1" colspan="1">PASI 75 (%)</th><th align="center" rowspan="1" colspan="1">PASI 90 (%)</th><th align="center" rowspan="1" colspan="1">PGA (%)</th><th align="center" rowspan="1" colspan="1">DLQI (%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>Bagel J (144)</bold></td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">78</td><td align="center" rowspan="1" colspan="1">54</td><td align="center" rowspan="1" colspan="1">23</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">&#160;</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Gottlieb AB (151)</bold></td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">39.6</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">29.5</td><td align="center" rowspan="1" colspan="1">&#160;</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Van de Kerkhof PCM (155)</bold></td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">37.5</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">38.5</td><td align="center" rowspan="1" colspan="1">49.2</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Krueger (158)</bold></td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">46</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">&#160;</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Feldman ST (149)</bold></td><td align="center" rowspan="1" colspan="1">25</td><td align="center" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">22</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">&#160;</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Feldman ST (149)</bold></td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">26</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">&#160;</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Feldman ST (149)</bold></td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">35</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">&#160;</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Papp KA (167)</bold></td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">55</td><td align="center" rowspan="1" colspan="1">29</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">35</td><td align="center" rowspan="1" colspan="1">&#160;</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Papp KA (167)</bold></td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">68</td><td align="center" rowspan="1" colspan="1">43</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">53</td><td align="center" rowspan="1" colspan="1">&#160;</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Gottlieb AB (152)</bold></td><td align="center" rowspan="1" colspan="1">25</td><td align="center" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">28</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">&#160;</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Leonardi CL (162)</bold></td><td align="center" rowspan="1" colspan="1">25</td><td align="center" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">27</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">18</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Leonardi CL (162)</bold></td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">44</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">29</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Leonardi CL (162)</bold></td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">60</td><td align="center" rowspan="1" colspan="1">45</td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">44</td></tr></tbody></table></table-wrap></sec></sec><sec><title>6.3 What is the efficacy and risk of infliximab for the treatment of
psoriasis?</title><sec><title>Recommendations:</title><p>The induction treatment with infliximab in moderate to severe plaque
psoriasis for the period of 10 weeks, was effective with the evaluation of
the PASI 75 response (65.8-79.6%) and improvement in quality of life with
the DLQI score (8.9 to 9.9%), besides being safe, com few mild to moderate
side effects reported, mainly infusion reactions, with the doses of 3mg/kg,
5mg/kg or 10mg/kg, on weeks 0, 2 and 6 (<xref rid="t3" ref-type="table">Table 3</xref>).<sup><xref rid="r6" ref-type="bibr">6</xref>,<xref rid="r12" ref-type="bibr">12</xref>,<xref rid="r146" ref-type="bibr">146</xref>,<xref rid="r148" ref-type="bibr">148</xref></sup></p><table-wrap id="t3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Evaluation of infliximab expressed by the benefit estimated in
percentage</p></caption><table frame="hsides" rules="groups" style="background-color:#edf5f4"><colgroup span="1"><col width="14%" span="1"/><col width="14%" span="1"/><col width="14%" span="1"/><col width="14%" span="1"/><col width="14%" span="1"/><col width="14%" span="1"/><col width="14%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Author</th><th align="center" rowspan="1" colspan="1">Dose</th><th align="center" rowspan="1" colspan="1">Time of follow-up PASI 50 (%)</th><th align="center" rowspan="1" colspan="1">PASI 75 (%)</th><th align="center" rowspan="1" colspan="1">PASI 90 (%)</th><th align="center" rowspan="1" colspan="1">PGA (%)</th><th align="center" rowspan="1" colspan="1">DLQI (%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>Feldman ST (148)</bold></td><td align="center" rowspan="1" colspan="1">3mg/kg</td><td align="center" rowspan="1" colspan="1">10 weeks</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">8.9</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Feldman ST (148)</bold></td><td align="center" rowspan="1" colspan="1">5mg/kg</td><td align="center" rowspan="1" colspan="1">10 weeks</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">9.9</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Reich K (12)</bold></td><td align="center" rowspan="1" colspan="1">5mg/kg</td><td align="center" rowspan="1" colspan="1">10 weeks</td><td align="center" rowspan="1" colspan="1">79.6</td><td align="center" rowspan="1" colspan="1">55.8</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">9.9</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Gottlieb AB (6)</bold></td><td align="center" rowspan="1" colspan="1">3mg/kg</td><td align="center" rowspan="1" colspan="1">10 weeks 62.2</td><td align="center" rowspan="1" colspan="1">65.8</td><td align="center" rowspan="1" colspan="1">45.5</td><td align="center" rowspan="1" colspan="1">61.9</td><td align="center" rowspan="1" colspan="1">&#160;</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Gottlieb AB (6)</bold></td><td align="center" rowspan="1" colspan="1">5mg/kg</td><td align="center" rowspan="1" colspan="1">10 weeks 75.4</td><td align="center" rowspan="1" colspan="1">82</td><td align="center" rowspan="1" colspan="1">55.6</td><td align="center" rowspan="1" colspan="1">80.1</td><td align="center" rowspan="1" colspan="1">&#160;</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Chaudhari U (146)</bold></td><td align="center" rowspan="1" colspan="1">5mg/kg</td><td align="center" rowspan="1" colspan="1">10 weeks</td><td align="center" rowspan="1" colspan="1">63.6</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">&#160;</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Chaudhari U (146)</bold></td><td align="center" rowspan="1" colspan="1">10mg/kg</td><td align="center" rowspan="1" colspan="1">10 weeks</td><td align="center" rowspan="1" colspan="1">54.5</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">&#160;</td></tr></tbody></table></table-wrap></sec></sec><sec><title>6.4 What is the efficacy and risk of adalimumab for the treatment of
psoriasis?</title><sec><title>Recommendations:</title><p>The treatment of moderate to severe plaque psoriasis with adalimumab, during
12 to 16 weeks, was effective with the evaluation of the PASI 75 response
and improvement in quality of life with the DLQI score (49-81%), in the
following therapeutic regimen: 40 mg every two weeks (PASI 75 57.9-79.6%,
PASI 90 43%, PASI 100 16.7-19% and PGA 80.5%); 80 mg in week 0 followed by
40 mg every two weeks (PASI 75 62.8%); and 80 mg every two weeks (PASI 75
81%); besides being safe, with the report of few mild to moderate adverse
events (<xref rid="t4" ref-type="table">Table 4</xref>).<sup><xref rid="r136" ref-type="bibr">136</xref>,<xref rid="r137" ref-type="bibr">137</xref>,<xref rid="r143" ref-type="bibr">143</xref>,<xref rid="r145" ref-type="bibr">145</xref>,<xref rid="r150" ref-type="bibr">150</xref>,<xref rid="r170" ref-type="bibr">170</xref></sup></p><table-wrap id="t4" orientation="portrait" position="float"><label>Table 4</label><caption><p>Evaluation of adalimumab expressed by the benefit estimated in
percentage</p></caption><table frame="hsides" rules="groups" style="background-color:#edf5f4"><colgroup span="1"><col width="12%" span="1"/><col width="12%" span="1"/><col width="12%" span="1"/><col width="12%" span="1"/><col width="12%" span="1"/><col width="12%" span="1"/><col width="12%" span="1"/><col width="12%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Author</th><th align="center" rowspan="1" colspan="1">Dose (mg/sem)</th><th align="center" rowspan="1" colspan="1">Time of follow-up</th><th align="center" rowspan="1" colspan="1">PASI 50 (%)</th><th align="center" rowspan="1" colspan="1">PASI 75 (%)</th><th align="center" rowspan="1" colspan="1">PASI 90 (%)</th><th align="center" rowspan="1" colspan="1">PASI 100 (%)</th><th align="center" rowspan="1" colspan="1">PGA (%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>Cai L (145)</bold></td><td align="left" rowspan="1" colspan="1">40 + 80</td><td align="center" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">77.8</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">80.5</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Reich K (136)</bold></td><td align="left" rowspan="1" colspan="1">80 + 40</td><td align="center" rowspan="1" colspan="1">16 weeks</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">79.6</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">16.7</td><td align="center" rowspan="1" colspan="1">&#160;</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Revicki D (170)</bold></td><td align="left" rowspan="1" colspan="1">80 + 40</td><td align="center" rowspan="1" colspan="1">16 weeks</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">64</td><td align="center" rowspan="1" colspan="1">43</td><td align="center" rowspan="1" colspan="1">19</td><td align="center" rowspan="1" colspan="1">&#160;</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Asahina A (143)</bold></td><td align="left" rowspan="1" colspan="1">40 every 2 weeks</td><td align="center" rowspan="1" colspan="1">16 weeks</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">57.9</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">&#160;</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Asashina A (143)</bold></td><td align="left" rowspan="1" colspan="1">0 every 2 weeks + 40 from week 2</td><td align="center" rowspan="1" colspan="1">16 weeks</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">62.8</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">&#160;</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Asashina A (143)</bold></td><td align="left" rowspan="1" colspan="1">80 every 2 weeks</td><td align="center" rowspan="1" colspan="1">16 weeks</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">81</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">&#160;</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Gordon KB (150)</bold></td><td align="left" rowspan="1" colspan="1">80 + 40 from week 1</td><td align="center" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">49</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">&#160;</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Gordon KB (150)</bold></td><td align="left" rowspan="1" colspan="1">80 + 40 from week 2</td><td align="center" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">76</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">&#160;</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Saurat JH (137)</bold></td><td align="left" rowspan="1" colspan="1">80 + 40 from week 2</td><td align="center" rowspan="1" colspan="1">16 weeks</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">79.6</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">&#160;</td></tr></tbody></table></table-wrap></sec></sec><sec><title>6.5 What is the efficacy and risk of ustekinumab for the treatment of
psoriasis?</title><sec><title>Recommendations:</title><p>the studies conducted in the evaluation of the efficacy and safety of
ustekinumab for moderate to severe plaque psoriasis showed improvement
evaluated by the PASI 75 response (52.9-76.5% for 45mg and 61.2-78.6% for
90mg) and in the quality of life with the DLQI score (46.4-58.1%), besides
mild to moderate adverse events, upon analysis of a period of 12 weeks
(<xref rid="t5" ref-type="table">Table 5</xref>).<sup><xref rid="r157" ref-type="bibr">157</xref>,<xref rid="r166" ref-type="bibr">166</xref>,<xref rid="r169" ref-type="bibr">169</xref>,<xref rid="r174" ref-type="bibr">174</xref>-<xref rid="r177" ref-type="bibr">177</xref></sup> When compared to
etanercept, ustekinumab in the 45 and 90mg doses was superior when PASI 75
and PGA 0/1 were evaluated in 12 weeks of follow-up. After this period,
although studies have performed a crossover, the treatment with ustekinumab
for up to five years was safe and effective after dose adjustment.</p><table-wrap id="t5" orientation="portrait" position="float"><label>Table 5</label><caption><p>Evaluation of ustekinumab expressed by the benefit estimated in
percentage</p></caption><table frame="hsides" rules="groups" style="background-color:#edf5f4"><colgroup span="1"><col width="11%" span="1"/><col width="11%" span="1"/><col width="11%" span="1"/><col width="11%" span="1"/><col width="11%" span="1"/><col width="11%" span="1"/><col width="11%" span="1"/><col width="11%" span="1"/><col width="11%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Author</th><th align="center" rowspan="1" colspan="1">Dose (mg)</th><th align="center" rowspan="1" colspan="1">Time of follow-up (weeks)</th><th align="center" rowspan="1" colspan="1">PASI 50 (%)</th><th align="center" rowspan="1" colspan="1">PASI 75 (%)</th><th align="center" rowspan="1" colspan="1">PASI 90 (%)</th><th align="center" rowspan="1" colspan="1">PASI 100 (%)</th><th align="center" rowspan="1" colspan="1">PGA(%)</th><th align="center" rowspan="1" colspan="1">DLQI(%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>Langley RG (174)</bold></td><td align="center" rowspan="1" colspan="1">45</td><td align="center" rowspan="1" colspan="1">244 weeks</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">76.5</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">&#160;</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Langley RG (174)</bold></td><td align="center" rowspan="1" colspan="1">90</td><td align="center" rowspan="1" colspan="1">244 weeks</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">78.6</td><td align="center" rowspan="1" colspan="1">55.5</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">&#160;</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Kimball AB (157)</bold></td><td align="center" rowspan="1" colspan="1">45</td><td align="center" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">47.2</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Kimball AB (157) Reich K
(169)</bold></td><td align="center" rowspan="1" colspan="1">90</td><td align="center" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">46.4</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Papp KA (175)</bold></td><td align="center" rowspan="1" colspan="1">45</td><td align="center" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">73</td><td align="center" rowspan="1" colspan="1">63</td><td align="center" rowspan="1" colspan="1">41.6</td><td align="center" rowspan="1" colspan="1">18.1</td><td align="center" rowspan="1" colspan="1">72.6</td><td align="center" rowspan="1" colspan="1">48.9</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Reich K (169)</bold></td><td align="center" rowspan="1" colspan="1">90</td><td align="center" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">78.7</td><td align="center" rowspan="1" colspan="1">72</td><td align="center" rowspan="1" colspan="1">50.2</td><td align="center" rowspan="1" colspan="1">18.2</td><td align="center" rowspan="1" colspan="1">71.4</td><td align="center" rowspan="1" colspan="1">54.6</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Nakagawa H (166) Nakagawa H
(166)</bold></td><td align="center" rowspan="1" colspan="1">45</td><td align="center" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">69.9</td><td align="center" rowspan="1" colspan="1">52.9</td><td align="center" rowspan="1" colspan="1">29.6</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">58.1</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Igarashi A (176)</bold></td><td align="center" rowspan="1" colspan="1">90</td><td align="center" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">71</td><td align="center" rowspan="1" colspan="1">61.2</td><td align="center" rowspan="1" colspan="1">40.3</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">54.1</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Tsai TF (177)</bold></td><td align="center" rowspan="1" colspan="1">45</td><td align="center" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">62.2</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">62.2</td><td align="center" rowspan="1" colspan="1">&#160;</td></tr></tbody></table></table-wrap></sec></sec><sec><title>6.6 What is the efficacy and risk of guselkumab for the treatment of
psoriasis?</title><sec><title>Recommendations:</title><p>the studies on the evaluation of efficacy and safety of guselkumab for
moderate to severe plaque psoriasis showed improvement in 16 weeks,
evaluated by the PASI 90 response (50mg of 70.8% and 100mg of 69.8-73.3%)
and PGA (0/1) (<xref rid="t6" ref-type="table">Table 6</xref>).178,179 Mild
to moderate adverse events occurred in the analysis during a period of 36
weeks. When compared to adalimumab, guselkumab (100mg) was superior to
adalimumab (80 and 40mg) in the PGA and PASI 90 response.</p><table-wrap id="t6" orientation="portrait" position="float"><label>Table 6</label><caption><p>Evaluation of guselkumab expressed by the benefit estimated in
percentage</p></caption><table frame="hsides" rules="groups" style="background-color:#edf5f4"><colgroup span="1"><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Author</th><th align="center" rowspan="1" colspan="1">Dose</th><th align="center" rowspan="1" colspan="1">Time of follow-up</th><th align="center" rowspan="1" colspan="1">PASI 75 (%)</th><th align="center" rowspan="1" colspan="1">PASI 90 (%)</th><th align="center" rowspan="1" colspan="1">PGA (%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>Ohtsuki M (178)</bold></td><td align="center" rowspan="1" colspan="1">50mg</td><td align="center" rowspan="1" colspan="1">16 weeks</td><td align="center" rowspan="1" colspan="1">89.2</td><td align="center" rowspan="1" colspan="1">70.8</td><td align="center" rowspan="1" colspan="1">92.3</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Ohtsuki M (178)</bold></td><td align="center" rowspan="1" colspan="1">100mg</td><td align="center" rowspan="1" colspan="1">16 weeks</td><td align="center" rowspan="1" colspan="1">84.1</td><td align="center" rowspan="1" colspan="1">69.8</td><td align="center" rowspan="1" colspan="1">88.9</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Blauvelt A (179)</bold></td><td align="center" rowspan="1" colspan="1">100mg</td><td align="center" rowspan="1" colspan="1">16 weeks</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">73.3</td><td align="center" rowspan="1" colspan="1">85.1</td></tr></tbody></table></table-wrap></sec></sec><sec><title>6.7 What is the efficacy and risk of ixekizumab for the treatment of
psoriasis?</title><sec><title>Recommendations:</title><p>the studies performed for the evaluation of the efficacy and safety of
ixekizumab for the treatment of moderate to severe plaque psoriasis showed
improvement evidenced by the PASI 75 (90-93.4%), PASI 90 (79.7%), PASI 100
(56.3%) and PGA (57-81.9%) responses (<xref rid="t7" ref-type="table">Table
7</xref>).<sup><xref rid="r180" ref-type="bibr">180</xref>,<xref rid="r181" ref-type="bibr">181</xref></sup> When compared to
etanercept, the results of ixekizumab used in doses every two or four weeks
were significantly better for the outcomes PASI 75, PASI 90, PASI 100 and
PGA 0/1. Mild to moderate adverse events were observed in the analysis of a
period of 96 weeks, that did not require discontinuation of treatment.</p><table-wrap id="t7" orientation="portrait" position="float"><label>Table 7</label><caption><p>Evaluation of ixequizumab expressed by the benefit estimated in
percentage</p></caption><table frame="hsides" rules="groups" style="background-color:#edf5f4"><colgroup span="1"><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Author</th><th align="center" rowspan="1" colspan="1">Dose (mg)</th><th align="center" rowspan="1" colspan="1">Time of follow-up</th><th align="center" rowspan="1" colspan="1">PASI 75 (%)</th><th align="center" rowspan="1" colspan="1">PASI 90 (%)</th><th align="center" rowspan="1" colspan="1">PASI 100 (%)</th><th align="center" rowspan="1" colspan="1">PGA (%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>Blauvelt A (180)</bold></td><td align="center" rowspan="2" colspan="1">80 every 4 weeks</td><td align="center" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">93.4</td><td align="center" rowspan="1" colspan="1">79.7</td><td align="center" rowspan="1" colspan="1">56.3</td><td align="center" rowspan="1" colspan="1">57.0</td></tr><tr><td rowspan="1" colspan="1"><bold>Leonardi C (181)</bold></td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Blauvelt A (180)</bold></td><td align="center" rowspan="2" colspan="1">80 every 2 weeks</td><td align="center" rowspan="1" colspan="1">60 weeks</td><td align="center" rowspan="1" colspan="1">90</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">81.9</td></tr><tr><td rowspan="1" colspan="1"><bold>Leonardi C (181)</bold></td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td><td rowspan="1" colspan="1">&#160;</td></tr></tbody></table></table-wrap></sec></sec><sec><title>6.8 What is the efficacy and risk of secukinumab for the treatment of
psoriasis?</title><sec><title>Recommendations:</title><p>the studies conducted in the evaluation of the efficacy and safety of
secukinumab for moderate to severe plaque psoriasis showed improvement
evaluated by the PASI 75 response (77.1-81.6% for 300mg and 67.0-71.6% for
150mg) and PGA 0 or 1, and maintenance of quality of life (DLQI) with the
use for up to three years, with the best results achieved with the weekly
dose of 300 mg in the first four weeks of treatment, followed by 300mg every
four weeks (<xref rid="t8" ref-type="table">Table 8</xref>).<sup><xref rid="r159" ref-type="bibr">159</xref>,<xref rid="r182" ref-type="bibr">182</xref></sup> It was superior when compared to
etanercept, evidenced by better results in the response rates for PASI 90
and PASI 100 in 12 weeks (54.2% vs. 20.7% and 24.1 vs. 4.3%,
respectively).</p><table-wrap id="t8" orientation="portrait" position="float"><label>Table 8</label><caption><p>Evaluation of secukinumab expressed by the benefit estimated in
percentage</p></caption><table frame="hsides" rules="groups" style="background-color:#edf5f4"><colgroup span="1"><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Author</th><th align="center" rowspan="1" colspan="1">Dose (mg)</th><th align="center" rowspan="1" colspan="1">Time of follow-up</th><th align="center" rowspan="1" colspan="1">PASI 75 (%)</th><th align="center" rowspan="1" colspan="1">PASI 90 (%)</th><th align="center" rowspan="1" colspan="1">PASI 100 (%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>Bissonnette R (182)</bold></td><td align="center" rowspan="1" colspan="1">300/ 150</td><td align="center" rowspan="1" colspan="1">3 years</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">63.8</td><td align="center" rowspan="1" colspan="1">42.6</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Langley RG (159)</bold></td><td align="center" rowspan="1" colspan="1">300</td><td align="center" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">81.6</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">&#160;</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Langley RG (159)</bold></td><td align="center" rowspan="1" colspan="1">150</td><td align="center" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">71.6</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">&#160;</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Langley RG (159)</bold></td><td align="center" rowspan="1" colspan="1">300</td><td align="center" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">77.1</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">&#160;</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Langley RG (159)</bold></td><td align="center" rowspan="1" colspan="1">150</td><td align="center" rowspan="1" colspan="1">12 weeks</td><td align="center" rowspan="1" colspan="1">67.0</td><td align="center" rowspan="1" colspan="1">&#160;</td><td align="center" rowspan="1" colspan="1">&#160;</td></tr></tbody></table></table-wrap></sec></sec><sec><title>6.9 Is there a difference of safety and efficacy between immunobiologic
treatments?</title><p>In the comparison between ustekinumab (UST) and etanercept, there was a
significant improvement for PASI 75 for the use of UST 45mg in relation to
etanercept in 10.7% (CI95% 2.4 to 19, p=0.001, NNT=10) and for the use of UST
90mg in relation to etanercept in 17% (CI95% 10 to 24, p&lt;0.001, NNT=6). For
PASI 90, the benefit was of 13.3% for UST 45mg in relation to etanercept (CI95%
5.8 to 20.7, p&lt;0.001, NNT=8) and of 21.6% for the use of UST 90mg in relation
to etanercept (CI95% 14.6 to 28.5, p&lt;0.001, NNT=5). In the evaluation with
PGA score regarding resolution of the lesions, the benefit was of 16.1% for UST
45mg in relation to etanercept (CI95% 7.6 to 24.2, p&lt;0.001, NNT=7) and of
21.6% for the use of UST 90mg in relation to etanercept (CI95% 14.4 to 28.6,
p&lt;0.001, NNT=5) <bold>(A)</bold>.<sup><xref rid="r183" ref-type="bibr">183</xref></sup></p><p>In a comparative study with certolizumab pegol, CZP 400 mg was superior (NNT=19,
p&lt;0.0001) on week 12 to etanercept for the PASI 75 response rate. (184)
<bold>(A)</bold>.</p><p>Evaluating the response measured with PGA and PASI90, guselkumab was superior to
adalimumab in PGA 0/1 (NNT=6, p&lt;0.001) and PASI 90 (NNT=5, p&lt;0.001) on
week 16 (85.1% vs 65.9% and 73.3% vs 49.7%); on week 24 (84.2% vs 61.7% (NNT=5,
p&lt;0.001) and 80.2% vs 53.0% (NNT=4, p&lt;0.001)) and on week 48 (80.5% vs
55.4% (NNT=4, p&lt;0.001) and 76.3% vs 47.9% (NNT=4, p&lt;0.001)). The rates of
adverse events were similar between treatments <bold>(A)</bold>.<sup><xref rid="r179" ref-type="bibr">179</xref></sup></p><p>When compared to etanercept 100mg/week, ixekizumab 160 mg at week 0 followed by
80 mg every two weeks for 12 weeks, demonstrated superior PASI 75, 90 and 100
response rates (41.6% vs. 89.7%, 18.7% vs. 70.7% and 5.3% vs. 40.5%-
p&lt;0.0001).<sup><xref rid="r180" ref-type="bibr">180</xref></sup></p><p>In a study comparing two doses of brodalumab and ustekinumab, PASI 90 response
rates on week 12 were significantly higher with 210mg brodalumab than with
ustekinumab (44% vs 22% [AMAGINE-2] and 37% vs 19% [AMAGINE-3], (NNT= 5 and
NNT=6, p&lt;0.001). PASI 100 response rates with brodalumab 140mg were 26% in
AMAGINE-2 (p=0.08 for the comparison with ustekinumab) and 27% in AMAGINE-3
(p=0.007) <bold>(A)</bold>.<sup><xref rid="r184" ref-type="bibr">184</xref></sup></p><p>Secukinumab 300mg on weeks 0, 1, 2, 3 and 4 and every four weeks thereafter also
demonstrated better PASI 75, 90 and 100 response rates when compared to
etanercept 100mg per week for 12 weeks (77.1% vs. 44%, 54.2% vs. 20.7% and 24.1%
vs. 4.3%, respectively) on week 12 (p&lt;0.001) <bold>(A)</bold>.<sup><xref rid="r185" ref-type="bibr">185</xref></sup></p><p>In a study that evaluated the difference between PASI 75 outcomes, comparing
briakinumab and etanercept in 12 weeks, the result was 41% superior for
briakinumab in relation to etanercept (p&lt;0.001, NNT=3)
<bold>(A)</bold>.<sup><xref rid="r173" ref-type="bibr">173</xref></sup></p><sec><title>Recommendations:</title><p>In the evaluation of immunobiologic drugs regarding PASI 75 score, similar
benefits were found with: etanercept, infliximab, adalimumab, ustekinumab,
guselkumab, ixekizumab, secukinumab. Guselkumab was superior to adalimumab
in IGA 0/1 and PASI 90.</p><p>There was a significant improvement for PASI 75 and in the evaluation with
PGA score for the use of ustekinumab in relation to etanercept. Results of
ixekizumab used in doses every two or four weeks were significantly better
for the outcomes PASI 75, 90, 100 and IGA 0/1 when compared to etanercept.
There was a significant improvement for PASI 75, 90 and 100, as well as for
PGA 0/1 for the use of secukinumab in relation to etanercept.</p><p>Even though not all drugs have studies assessing the PGA score, the best
results were with: ustekinumab, guselkumab, secukinumab and ixekizumab.</p></sec></sec><sec><title>6.10 Is there a difference of efficacy and risk when we compare the treatment
of psoriasis with the classic drugs (methotrexate, acitretin and cyclosporine)
and immunobiologics?</title><p>The study that compared the efficacy of adalimumab in relation to methotrexate
and placebo showed statistically significant superior therapeutic responses with
adalimumab, achieving PASI 75 response in 16 weeks in 79.6% of patients using
adalimumab, 35.5% of those using methotrexate and 18.9% of those using placebo
<bold>(A)</bold>.<sup><xref rid="r137" ref-type="bibr">137</xref></sup> In a
study comparing infliximab (n=653) with methotrexate (n=215), here was a
significantly better improvement in patients treated with infliximab (78% vs.
42%, p&lt;0.001, NNT=3) and the proportion of patients achieving PASI 90 was
significantly higher (p&lt;0.001) in patients in the infliximab group
<bold>(A)</bold>.<sup><xref rid="r186" ref-type="bibr">186</xref></sup></p><p>Sixty patients were included in a study, and of these 30 were using etanercept
50mg twice weekly and the other 30 patients were using acitretin 0.4mg/kg/day;
56.7% of the patients in the etanercept group and 26.7% of the patients in the
acitretin group showed PASI 75 response (p&lt;0.005, NNT=4)
<bold>(A).</bold><sup><xref rid="r187" ref-type="bibr">187</xref></sup></p><p>Regarding safety, the study comparing adalimumab with methotrexate showed similar
rates of adverse events among patients using methotrexate and adalimumab.
Regarding the study that compared etanercept with acitretin, safety data between
both groups were also very similar.</p><p>In the study that evaluated the efficacy and safety of infliximab and
methotrexate for the treatment of psoriasis, severe adverse events were reported
more frequently in the group using infliximab, encompassing severe infections
(tuberculosis, opportunistic infections such as P. carinii pneumonia,
listeriosis, atypical mycobacteria, histoplasmosis, salmonellosis and viral
infections) and infusion reactions <bold>(A)</bold>.<sup><xref rid="r186" ref-type="bibr">186</xref></sup></p><sec><title>Recommendations:</title><p>Immunobiologics are more effective in the treatment of moderate to severe
plaque psoriasis when compared to the classic treatment. Except for
infliximab, immunobiologics are safer and better tolerated when compared to
the classic drugs. Studies with infliximab showed higher risk of severe
infections and infusion reactions.</p></sec></sec><sec><title>6.11 Is there a difference in the efficacy of the treatment with
immunobiologics in patients with psoriasis that already used one or more
immunobiologics in comparison to those patients who never used an
immunobiologic?</title><p>In a publication presenting integrated data of efficacy results of 12 weeks of
two phase 3 studies, where patients were treated with ixekizumab 80mg every two
weeks (n=736), ixekizumab 80mg every four weeks (n=733) after initial 160mg
dose, or etanercept 50mg twice weekly, patients with and without previous use of
immunobiologic were included. Of the total of patients evaluated, 497 (19.3%)
had been previously exposed to immunobiologics. In patients being treated with
ixekizumab, PASI 75 response rates were very similar among patients with
previous use of immunobiologics (91.5%) and with no previous use of
immunobiologics (87.7%). For patients being treated with etanercept, PASI 75
response rates were superior in the group that did not previously use
immunobiologics (50.7%) when compared to those that has used immunobiologics
previously (34.6%) <bold>(B)</bold>.<sup><xref rid="r188" ref-type="bibr">188</xref></sup></p><p>A study evaluated the efficacy of adalimumab in 30 patients with moderate to
severe plaque psoriasis with primary or secondary treatment failure
(PASI&lt;50), or intolerance to etanercept. In relation to PASI scores prior to
commencement of etanercept, PASI 75 response was obtained in 27% (NNT=4), 36%
(NNT=3) of patients on weeks 12 and 24, respectively, of treatment with
adalimumab. These response rates are similar to those presented by patients who
responded to etanercept. The total rate of adverse events per year with
etanercept was of 3.41% compared to 3.18% in patients treated with adalimumab.
The most frequent events were infections, mainly respiratory, muscular, joint,
gastrointestinal complaints, and dermatological abnormalities. The efficacy of
treatment with adalimumab was not influenced by previous failure to etanercept
<bold>(B)</bold>.<sup><xref rid="r189" ref-type="bibr">189</xref></sup></p><p>Sixty-nine treated with adalimumab were evaluated, which have already had
previous treatment with other immunobiologics and/or TNF-alpha blockers
(etanercept, efalizumab, alefacept, infliximab or ustekinumab). The comparison
was with 16 patients using adalimumab as the first immunobiologic treatment. In
relation to the original baseline (beginning of the study), the difference to
PASI 75 in the evaluation at 12 weeks was of 27% favoring the group that used
immunobiologics for the first time (NNT=4, p=0.004). There was no significant
difference between the comparison groups for PASI 75 response rate in the
evaluation at 24 and 48 weeks. Of all patients in the study, 19% presented
adverse events, and only 29% of these were possibly or probably related to the
drug being investigated <bold>(B)</bold>.<sup><xref rid="r190" ref-type="bibr">190</xref></sup></p><p>The evaluation of 282 patients using adalimumab which had not used TNF-alpha
blocker previously, was compared to 448 patients on adalimumab, with previous
use of TNF-alpha blockers. In the evaluation at 16 weeks, there was a 22.7%
difference for PASI 75 favoring patients who had not been previously treated
with TN-F-alpha blockers, compared to the group of patients that had been
previously treated with two or more TNF-alpha blockers (NNT=5, p=0.016). the
adverse events were similar in both groups, with the presence of infections
being the most common <bold>(A)</bold>.<sup><xref rid="r191" ref-type="bibr">191</xref></sup></p><p>Another study had 26 patients on etanercept as the intervention group, after
treatment failure with a previous immunobiologic drug; and comparison with 98
patients on etanercept as the first immunobiologic drug. After 12 weeks of
follow-up, that patients that were not previously treated with immunobiologic
had a gain of 11% (NNT=9) for PASI 50 and 12.9% (NNT=8) for PASI 75; after 24
weeks of follow-up, the patients with no previous treatment with immunobiologics
kept the 20.3% gain (NNT=5) for PASI 50 and 10.1% (NNT=10) for PASI 75. All
evaluations at 12 and 24 weeks were significant when the comparison was
performed according to baseline (p&lt;0.001), but there was no statistically
significant difference in the evaluation of the results between weeks 12 versus
week 24. The adverse events reported were injection site reactions (n=11),
asthenia (n=9), cystitis (n=6), headache (n=5), labial herpes (n=3), pharyngitis
(n=2), and otitis (n=1). None of these reactions required discontinuation of
treatment <bold>(B)</bold>.<sup><xref rid="r192" ref-type="bibr">192</xref></sup></p><sec><title>Recommendations:</title><p>In the efficacy evaluations at treatment weeks 12 and 16, adalimumab showed
better response rates for the patients who were not previously treated with
other immunobiologic drugs or tumor necrosis factor blockers; however, in
the evaluations at 24 and 48 weeks this benefit was not observed.</p><p>In the efficacy evaluations at treatment weeks 12 and 24, etanercept 50mg
demonstrated better response rates in patients that did not receive previous
treatment with immunobiologics.</p><p>Regarding ixekizumab, there was no difference between those previously
treated with other immunobiologics and those not.</p></sec></sec></sec><sec><title>7 - COMBINED TREATMENT</title><p>With the aim of establishing the recommendations on the combined treatment of plaque
psoriasis with different drugs (immunobiologics, phototherapy and drugs from the
classic regimen - Acitretin, Methotrexate and Cyclosporine), a search was carried
out using Medline-PubMed database and 24 studies were selected to answer the
clinical questions.<sup><xref rid="r118" ref-type="bibr">118</xref>,<xref rid="r119" ref-type="bibr">119</xref>,<xref rid="r187" ref-type="bibr">187</xref>-<xref rid="r208" ref-type="bibr">208</xref></sup></p><sec><title>7.1 What are the advantages and disadvantages of the combined treatment
between drugs of the classic regimen (acitretin, methotrexate and cyclosporine)
when compared to isolated treatments?</title><p>Thirty-nine male patients with plaque psoriasis, randomly allocated into control
group (n=10), acitretin (n=11), methotrexate (n=9) and combination methotrexate
+ acitretin (n=9) were evaluated. The patients were treated for four weeks, with
the following doses: Acitretin 20mg/day; and methotrexate 7.5mg/week on the
first week, followed by 25mg/week. The combination group had better responses
(PASI and DLQI) than the acitretin and methotrexate and lower DLQI than the
acitretin group (p&lt;0.05). PASI 50 and PASI 75 responses were also calculated,
showing that the combination group had more patients achieving PASI 50 than the
other groups. The patients tolerated well the use of both medications in
combinations, in the usual doses <bold>(B)</bold>.<sup><xref rid="r193" ref-type="bibr">193</xref></sup></p><p>In a retrospective study, 18 patients receiving combined treatment (methotrexate
+ cyclosporine) were evaluated. The doses of cyclosporine used ranged from 150
to 250mg/day, with the initial dose of 3mg/kg/day. Methotrexate doses ranged
from 7.5 to 22.5 mg/week. Of the total 18 patients, 14 had a short-term
treatment (3 months) and 4 patients had long-term treatment (mean duration 284.5
&#177; 93.2 days). Twelve patients from the group receiving short-term
combined treatment and all patients receiving combined treatment for longer than
three months achieved PASI 50 response. PASI 75 response was achieved in five
patients in the short-term group and one patient in the long-term group. Nine
patients from the first group and all patients from the second group had adverse
events, being the main ones increase in creatinine levels, hypertension,
hypertriglyceridemia, depression and raised transaminases. The most common
adverse event was increased levels of creatinine (higher than 30%), observed in
eight patients (57%) <bold>(B)</bold>.<sup><xref rid="r203" ref-type="bibr">203</xref></sup></p><p>Twenty patients received combined treatment with intramuscular methotrexate 10 mg
per week associated to cyclosporine 3.5 mg/kg/day, divided into two doses. The
mean combined treatment was 9.5 weeks and median PASI reduction was of 77.4%
(ranging from 51.2 to 90.2) (p&lt;0.001). Fourteen patients had some kind of
adverse event, being gastrointestinal and renal and hepatic abnormalities the
most common <bold>(B)</bold>.<sup><xref rid="r195" ref-type="bibr">195</xref></sup></p><sec><title>Recommendations:</title><p>Although the treatment combination (methotrexate + cyclosporine and
methotrexate + acitretin) show superior efficacy data when compared to
efficacy data as monotherapy, the lack of studies proving the safety of
these associations limit the recommendations for their use in the management
of patients with moderate to severe plaque psoriasis.</p></sec></sec><sec><title>7.2 What are the advantages and disadvantages of the combined treatment with
phototherapy and drugs from the classic regimen (acitretin, methotrexate and
cyclosporine) when compared to the isolated treatments?</title><p>One-hundred and twenty patients with plaque psoriasis, allocated into three
groups, were evaluated: group 1 with 38 patients receiving the combination of
NB-UVB phototherapy associated to methotrexate in the dose of 0.2mg/kg per week,
with a maximum of 20mg per week; group 2 with 38 patients receiving NB-UVB
phototherapy alone and group 3 with 37 patients receiving methotrexate alone. A
minimum 90% clearance of the lesions was observed in 94.74% of the patients in
the group using the combination of treatments, in 92.11% of the patients using
phototherapy alone and in 89.19% of the patients receiving methotrexate alone,
with no significant difference between the three groups (p=0.674). However, the
mean number of weeks to achieve clearance was significantly lower in the
combined treatment group (6.11 weeks vs. 11.42 weeks vs. 20.87 weeks,
p&lt;0.0001). Also, there was no significant difference between the groups for
relapse during follow-up period and for the adverse events described
<bold>(A)</bold>.119</p><p>In another study, the efficacy of combined treatment (NB-UVB + oral methotrexate)
was compared to NB-UVB phototherapy alone. PASI 75 response was observed in 95%
of patients with the combined treatment and in 70% of the phototherapy treatment
only (NNT=4, p&lt;0.04). The mean number of weeks (p=0.001), the mean cumulative
dose of NB-UVB (p=0.001) and the number of phototherapy treatments (p=0.0001) to
achieve PASI 75 were significantly lower in the combined treatment group in
relation to phototherapy alone <bold>(A)</bold>.<sup><xref rid="r202" ref-type="bibr">202</xref></sup></p><p>In another study including 24 patients, the efficacy of phototherapy (NB-UVB)
associated to methotrexate 15mg/week was compared to phototherapy (NB-UVB)
associated to placebo. Best results were observed in the combination group of
phototherapy + methotrexate, and the difference of the median PASI score
reduction between both groups was 5.6 (p=0.013). The number of adverse events in
both comparison groups did not change from four cases of mild erythema, two in
each group, and generalized hyperpigmentation in all patients
<bold>(A).</bold><sup><xref rid="r194" ref-type="bibr">194</xref></sup></p><p>Another study evaluated the efficacy of the combination of UVB phototherapy +
acitretin, compared to the monotherapy with UVB phototherapy and monotherapy
with acitretin. Patients were allocated into three groups: 16 patients receiving
acitretin 50 mg per day associated to ultraviolet B (UVB), 18 patients receiving
UVB only and 16 patients receiving acitretin only. The patients with the
combined treatment of acitretin associated to UVB showed superior response rates
in comparison to the groups receiving single treatment. There was no significant
difference between the adverse events of the three comparative groups
<bold>(A)</bold>.<sup><xref rid="r201" ref-type="bibr">201</xref></sup></p><p>The association of PUVA + acitretin versus PUVA alone was evaluated in 60
patients with severe psoriasis. Patients were allocated into two groups, with 30
patients using acitretin 1mg/kg/day associated to PUVA and 30 treated with PUVA
alone. Complete or almost complete improvement (minimum 90% clearance of
lesions) occurred in 96% patients in the group receiving combined treatment and
in 80% of those treated with PUVA (NNT=7). The most frequent adverse events in
both comparison groups were cheilitis, dryness of mucous membranes of the nose
and mouth, conjunctivitis, scaling, asteatosis, pruritus and hair loss
<bold>(A)</bold>.<sup><xref rid="r206" ref-type="bibr">206</xref></sup></p><p>Authors studied nine patients being treated with UVB phototherapy and low dose of
acitretin (0.34 to 0.44mg/kg), comparing with 32 patients treated with UVB
phototherapy alone. Clearance of lesions occurred significantly more in patients
under combined treatment compared to patients using only UVB (89% vs. 62.5%,
NNT=4) <bold>(A)</bold>.<sup><xref rid="r200" ref-type="bibr">200</xref></sup></p><sec><title>Recommendations:</title><p>The combination of phototherapy (UVB and PUVA) with classic systemic
treatments showed higher efficacy than the respective treatments separately,
according to evaluation of both PGA 0 or 1 response and PASI 75
response.</p></sec></sec><sec><title>7.3 What are the advantages and disadvantages of the combined treatment with
phototherapy and immunobiologics when compared to those treatments
separately?</title><p>In the first phase of the study (8 weeks), 322 patients were treated with
phototherapy as the first line treatment option. After eight weeks of
phototherapy, patients who did not achieve PASI 75 response joined the second
phase of the study, and were treated with conventional systemic therapies or
etanercept 50mg twice weekly. After the end of the second phase of the study,
those who did not achieve PASI 75 in 12 weeks, joined the third phase of the
study, where NB-UVB phototherapy was added. After finishing the first phase of
the study, PASI 75 response was obtained in 262 patients (81.4%) treated with
NB-UVB phototherapy. In the second phase of the study, 24 patients (7.5%) were
treated with at least one of the conventional systemic treatments for psoriasis
and 20 patients (6.2%) were treated with etanercept. Of the patients who were
treated with etanercept in the second phase of the study, eight (2.5%) joined
the third phase of the study and NB-UVB was associated. All these patients
achieved PASI 75 and three of them had complete remission after 14.6&#177;3.3
NV-UVB exposures. Combination treatment was well tolerated, with no acute
adverse events <bold>(B)</bold>.<sup><xref rid="r196" ref-type="bibr">196</xref></sup></p><p>In a 2-phase study, 30 patients were treated with etanercept 50mg once weekly for
12 weeks in the first phase. In the second phase of the study (weeks 12 to 24),
patients were randomized into two groups: one group received etanercept alone,
and the other group etanercept associated to NB-UVB phototherapy three times per
week. At the end of the first phase, 48% of all patients studied achieved PASI
75 response, 41.7% of them with BMI above 35. On week 24, PASI 75 response rates
were similar in the etanercept group and combination etanercept + phototherapy
(46.7% vs. 53.3%, respectively) <bold>(A)</bold>.<sup><xref rid="r205" ref-type="bibr">205</xref></sup></p><p>Seventy-five plaque psoriasis patients who did not achieve PASI 90 response in 12
weeks of treatment with etanercept 50mg twice weekly were assessed. These
patients were randomized into two groups: 37 patients treated with NB-UVB
phototherapy three times per week for at least four weeks associated to
etanercept, and 38 patients using only etanercept in the comparison group. On
week 24, PASI 90 was achieved by 16.2% of patients with combined treatment of
etanercept and NB-UVB, in comparison with 15.8% of patients who received
monotherapy with etanercept (there was no statistically significant difference;
p=1.000). On week 16, the proportion of patients that achieved PASI 90 was 39.5%
more in the group with combined treatment (p=0.018). There was no significant
difference for treatment safety between the comparison groups
<bold>(A)</bold>.<sup><xref rid="r119" ref-type="bibr">119</xref></sup></p><p>In another study, 10 patients treated with ustekinumab 45 mg or 90 mg (dose
standardized according to the weight), subcutaneous on weeks 0 and 4, were
treated with NB-UVB on one half of the body, three times a week for six weeks.
The end point was to compare PASI response of the half of the body that received
phototherapy to the half of the body that did not. On week six, PASI 75 was
achieved in 78% of those treated with the combined treatment and in 11% of those
receiving monotherapy (NNT=2, p=0.007). On week 12, the synergistic effect of
phototherapy did not show a significant difference <bold>(A</bold>).<sup><xref rid="r207" ref-type="bibr">207</xref></sup></p><sec><title>Recommendations:</title><p>In the comparison of etanercept as monotherapy or associated to NB-UVB
phototherapy, there was no difference for PASI 75 or PASI 90 in the
evaluation at 24 weeks. However, in the evaluation at 12 and 16 weeks after
starting the treatment, there are controversies regarding the benefit of the
combined treatment for PASI 90.</p><p>With ustekinumab, the association with UVB phototherapy speed up the process
of improvement of the lesions on week 6, with a difference of PASI 75 in 67%
for the half of the body receiving the combined therapy (NNT=2), in relation
to the half of the body that was treated with the immunobiologic alone.</p></sec></sec><sec><title>7.4 What are the advantages and disadvantages of the combined treatment with
drugs from the classic regimen and immunobiologics when compared to their use
separately?</title><p>In a randomized, double-blind study, 60 patients were randomized into three
treatment groups: (a) etanercept 50mg twice weekly every week for 12 weeks,
followed by etanercept 25mg twice weekly every week for 12 more weeks (ETN-ETN);
(b) etanercept 25 mg twice weekly every week and acitretin 20 mg/day for 24
weeks (ETN-ACT); (c) acitretin 20mg/day for 24 weeks. The proportions of
patients with PASI 75, PASI 50 and PGA 0 or 1 on week 24 in the groups ETN-ETN
(52.4, 71.4 and 52.4%, respectively) and ETN-ACT (57.9, 84.2 and 52.6%,
respectively) were higher than in the ACT group (22.2; 44.4; and 16.7%,
respectively).the incidence of adverse events was similar in all three groups
<bold>(A)</bold>.<sup><xref rid="r187" ref-type="bibr">187</xref></sup></p><p>In a study, 478 patients with moderate to severe plaque psoriasis with normal
liver and hematologic functions were included. All patients were treated with
etanercept 50mg, subcutaneously, twice weekly for 12 weeks, followed by 50mg per
week. In the intervention group (n=239), weekly oral methotrexate, in doses of
7.5 mg to 15 mg was added from week 12 to 24. In the comparison group, all
patients received etanercept associated to placebo only after the 12th week
(n=211). On week 24, there was a 17% difference in PASI 75 response, favoring
patients treated with the combined therapy (NNT=6, p&lt;0.0001); for PASI 50,
the difference was of 7% (NNT=15, p=0.01) favoring the group of combined
therapy, and for PASI 90, the difference was of 19.6% (NNT=6, p=0.01), also
favoring the group receiving the combined therapy. of the patients, 74.9% of the
combined therapy group and 59.8% of the monotherapy group had adverse events.
The most common events were nasopharyngitis, headache, upper respiratory tract
infection and nausea <bold>(A)</bold>.<sup><xref rid="r199" ref-type="bibr">199</xref></sup></p><p>In a double-blind, randomized study, 60 patients with moderate to severe plaque
psoriasis allocated into three groups were evaluated: group 1 with 22 patients
receiving etanercept 25mg, twice weekly, subcutaneously; group 2 with 20
patients using acitretin 0.4mg/kg/day, orally; group 3 with 18 patients using
etanercept 25mg per week, associated to acitretin 0.4mg/kg/day. On week 24,
45%of the patients in group 1, 30% of patients in group 2 and 44% of patients in
group 3 achieved PASI 75 (p=0.001 for both groups receiving etanercept in
comparison to the patients who were treated with acitretina only). There was no
significant difference regarding the variation of the mean values of ALT, AST,
cholesterol and triglycerides between the three groups
<bold>(A)</bold>.<sup><xref rid="r198" ref-type="bibr">198</xref></sup></p><p>In another study, with 24 weeks duration, patients with partial response to
methotrexate (at least three months of treatment) were included and allocated
into two groups: the first group (n=28) received etanercept for 24 weeks
associated to a short course of oral methotrexate (four weeks); and the second
group (n=31) received subcutaneous etanercept and continuous oral methotrexate
for 24 weeks. Etanercept was administered subcutaneously, in the dose of 50mg
twice weekly every week for 12 weeks, followed by 25 mg twice weekly for another
12 weeks. PGA 0 or 1 response was superior in the group using methotrexate
continuously (66.7 vs 37.0%, respectively) (NNT=4, p=0.025). Both comparison
groups showed PASI improvement compared to baseline. However, the difference was
significant for PASI 75 on week 24 (p=0.013) in the group receiving etanercept
associated to continuous methotrexate and there was no significant reduction for
PASI 90 (p=0.077). regarding adverse events, there was no difference between the
comparison groups, with the most common events being infections, pustular
psoriasis on the hands, pneumonia, heart failure/atrial fibrillation
<bold>(A)</bold>.<sup><xref rid="r208" ref-type="bibr">208</xref></sup></p><sec><title>Recommendations:</title><p>In the evaluation of the use of etanercept as monotherapy compared to the
immunobiologic associated to methotrexate or acitretin, there was
improvement to PASI 75 on week 24 in patients treated with the association.
Adverse events were reported in 74.9% of the patients receiving combined
therapy and in 59.8% of the patients receiving monotherapy with
immunobiologic or the classic treatment.</p></sec></sec></sec><sec><title>8. TREATMENT OF PREGNANT AND BREASTFEEDING WOMEN</title><p>Psoriasis is a chronic inflammatory condition that is more frequent in adults and the
need for therapeutic intervention in women of child-bearing age is common. With the
aim of establishing the recommendations for the treatment of plaque psoriasis in
pregnant or breastfeeding women, a search was carried out using Medline-PubMed
database, retrieving 324 studies, out of which 43 were selected to answer the
clinical questions.<sup><xref rid="r209" ref-type="bibr">209</xref>-<xref rid="r251" ref-type="bibr">251</xref></sup></p><sec><title>8.1 Treatment of plaque psoriasis in pregnant women</title><sec><title>8.1.1 Topical Corticosteroids</title><p>The safety of topical glucocorticoids varies according to the strength of the
agent and the specific vehicle used. Current evidence suggests that
mild/moderate topical corticosteroids are preferred during pregnancy. The
risk of high potency applied in large areas of the body surface approach
those seen with systemic steroids due to the increased potential of systemic
absorption <bold>(D)</bold>.<sup><xref rid="r247" ref-type="bibr">247</xref></sup></p><p>It was also observed in one study that the use of low and medium potency did
not show significant increase of the risk of fetal growth restriction, on
the other hand, those of high and very high potency showed increase of the
risk (RR 2.08; 95% CI 1.40-3.10; p&lt;0.001, NNH=168). There was no
association between maternal exposure to topical corticosteroids of all
potencies and increased risk of fetal death, premature labor or fetal
malformations <bold>(B)</bold>.<sup><xref rid="r216" ref-type="bibr">216</xref></sup></p></sec><sec><title>8.1.2 Calcineurin inhibitors (Tacrolimus)</title><p>Authors found an association with prematurity and low birth weight. When used
topically, calcineurin inhibitors are weakly absorbed systemically (242)
(D). Their use is allowed in small areas when there is no other alternative,
due to the lack of studies on safety during pregnancy
<bold>(B)</bold>.<sup><xref rid="r241" ref-type="bibr">241</xref></sup></p></sec><sec><title>8.1.3 Vitamin D analogues (Calcipotriol)</title><p>Calcipotriol or calcipotriene, vitamin D analogue, when applied in small
areas and doses &lt; 10,000 IU/day has a small risk of systemic absorption
(D).<sup><xref rid="r210" ref-type="bibr">210</xref></sup> There are
no studies conducted on pregnant women (B).<sup><xref rid="r223" ref-type="bibr">223</xref></sup></p><p>In animal studies, calcipotriol resulted in a higher incidence of skeletal
abnormalities, including incomplete ossification of the pubic bones and
anterior phalanges <bold>(D)</bold>.<sup><xref rid="r211" ref-type="bibr">211</xref>,<xref rid="r234" ref-type="bibr">234</xref></sup></p><p>When there are no alternatives, the topical use of calcipotriol on small
surfaces is allowed, but it should be avoided under occlusive dressings,
avoiding systemic absorption and reducing the risk of toxicity
<bold>(D)</bold>.<sup><xref rid="r247" ref-type="bibr">247</xref></sup></p></sec><sec><title>8.1.4 Topical retinoids (adapalene, tretinoin and tazarotene)</title><p>Some topical retinoids, such as adapalene and tretinoin, are categorized into
pregnancy category C according to the FDA&#8217;s classification, due to the risk
of teratogenesis. On the other hand, tazarotene is currently labeled as
pregnancy category X, and is totally contraindicated in pregnant women due
to the risk of teratogenesis. Its risk is enhanced by the fact that it is
applied on large areas of the body surface in cases of moderate to severe
psoriasis, therefore increasing its systemic absorption. Topical tazarotene
should be avoided in pregnant women (D).<sup><xref rid="r227" ref-type="bibr">227</xref></sup></p></sec><sec><title>8.1.5 Salicylates</title><p>There are many concerns regarding the use of topical salicylates during
pregnancy. When combined to other drugs, particularly topical
corticosteroids, salicylic acid increases percutaneous absorption of other
agents. There is also a concern with the systemic absorption of the
salicylic acid itself applied topically, in concentrations ranging from 9%
to 25%. Some cases of acute systemic toxicity by salicylates after topical
use have been reported, usually with the prolonged use on extensive body
surfaces and/or the use of occlusive dressings <bold>(D)</bold>.<sup><xref rid="r227" ref-type="bibr">227</xref></sup></p></sec><sec><title>8.1.6 Tar Derivatives</title><p>A retrospective study evaluated 23 pregnant women who used coal tar during
pregnancy and no increase in the risk of mal-formations was observed, when
compared to population data (B).<sup><xref rid="r220" ref-type="bibr">220</xref></sup></p><p>Even though there are animal studies demonstrating that the maternal exposure
to high doses resulted in perinatal mortality and increased risk of palate
fissures and pulmonary abnormalities in the offspring, literature on human
exposure did not reveal any effect (D).<sup><xref rid="r234" ref-type="bibr">234</xref></sup></p><p>The use of dithranol and coal tar is not recommended during pregnancy
<bold>(D)</bold>.<sup><xref rid="r247" ref-type="bibr">247</xref></sup></p></sec><sec><title>8.1.7 Methotrexate</title><p>Methotrexate was shown to be teratogenic and abortive during pregnancy. There
are evidences that methotrexate is found on the liver for up to four months
after exposure and a prospective review of nine cases of methotrexate
exposure prior to pregnancy showed that in four cases, where the exposure
took place within six months of the pregnancy, spontaneous abortions
occurred <bold>(D)</bold>.<sup><xref rid="r211" ref-type="bibr">211</xref>,<xref rid="r234" ref-type="bibr">234</xref>,<xref rid="r251" ref-type="bibr">251</xref></sup> There are reports of
spontaneous abortions after its use on the first trimester of pregnancy
<bold>(B)</bold>.<sup><xref rid="r231" ref-type="bibr">231</xref></sup></p><p>Multiple malformations (craniofacial, skeletal, cardiopulmonary and
gastrointestinal) were detected on the 18<sup>th</sup> week of gestation in
a patient who received the drug on the first week of gestation
<bold>(C)</bold>.<sup><xref rid="r219" ref-type="bibr">219</xref>,<xref rid="r236" ref-type="bibr">236</xref></sup></p></sec><sec><title>8.1.8 Acitretin</title><p>Acitretin, a synthetic derivative of vitamin A, was shown to be teratogenic
in animal studies, supporting it being absolutely contraindicated in
pregnant women <bold>(D).</bold><sup><xref rid="r224" ref-type="bibr">224</xref></sup></p><p>The teratogenic effects associated to retinoids and hypervitaminosis A
include craniofacial dysmorphia, hip malformations, meningomyelocele,
meningoencephalocele, multiple synostoses and limb abnormalities. There are
six known cases of fatal outcome after exposure to acitretin, including two
with malformations consistent with the teratogenic effects
<bold>(D),</bold><sup><xref rid="r251" ref-type="bibr">251</xref></sup>
<bold>(B)</bold>.<sup><xref rid="r214" ref-type="bibr">214</xref></sup></p><p>Since acitretin can be re-esterified into etretinate, that has a longer
elimination half-life (up to 150 weeks), it is necessary to ensure
contraception for at least two years after finishing treatment with
acitretin <bold>(D)</bold>,<sup><xref rid="r251" ref-type="bibr">251</xref></sup>
<bold>(B)</bold>.<sup><xref rid="r214" ref-type="bibr">214</xref></sup></p></sec><sec><title>8.1.9 Cyclosporine</title><p>The physiologic adaptations and clinical changes that occur in pregnant women
can affect cyclosporine absorption, distribution and clearance. Gastric
emptying and motility of the small intestine are reduced during pregnancy,
what can lead to a higher absorption time and a lower peak serum level of
cyclosporine. Therefore, it is paramount that its serum levels be monitored
more frequently and, when necessary, dose adjustments be made
<bold>(B)</bold>.<sup><xref rid="r238" ref-type="bibr">238</xref></sup>
High levels of cyclosporine in the placenta and/or umbilical cord blood were
found in many studies, with 6% of the maternal concentration of cyclosporine
reaching the fetus albeit no detection of the drug in the maternal or fetal
brain <bold>(B)</bold>.<sup><xref rid="r238" ref-type="bibr">238</xref></sup></p><p>A meta-analysis with 15 studies including 410 pregnant women who underwent a
transplant and were exposed to cyclosporine during gestation was conducted
to determine if exposure to cyclosporine during pregnancy is associated to
an increased risk of congenital malformations, premature labor or low birth
rate. The results suggest that the use of cyclosporine during pregnancy is
not teratogenic, but can be associated to premature labor and low birth
weight in children (2,500g) <bold>(B)</bold>,<sup><xref rid="r212" ref-type="bibr">212</xref></sup>
<bold>(D).</bold>
<sup><xref rid="r211" ref-type="bibr">211</xref></sup></p><p>Many studies indicate that a short course of cyclosporine (3 to 4 months),
with a low dose (less than 5 mg/kg/day), results in an 80-90% improvement in
psoriasis, demonstrating the efficacy of cyclosporine use during pregnancy
to control severe psoriasis. No incidence of maternal complications was
reported, although prematurity and/or low birth weight are common
<bold>(B)</bold>. <sup><xref rid="r238" ref-type="bibr">238</xref></sup></p></sec><sec><title>8.1.10 Phototherapy</title><p>Phototherapy, narrowband ultraviolet B (NB-UVB) and broadband ultraviolet V
(BB-UVB) are considered safe options during pregnancy
<bold>(D)</bold>.<sup><xref rid="r238" ref-type="bibr">238</xref></sup></p><p>The use of narrowband UVB seems to reduce the serum levels of folate, and can
increase the risks of neural tube defects in the fetus/ therefore, the
concurrent use of folic acid 5 mg/day is recommended
<bold>(B)</bold>.<sup><xref rid="r218" ref-type="bibr">218</xref></sup></p><p>In a prospective study that followed 159 pregnant women, psoralen + UVA
(PUVA) did not show an increase in the incidence of fetal malformations or
fetal deaths <bold>(B)</bold>.<sup><xref rid="r225" ref-type="bibr">225</xref>,<xref rid="r246" ref-type="bibr">246</xref></sup> Since
psoralen is a known mutagen and teratogen, avoidance of treatment with PUVA
during pregnancy is recommended <bold>(D)</bold>.<sup><xref rid="r234" ref-type="bibr">234</xref></sup></p></sec><sec><title>8.1.11 Immunobiologics</title><p>There are reports that the use of infliximab during pregnancy did not cause
abnormalities in fetal development <bold>(C)</bold>.<sup><xref rid="r245" ref-type="bibr">245</xref></sup></p><p>Adalimumab and infliximab are complete IgG1 antibodies, so its transplacental
transport is expected. An international, multicentric, prospective cohort
study of 80 pregnant women with inflammatory bowel disease (IBD) that
received adalimumab or infliximab, found an inverse correlation between the
time since the last exposure to the drug during pregnancy and the
concentration in the blood from the cord <bold>(B)</bold>.<sup><xref rid="r228" ref-type="bibr">228</xref></sup></p><p>A case report found a ratio of concentration of etanercept between maternal
blood and blood from the umbilical cord of 14:1 during delivery, in a woman
with ankylosing spondylitis receiving 25 mg subcutaneously once a week
during the second and third trimester, evidencing the low transplacental
transport <bold>(B)</bold>.<sup><xref rid="r228" ref-type="bibr">228</xref></sup> Anti-TNF-alpha transplacental transport seems not to
occur before the second trimester and, although it increases during the
third trimester, etanercept shows considerably less transport than other
anti-TNFs <bold>(B)</bold>.<sup><xref rid="r215" ref-type="bibr">215</xref></sup></p><p>Two ustekinumab studies on fetal development conducted in monkeys did not
reveal any evidence of maternal toxicity, embryotoxicity or teratogenicity.
There are very limited data on treatment safety, with only two case reports
in the literature, all with healthy infants. A report grouped 4-year data of
clinical trials with 31 pregnant women, with no incidences of fetal
malformations or death. The FDA attributed pregnancy category B to
ustekinumab, similar to anti-TNF-alpha; however, due to lack of evidences
proving its safety during pregnancy, its use is not recommended
<bold>(D)</bold>.<sup><xref rid="r211" ref-type="bibr">211</xref></sup></p><p>Animal studies with secukinumab, a monoclonal antibody against IL-17A, do not
show harmful effects regarding the pregnancy, embryonic/fetal development,
labor or post-natal development, including that of the immune system
<bold>(B)</bold>.<sup><xref rid="r249" ref-type="bibr">249</xref></sup></p><p>In a global safety database, the results of pregnancies where there was
maternal or paternal exposure to secukinumab were analyzed, and overall
rates of spontaneous abortion were 30/292 (10.3%), according to the rates
observed for the general population. Most of the spontaneous abortions
happened within 10 weeks of gestation and there were no stillbirths (&gt; 20
weeks&#8217; gestation). Of the 38 cases of exposure in patients with psoriatic
arthritis spontaneous abortions occurred in 7.9% and in 6.7% of 15 patients
with adverse events. Most patients discontinued the treatment in the first
trimester, knowing that secukinumab is transferred through the placenta in
the third trimester. There are no human data about the effect of secukinumab
in the immune system of newborns after in utero exposure
<bold>(B)</bold>.<sup><xref rid="r249" ref-type="bibr">249</xref></sup></p><p>Ixekizumab, a humanized monoclonal antibody (IgG4) that binds to IL-17A, has
very limited usage data in pregnant women. In the development toxicity
studies, ixekizumab crossed the placenta and was present in the blood up to
six months of age, but animal studies still do not indicate directly or
indirectly harmful effects regarding pregnancy, embryos, or fetal
development, labor or post-natal development <bold>(D)</bold>.<sup><xref rid="r239" ref-type="bibr">239</xref></sup></p></sec><sec><title>Recommendations:</title><p>There are evidences that the use of low and medium potency topical
corticosteroids are safe for the treatment of the pregnant woman with
psoriasis. There seems to be an association of very high potency topical
corticosteroids with low birth weight, and it should be avoided.</p><p>Since tazarotene has teratogenic potential, it is contraindicated during
pregnancy.</p><p>Tacrolimus used topically is very little absorbed, however, due to the lack
of safety studies in pregnant women, it is indicated to be used on small
areas when there is no other therapeutic alternative.</p><p>There are no studies with calcipotriol conducted in pregnant women, and it
should be avoided in this population.</p><p>The use of topical salicylates should be avoided in pregnant women due to the
risk of systemic absorption of the salicylate and subsequent fetal risk.</p><p>Ultraviolet B phototherapy is the systemic therapy with best evidence of
safety during pregnancy. PUVA phototherapy should be avoided during
pregnancy due to the teratogenic potential of psoralen.</p><p>Despite being classified as category C by the FDA (US - Food and Drug
Administration Agency), cyclosporine has good evidences of safety for use
during pregnancy.</p><p>Acitretin is absolutely contraindicated in pregnant women because of its
teratogenic potential, and effective contraception must be ensured during
its use and for at least two years after ceasing the drug.</p><p>Methotrexate is contraindicated during pregnancy because it is teratogenic
and abortive.</p><p>There are reports that the use of infliximab, etanercept and adalimumab do
not alter fetal development, being safe to the fetus when used during
pregnancy. Nonetheless, there are no sufficient data for recommending these
medications for the treatment of psoriasis in the pregnant woman, and
effective contraception is recommended during their use in women of
childbearing age.</p><p>There are very limited data on the safety of the treatment with ustekinumab,
secukinumab, ixekizumab and guselkumab during pregnancy, with not enough
data yet to recommend their use in pregnant women; effective contraception
is recommended during their use in women of childbearing age.</p></sec></sec><sec><title>8.2 Treatment of plaque psoriasis in breastfeeding women</title><sec><title>8.2.1 Topical Corticosteroids</title><p>The first line of treatment for breastfeeding mothers is limited to
emollients and low to medium potency topical corticosteroids
<bold>(D)</bold>.<sup><xref rid="r232" ref-type="bibr">232</xref></sup></p><p>Topical corticosteroids have been proven safe during breastfeeding
<bold>(C)</bold>.<sup><xref rid="r250" ref-type="bibr">250</xref></sup>
There is one report of hypertensive crisis in an infant after maternal use
of high potency topical corticosteroid <bold>(C)</bold>.<sup><xref rid="r244" ref-type="bibr">244</xref></sup></p></sec><sec><title>8.2.2 Calcipotriol</title><p>Regarding calcipotriol, a vitamin D analogue, it presents a low risk of
systemic absorption when used in small doses &lt; 10,000 IU/day, however,
there are no reports of its use during breastfeeding
<bold>(D)</bold>.<sup><xref rid="r223" ref-type="bibr">223</xref></sup></p></sec><sec><title>8.2.3 Tar Derivatives</title><p>Coal tar can be transferred to the infant during breastfeeding through
skin-to-skin or skin-to-mouth contact <bold>(C)</bold>.<sup><xref rid="r243" ref-type="bibr">243</xref></sup> Cases of detection of
tar derivatives in breast milk have been reported
<bold>(D)</bold>.<sup><xref rid="r232" ref-type="bibr">232</xref></sup></p></sec><sec><title>8.2.4 Phototherapy</title><p>Ultraviolet B (UVB) phototherapy is compatible with breastfeeding. Regarding
PUVA, topical psoralen has little systemic absorption, however, it is
unknown if it is absorbed into breast milk. PUVA phototherapy is
contraindicated during breastfeeding <bold>(B)</bold>.<sup><xref rid="r210" ref-type="bibr">210</xref></sup></p></sec><sec><title>8.2.5 Acitretin</title><p>Acitretin should be avoided during breastfeeding due to its cumulative toxic
effect. Breastfeeding infants are not capable of excreting the drug through
the kidneys or liver due to the immaturity of these organs; this would
increase the serum levels of the drug and it could reach toxic levels.</p><p>It was recently described that there are traces of acitretin (30-40 ng/ml)
excreted in the breast milk; this corresponds to a ratio of concentration
milk/serum of 0.18. the estimated dose for the infant is 1.5% of the
maternal dose. Acitretin is almost exclusively found in the fat component of
breast milk, thus, there are no reports of neonatal toxicity after exposure
to acitretin in breast milk; however, it should be avoided in breastfeeding
women. Recommendations are lacking regarding the time frame after finishing
treatment during which breastfeeding should be contraindicated
<bold>(B)</bold>.<sup><xref rid="r214" ref-type="bibr">214</xref></sup></p></sec><sec><title>8.2.6 Methotrexate</title><p>Methotrexate has reports of transference into breast milk in small
concentrations, and can be deposited in the child&#8217;s tissues for many months.
Due to the limited number of studies in breastfeeding women and analysis of
its long term effects in infants, its use is not recommended
<bold>(C)</bold>.<sup><xref rid="r229" ref-type="bibr">229</xref></sup></p><p>Two-hourly samples of breast milk from a patient treated with a first dose of
22.5mg of methotrexate for postpartum choriocarcinoma showed it was excreted
in small concentrations in the breast milk. The maximum level of
methotrexate measured in the breast milk was around 3% of the maximum
maternal serum level, with the higher ratio milk-serum of 0.08 at 10 hours
<bold>(D)</bold>.<sup><xref rid="r251" ref-type="bibr">251</xref></sup>
The meaning of these measures is uncertain due to limited reports, and its
use is contraindicated during breastfeeding <bold>(B)</bold>,<sup><xref rid="r210" ref-type="bibr">210</xref></sup>
<bold>(D)</bold>.<sup><xref rid="r226" ref-type="bibr">226</xref></sup></p></sec><sec><title>8.2.7 Cyclosporine</title><p>There are reports of infants, born from renal transplant recipients using
cyclosporine during breastfeeding, who did not develop renal toxicity or
other side effects, with undetectable levels of cyclosporine
<bold>(B)</bold>,<sup><xref rid="r237" ref-type="bibr">237</xref></sup>
even though other reports show cytotoxicity and suggest avoiding the drug
during breastfeeding <bold>(C)</bold>.<sup><xref rid="r221" ref-type="bibr">221</xref></sup></p><p>Data show that the use of calcineurin inhibitors such as cyclosporine during
pregnancy does not increase the risk of congenital defects in breastfeeding
infants. Besides, it is known that cyclosporine is excreted in breast milk
and the American Association of Pediatrics advises against breastfeeding
during the use of the drug. Of the 15 cumulative breastfeeding infants in
different reports, only one had detectable cyclosporine. The mother ceased
breastfeeding and the child was well and developing adequately in the last
follow-up. Although any immunosuppressing exposure to the baby can exceed
safety limits, the relatively small amount of the drug transferred and the
absence of reported adverse events, together with the documented benefits
from breastfeeding, can overcome theoretical risks of this exposure
<bold>(B)</bold>.<sup><xref rid="r238" ref-type="bibr">238</xref></sup></p></sec><sec><title>8.2.8 Immunobiologics</title><p>Data on the use of immunobiologic drugs are still scarce. The absorption of
maternal antibodies through breast milk in humans is limited. Small amounts
of IgG and other larger immunoglobulins cross mammary acini and, therefore,
would hardly reach significant concentrations in the infant&#8217;s blood. For
this reason, the flow of anti-TNF drugs through breast milk is expected to
be minimal <bold>(D)</bold>.<sup><xref rid="r232" ref-type="bibr">232</xref></sup></p><p>Adalimumab and infliximab are complete IgG1-type antibodies, and can cross
the placental barrier. The mean clearance time for adalimumab in
breastfeeding infants is four months, and for infliximab is 7.3 months. The
latter was detected until 12 months of age <bold>(B)</bold>.<sup><xref rid="r228" ref-type="bibr">228</xref></sup></p><p>Etanercept is only found in small concentrations in breast milk and is
undetectable in the blood of breastfeeding infants
<bold>(C)</bold>.<sup><xref rid="r213" ref-type="bibr">213</xref>,<xref rid="r235" ref-type="bibr">235</xref></sup> In all
case reports of mothers using etanercept, the breastfeeding infants achieved
all development milestones. The authors described the concentration in
breast milk of 5 ng/ml and etanercept was not detected in the infants&#8217;
blood. Because it is a large protein, oral absorption of etanercept is
believed to be minimal or absent <bold>(D)</bold>.<sup><xref rid="r232" ref-type="bibr">232</xref></sup> Adalimumab and infliximab had similar
results to etanercept and seem to be safe for use during breastfeeding
according to some reports <bold>(C)</bold>.<sup><xref rid="r213" ref-type="bibr">213</xref>,<xref rid="r221" ref-type="bibr">221</xref>,<xref rid="r230" ref-type="bibr">230</xref>,<xref rid="r245" ref-type="bibr">245</xref></sup></p><p>Ixekizumab is excreted in low levels in breast milk from cynomolgus monkeys,
but it is unknown if it is excreted in human breast milk or if it is
systemically absorbed after ingestion. It is a large protein molecule
(molecular weight of 146,000 kDa), therefore, absorption is unlikely after
the first weeks after delivery. The same is described for secukinumab
(molecular weight 151,000 kDa) <bold>(D)</bold>.<sup><xref rid="r239" ref-type="bibr">239</xref></sup></p><p>Data on monoclonal antibodies anti-IL-12/23 are very immature to make any
recommendations. Since ustekinumab has a molecular weight of 149,000 kDa,
the amount in breast milk is likely to be very low and the absorption is
unlikely due to its destruction in the infant&#8217;s gastrointestinal tract
<bold>(D)</bold>.<sup><xref rid="r239" ref-type="bibr">239</xref></sup></p><p>The effects of the use of ustekinumab during breastfeeding were studied in
cynomolgus monkeys, in which low levels of ustekinumab (1/1000 of the level
found in maternal serum) were found in breast milk. There are no reports of
breastfeeding in humans; however, due to the fact that other immunoglobulins
and proteins are present in colostrum, it is suggested that ustekinumab is
excreted in breast milk <bold>(B)</bold>.<sup><xref rid="r214" ref-type="bibr">214</xref></sup></p></sec><sec><title>Recommendations:</title><p>Topical corticosteroids have been proven safe during breastfeeding.</p><p>There are no reports on the use of calcipotriol during breastfeeding.</p><p>Ultraviolet B phototherapy is the safest modality of systemic treatment to be
indicated during breastfeeding. PUVA phototherapy should be avoided.</p><p>Methotrexate, acitretin, cyclosporine and psoralen (PUVA) are contraindicated
during breastfeeding.</p><p>Adalimumab, infliximab and etanercept are safe for use during
breastfeeding.</p><p>The lack of data on ustekinumab, ixekizumab, secukinumab and guselkumab does
not allow to recommend their use during breastfeeding.</p></sec></sec></sec><sec><title>9. MEDICATIONS ASSOCIATED TO THE DEVELOPMENT OR AGGRAVATION OF PSORIASIS</title><p>With the aim of establishing the recommendations on systemic medications associated
to the development or aggravation of psoriasis, a search was carried out using
Medline-PubMed database, and the best scientific evidences were selected to answer
the clinical questions. This search encompassed drugs that have been historically
associated to the development and/or aggravation of psoriasis: angiotensin
converting enzyme I inhibitors, angiotensin II receptor antagonists, lithium,
beta-blockers, anti-inflammatories, antimalarials and interferon.</p><sec><title>9. Which systemic medications are associated to the development or
aggravation of psoriasis?</title><sec><title>9.1 TNF-alpha blockers</title><p>Patients with chronic inflammatory conditions being treated with TNF-alpha
blockers can progress with psoriasis as a paradoxical effect, also known as
reactive psoriasis, most frequently reported in patients with inflammatory
bowel disease (C).<sup><xref rid="r252" ref-type="bibr">252</xref>-<xref rid="r256" ref-type="bibr">256</xref></sup> Many studies evidenced
this relationship, with incidence ranging from 1.6% to 2.5% (253-256) (C).
Smoking (C)<sup><xref rid="r252" ref-type="bibr">252</xref>,<xref rid="r256" ref-type="bibr">256</xref></sup> and female gender (C)
<sup><xref rid="r254" ref-type="bibr">254</xref>,<xref rid="r256" ref-type="bibr">256</xref></sup> were considered
significant among the factors possibly related with the development of
psoriasis as a paradoxical effect.</p></sec><sec><title>9.2 Interferon Alpha</title><p>During treatment with interferon alpha for the Hepatitis C, 36 cases of
patients who developed psoriasis lesions (aggravation in 22 cases and
triggering in 14 cases) were reported in 32 publications
(<bold>C</bold>).<sup><xref rid="r257" ref-type="bibr">257</xref></sup></p></sec><sec><title>9.3 Angiotensin II Receptor Antagonists</title><p>The use of losartan for the treatment of hypertension in a 49-year-old man
lead to the subsequent appearance of psoriasiform lesions (confirmed by
biopsy) one week after the medication was commenced. The skin lesions
gradually resolved after discontinuation of losartan (C).<sup><xref rid="r258" ref-type="bibr">258</xref></sup></p></sec><sec><title>9.4 Nonsteroidal Anti-inflammatories</title><p>Isolated cases of patients with inflammatory arthopathies are reported with
the development of psoriasis for using nimesulide<sup><xref rid="r259" ref-type="bibr">259</xref></sup> (C) and rofecoxib (C)<sup><xref rid="r260" ref-type="bibr">260</xref></sup>, with subsequent
remission of psoriasis after withdrawal of the anti-inflammatory.</p><p>The association between many pain killers widely used, including aspirin,
nonsteroidal anti-inflammatories (NSAIDs) and acetaminophen (paracetamol)
and the risk for psoriasis and psoriatic arthritis (PsA) was evaluated in
95,540 participants during follow-up. During 1,321,280 person-years of
follow-up, 646 cases of psoriasis and 165 cases of PsA were documented.
Compared to women who did not report their use, regular acetaminophen and
NSAIDs users, with longer than 10 years of use, showed multivariate risk
rates of 3.60 (CI95%:2.02-6.41] and 2.10 (CI95%:1.11-3.96), respectively,
for PsA. There was no clear association between aspirin and psoriasis risk
or PsA. In conclusion, the prolonged use of acetaminophen and NSAIDs can be
associated to an increased risk of psoriasis and PsA
<bold>(B).</bold><sup><xref rid="r261" ref-type="bibr">261</xref></sup></p></sec><sec><title>9.5 Betablockers</title><p>An analysis of 36,702 patients (and the same number of controls) with
first-time diagnosis of psoriasis who used cardioselective and
non-cardioselective betablocker revealed that according to the number of
prescriptions (1-4, 5-19, &gt;20) the incidence of psoriasis was,
respectively OR 0.93 (0.70 to 1.13 CI95%), 1.10 (0.97 to 1.24 ) and 1.10
(1.01 to 1.20), not supporting evidences that the use of betablockers
increase the incidence of psoriasis (<bold>B</bold>).<sup><xref rid="r262" ref-type="bibr">262</xref></sup></p><p>Twenty-three psoriasis patients using betablockers first developed psoriasis
after commencing the drug in seven cases, and this number was statistically
significant when compared to the control group (psoriasis patients with no
previous use of betablocker) - p&lt;0.001. four of these patients had a
generalized presentation (severe) of psoriasis and in three the symptoms
remitted after discontinuation (B).<sup><xref rid="r263" ref-type="bibr">263</xref></sup></p></sec><sec><title>9.6 Lithium</title><p>The use of lithium in 36,702 patients (and the same number of controls) with
first-time diagnosis of psoriasis registered between 1994 and 2005, when
compared to non-use prior to development of psoriasis, resulted in an Odds
Ratio (OR) of 1.68 (CI95% 1.18- 2.39, p&lt;0.01), demonstrating that the use
of lithium was associated to a small risk of an increased incidence of
psoriasis (<bold>B</bold>).<sup><xref rid="r264" ref-type="bibr">264</xref></sup></p><p>Patients with psychiatric disorders that received lithium for the first time
developed psoriasis in 6% of cases (of the 51 patients receiving lithium,
three developed lesions); compared to the control group, <italic toggle="yes">p</italic>
value was not significant (<bold>B</bold>).<sup><xref rid="r265" ref-type="bibr">265</xref></sup></p></sec><sec><title>9.7 Angiotensin I Converting Enzyme Inhibitors</title><p>There are reports that the angiotensin II converting enzyme inhibitors (ACEI)
captopril and lisinopril exacerbated or triggered psoriasiform lesions
(<bold>C</bold>).<sup><xref rid="r266" ref-type="bibr">266</xref></sup></p><p>In a cohort where 16,342 patients received captopril, 25,686 patients
received enalapril maleate and 11,235 patients received lisinopril, six
developed psoriasiform lesions (one case of exacerbation and five cases of
new onset). The rate of association of psoriasiform lesions was 1.3 for
10,000 in total, 2.1 for each 10,000 women and 0.4 for each 10,000 men
(<bold>C</bold>).<sup><xref rid="r267" ref-type="bibr">267</xref></sup></p></sec><sec><title>9.8 Antimalarials</title><p>Six days after starting chloroquine phosphate 500mg/week and proguanil
200mg/day for malaria prophylaxis, a 45-year-old patient with psoriasis
presented with worsening of the inflammation and pain in preexisting lesions
(<bold>C</bold>).<sup><xref rid="r268" ref-type="bibr">268</xref></sup></p><p>Another report revealed exacerbation of plaque psoriasis lesions in a patient
using chloroquine sulfate 400mg/week and proguanil 200mg/day as prophylaxis,
requiring hospitalization for systemic treatment with methotrexate
(<bold>C</bold>).<sup><xref rid="r269" ref-type="bibr">269</xref></sup></p></sec><sec><title>Recommendations:</title><p>TNF alpha blockers can paradoxically cause psoriasiform lesions in patients
with chronic inflammatory conditions, being more frequent in inflammatory
bowel disease, occurring in 1.6-2.5% of patients.</p><p>Results of the largest studies regarding betablockers and lithium are still
controversial because they are drugs with considerable evidences, however
insufficient, to cause or aggravate psoriasis.</p><p>Therapy with interferon alpha, nonsteroidal anti-inflammatories, angiotensin
receptor antagonists and ACE inhibitors seem to trigger or exacerbate
preexisting psoriasiform lesions, although with weak evidences of causal
relationship.</p></sec></sec></sec></body><back><fn-group><fn fn-type="other" id="fn1"><label>*</label><p>Work conducted at the Sociedade Brasileira de Dermatologia, Rio de Janeiro (RJ),
Brazil.</p></fn><fn fn-type="financial-disclosure"><p>Financial Support: None.</p></fn><fn fn-type="COI-statement"><p>Conflict of Interest: The coauthors hereby declare that they participated in
meetings and talks and/or received support from the following pharmaceutical
laboratories: Marcelo Arnone: Abbvie, Glenmark, Janssen, Leo Pharma, Lilly,
Novartis, Pfizer, UCB Biopharma; Maria Denise Fonseca Takahashi: Abbvie,
Janssen, and Pfizer; Andr&#233; Vicente Esteves de Carvalho: Abbvie, Janssen,
Lilly, Novartis, and UCB; Biopharma; Wanderley Marques Bernardo: none; Aline
Lopes Bressan: Abbvie; Andr&#233;a Machado Coelho Ramos: Abbvie, Janssen,
Lilly, Novartis, Sanofi, and UCB; Biopharma; Aripuana Cob&#233;rio Terena:
Abbvie, Janssen, Lilly, Novartis, and Sanofi; Cacilda da Silva Souza: Abbvie,
Janssen, Leo Pharma, Lilly, and Novartis; Daniel Holthausen Nunes: Abbvie,
Janssen, Novartis, and Sanofi; Maria Cec&#237;lia de Carvalho Bortoletto:
Abbvie, Janssen, and Novartis; Maria de F&#225;tima Santos Paim de Oliveira:
Abbvie, Janssen, Leo Pharma, and Novartis; Jane Marcy Neff&#225;: Abbvie and
Pfizer; Luciana Cristina Fieri: none; Luna Azulay-Abulafia: Abbvie, Janssen, Leo
Pharma, Lilly, Novartis, Pfizer, and Roche; Paulo Ant&#244;nio Oldani Felix:
Abbvie, Astra-Zeneca, Janssen, Leo Pharma, Lilly, Novartis, UCB Biopharma;
Renata Ferreira Magalhaes: Abbvie, Janssen, Lilly, Novartis, and Pfizer Ricardo
Romiti: Abbvie, Galderma, Janssen, Leo Pharma, Lilly, Novartis, Sanofi, and UCB
Biopharma; Tatiana Jerez Jaime: none</p></fn><fn fn-type="con"><p>AUTHORS&#8217; CONTRIBUTIONS</p><p>Marcelo Arnone</p><p>0000-0002-7192-5161</p><p>Approval of the final version of the manuscript; Design and planning of the
study; Preparation and writing of the manuscript; Data collection, analysis and
interpretation; Critical literature review; Critical manuscript review</p><p>Maria Denise Fonseca Takahashi</p><p>0000-0001-8671-6680</p><p>Approval of the final version of the manuscript; Design and planning of the
study; Preparation and writing of the manuscript; Data collection, analysis and
interpretation; Critical literature review; Critical manuscript review</p><p>Andr&#233; Vicente Esteves de Carvalho</p><p>0000-0002-0407-538X</p><p>Approval of the final version of the manuscript; Preparation and writing of the
manuscript; Data collection, analysis and interpretation; Critical literature
review; Critical manuscript review</p><p>Wanderley Marques Bernardo</p><p>0000-0002-8597-5207</p><p>Statistical analysis; Approval of the final version of the manuscript; Design and
planning of the study; Preparation and writing of the manuscript; Data
collection, analysis and interpretation; Critical literature review; Critical
manuscript review</p><p>Aline Lopes Bressan</p><p>0000-0002-3296-5232</p><p>Data collection, analysis and interpretation; Critical literature review</p><p>Andrea Machado Coelho Ramos</p><p>0000-0001-7414-3395</p><p>Data collection, analysis and interpretation; Critical literature review</p><p>Aripuan&#227; Cob&#233;rio Terena</p><p>0000-0002-2550-1341</p><p>Data collection, analysis and interpretation; Critical literature review</p><p>Cacilda da Silva Souza</p><p>0000-0002-8157-7658</p><p>Data collection, analysis and interpretation; Critical literature review</p><p>Daniel Holthausen Nunes</p><p>0000-0002-1303-5419</p><p>Data collection, analysis and interpretation; Critical literature review</p><p>Maria Cec&#237;lia de Carvalho Bortoletto</p><p>0000-0002-6156-6097</p><p>Data collection, analysis and interpretation; Critical literature review</p><p>Maria de F&#225;tima Santos Paim de Oliveira</p><p>0000-0002-8594-200X</p><p>Data collection, analysis and interpretation; Critical literature review</p><p>Jane Marcy Neff&#225;</p><p>0000-0002-7888-0154</p><p>Data collection, analysis and interpretation; Critical literature review</p><p>Luciana Cristina Fieri</p><p>0000-0002-7981-9398</p><p>Data collection, analysis and interpretation; Critical literature review</p><p>Luna Azulay-Abulafia</p><p>0000-0002-4698-2009</p><p>Data collection, analysis and interpretation; Critical literature review</p><p>Paulo Ant&#244;nio Oldani Felix</p><p>0000-0002-1055-0597</p><p>Data collection, analysis and interpretation; Critical literature review</p><p>Renata Ferreira Magalhaes</p><p>0000-0001-9170-932X</p><p>Data collection, analysis and interpretation; Critical literature review</p><p>Ricardo Romiti</p><p>0000-0003-0165-3831</p><p>Data collection, analysis and interpretation; Critical literature review</p><p>Tatiana Jerez Jaime</p><p>0000-0002-7594-620X</p><p>Data collection, analysis and interpretation; Critical literature review</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name name-style="western"><surname>Arnone</surname><given-names>M</given-names></name><name name-style="western"><surname>Carvalho</surname><given-names>AVE</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>MDF</given-names></name><name name-style="western"><surname>Bernardo</surname><given-names>WM</given-names></name><etal/></person-group><source>Projeto Diretrizes AMB: Psor&#237;ase</source><date-in-citation content-type="access-date">2018 dec 14</date-in-citation><comment>Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://diretrizes.amb.org.br/?s=psoriase">http://diretrizes.amb.org.br/?s=psoriase</ext-link></comment></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aktan</surname><given-names>S</given-names></name><name name-style="western"><surname>Ilknur</surname><given-names>T</given-names></name><name name-style="western"><surname>Akin</surname><given-names>C</given-names></name><name name-style="western"><surname>Ozkan</surname><given-names>S</given-names></name></person-group><article-title>Interobserver reliability of the Nail Psoriasis Severity Index.
Clin Exp Dermatol</article-title><source>Clin Exp Dermatol</source><year>2007</year><volume>32</volume><fpage>141</fpage><lpage>144</lpage><pub-id pub-id-type="pmid">17137477</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2230.2006.02305.x</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bronsard</surname><given-names>V</given-names></name><name name-style="western"><surname>Paul</surname><given-names>C</given-names></name><name name-style="western"><surname>Prey</surname><given-names>S</given-names></name><name name-style="western"><surname>Puzenat</surname><given-names>E</given-names></name><name name-style="western"><surname>Gourraud</surname><given-names>PA</given-names></name><name name-style="western"><surname>Aractingi</surname><given-names>S</given-names></name><etal/></person-group><article-title>What are the best outcome measures for assessing quality of life
in plaque type psoriasis? A systematic review of the
literature</article-title><source>JJ Eur Acad Dermatol Venereol</source><year>2010</year><volume>24</volume><issue>Suppl 2</issue><fpage>S17</fpage><lpage>S22</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1468-3083.2009.03563.x</pub-id><pub-id pub-id-type="pmid">20443996</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chularojanamontri</surname><given-names>L</given-names></name><name name-style="western"><surname>Griffiths</surname><given-names>CE</given-names></name><name name-style="western"><surname>Chalmers</surname><given-names>RJ</given-names></name></person-group><article-title>The Simplified Psoriasis Index (SPI): A Practical Tool for
Assessing Psoriasis</article-title><source>J Invest Dermatol</source><year>2013</year><volume>133</volume><fpage>1956</fpage><lpage>1962</lpage><pub-id pub-id-type="pmid">23807685</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/jid.2013.138</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gottlieb</surname><given-names>AB</given-names></name><name name-style="western"><surname>Merola</surname><given-names>JF</given-names></name><name name-style="western"><surname>Chen</surname><given-names>R</given-names></name><name name-style="western"><surname>Levi</surname><given-names>E</given-names></name><name name-style="western"><surname>Duffin</surname><given-names>KC</given-names></name></person-group><article-title>Assessing clinical response and defining minimal disease activity
in plaque psoriasis with the Physician Global Assessment and body surface
area (PGA &#215; BSA) composite tool: An analysis of apremilast phase 3
ESTEEM data</article-title><source>J Am Acad Dermatol</source><year>2017</year><volume>77</volume><fpage>1178</fpage><lpage>1180</lpage><pub-id pub-id-type="pmid">29132853</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaad.2017.06.162</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gottlieb</surname><given-names>AB</given-names></name><name name-style="western"><surname>Evans</surname><given-names>R</given-names></name><name name-style="western"><surname>Li</surname><given-names>S</given-names></name><name name-style="western"><surname>Dooley</surname><given-names>LT</given-names></name><name name-style="western"><surname>Guzzo</surname><given-names>CA</given-names></name><name name-style="western"><surname>Baker</surname><given-names>D</given-names></name><etal/></person-group><article-title>Infliximab induction therapy for patients with severe plaque-type
psoriasis: a randomized, double-blind, placebo-controlled
trial</article-title><source>J Am Acad Dermatol</source><year>2004</year><volume>51</volume><fpage>534</fpage><lpage>542</lpage><pub-id pub-id-type="pmid">15389187</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaad.2004.02.021</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Langley</surname><given-names>RG</given-names></name><name name-style="western"><surname>Ellis</surname><given-names>CN</given-names></name></person-group><article-title>Evaluating psoriasis with Psoriasis Area and Severity Index,
Psoriasis Global Assessment, and Lattice System Physician's Global
Assessment</article-title><source>J Am Acad Dermatol</source><year>2004</year><volume>51</volume><fpage>563</fpage><lpage>569</lpage><pub-id pub-id-type="pmid">15389191</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaad.2004.04.012</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ljosaa</surname><given-names>TM</given-names></name><name name-style="western"><surname>Mork</surname><given-names>C</given-names></name><name name-style="western"><surname>Stubhaug</surname><given-names>A</given-names></name><name name-style="western"><surname>Moum</surname><given-names>T</given-names></name><name name-style="western"><surname>Wahl</surname><given-names>AK</given-names></name></person-group><article-title>Skin pain and skin discomfort is associated with quality of life
in patients with psoriasis</article-title><source>J Eur Acad Dermatol Venereol</source><year>2012</year><volume>26</volume><fpage>29</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">21385220</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1468-3083.2011.04000.x</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lubrano</surname><given-names>E</given-names></name><name name-style="western"><surname>Scrivo</surname><given-names>R</given-names></name><name name-style="western"><surname>Cantini</surname><given-names>F</given-names></name><name name-style="western"><surname>Marchesoni</surname><given-names>A</given-names></name><name name-style="western"><surname>Mathieu</surname><given-names>A</given-names></name><name name-style="western"><surname>Olivieri</surname><given-names>I</given-names></name><etal/></person-group><article-title>Is the Nail Psoriasis Severity Index reliable in the assessment
of nail psoriasis by rheumatologists?</article-title><source>Arthritis Care Res (Hoboken)</source><year>2012</year><volume>64</volume><fpage>455</fpage><lpage>458</lpage><pub-id pub-id-type="pmid">22076786</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/acr.20691</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lundberg</surname><given-names>L</given-names></name><name name-style="western"><surname>Johannesson</surname><given-names>M</given-names></name><name name-style="western"><surname>Silverdahl</surname><given-names>M</given-names></name><name name-style="western"><surname>Hermansson</surname><given-names>C</given-names></name><name name-style="western"><surname>Lindberg</surname><given-names>M</given-names></name></person-group><article-title>Health-related quality of life in patients with psoriasis and
atopic dermatitis measured with SF-36, DLQI and a subjective measure of
disease activity</article-title><source>Acta Derm Venereol</source><year>2000</year><volume>80</volume><fpage>430</fpage><lpage>434</lpage><pub-id pub-id-type="pmid">11243637</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/000155500300012873</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mattei</surname><given-names>PL</given-names></name><name name-style="western"><surname>Corey</surname><given-names>KC</given-names></name><name name-style="western"><surname>Kimball</surname><given-names>AB</given-names></name></person-group><article-title>Psoriasis Area Severity Index (PASI) and the Dermatology Life
Quality Index (DLQI): the correlation between disease severity and
psychological burden in patients treated with biological
therapies</article-title><source>J Eur Acad Dermatol Venereol</source><year>2014</year><volume>28</volume><fpage>333</fpage><lpage>337</lpage><pub-id pub-id-type="pmid">23425140</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jdv.12106</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reich</surname><given-names>K</given-names></name><name name-style="western"><surname>Nestle</surname><given-names>FO</given-names></name><name name-style="western"><surname>Papp</surname><given-names>K</given-names></name><name name-style="western"><surname>Ortonne</surname><given-names>JP</given-names></name><name name-style="western"><surname>Evans</surname><given-names>R</given-names></name><name name-style="western"><surname>Guzzo</surname><given-names>C</given-names></name><etal/></person-group><article-title>Infliximab induction and maintenance therapy for
moderate-to-severe psoriasis: a phase III, multicentre, double-blind
trial</article-title><source>Lancet</source><year>2005</year><volume>366</volume><fpage>1367</fpage><lpage>1374</lpage><pub-id pub-id-type="pmid">16226614</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(05)67566-6</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rich</surname><given-names>P</given-names></name><name name-style="western"><surname>Scher</surname><given-names>RK</given-names></name></person-group><article-title>Nail Psoriasis Severity Index: a useful tool for evaluation of
nail psoriasis</article-title><source>J Am Acad Dermatol</source><year>2003</year><volume>49</volume><fpage>206</fpage><lpage>212</lpage><pub-id pub-id-type="pmid">12894066</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1067/s0190-9622(03)00910-1</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Robinson</surname><given-names>A</given-names></name><name name-style="western"><surname>Kardos</surname><given-names>M</given-names></name><name name-style="western"><surname>Kimball</surname><given-names>AB</given-names></name></person-group><article-title>Physician Global Assessment (PGA) and Psoriasis Area and Severity
Index (PASI): why do both? A systematic analysis of randomized controlled
trials of biologic agents for moderate to severe plaque
psoriasis</article-title><source>J Am Acad Dermatol</source><year>2012</year><volume>66</volume><fpage>369</fpage><lpage>375</lpage><pub-id pub-id-type="pmid">22041254</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaad.2011.01.022</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walsh</surname><given-names>JA</given-names></name><name name-style="western"><surname>McFadden</surname><given-names>M</given-names></name><name name-style="western"><surname>Woodcock</surname><given-names>J</given-names></name><name name-style="western"><surname>Clegg</surname><given-names>DO</given-names></name><name name-style="western"><surname>Helliwell</surname><given-names>P</given-names></name><name name-style="western"><surname>Dommasch</surname><given-names>E</given-names></name><etal/></person-group><article-title>Product of the Physician Global Assessment and body surface area:
a simple static measure of psoriasis severity in a longitudinal
cohort</article-title><source>J Am Acad Dermatol</source><year>2013</year><volume>69</volume><fpage>931</fpage><lpage>937</lpage><pub-id pub-id-type="pmid">24054760</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaad.2013.07.040</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Puzenat</surname><given-names>E</given-names></name><name name-style="western"><surname>Bronsard</surname><given-names>V</given-names></name><name name-style="western"><surname>Prey</surname><given-names>S</given-names></name><name name-style="western"><surname>Gourraud</surname><given-names>PA</given-names></name><name name-style="western"><surname>Aractingi</surname><given-names>S</given-names></name><name name-style="western"><surname>Bagot</surname><given-names>M</given-names></name><etal/></person-group><article-title>What are the best outcome measures for assessing plaque psoriasis
severity? A systematic review of the literature</article-title><source>J Eur Acad Dermatol Venereol</source><year>2010</year><volume>24</volume><issue>Suppl 2</issue><fpage>10</fpage><lpage>16</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1468-3083.2009.03562.x</pub-id><pub-id pub-id-type="pmid">20443995</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Awosika</surname><given-names>O</given-names></name><name name-style="western"><surname>Eleryan</surname><given-names>MG</given-names></name><name name-style="western"><surname>Rengifo-Pardo</surname><given-names>M</given-names></name><name name-style="western"><surname>Doherty</surname><given-names>L</given-names></name><name name-style="western"><surname>Martin</surname><given-names>LW</given-names></name><name name-style="western"><surname>Ehrlich</surname><given-names>A</given-names></name></person-group><article-title>A Case-control Study to Evaluate the Prevalence of Nonalcoholic
Fatty Liver Disease Among Patients with Moderate-to-severe
Psoriasis</article-title><source>J Clin Aesthet Dermatol</source><year>2018</year><volume>11</volume><fpage>33</fpage><lpage>37</lpage><pub-id pub-id-type="pmcid">PMC6011871</pub-id><pub-id pub-id-type="pmid">29942422</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baeta</surname><given-names>IG</given-names></name><name name-style="western"><surname>Bittencourt</surname><given-names>FV</given-names></name><name name-style="western"><surname>Gontijo</surname><given-names>B</given-names></name><name name-style="western"><surname>Goulart</surname><given-names>EM</given-names></name></person-group><article-title>Comorbidities and cardiovascular risk factors in patients with
psoriasis</article-title><source>An Bras Dermatol</source><year>2014</year><volume>89</volume><fpage>735</fpage><lpage>744</lpage><pub-id pub-id-type="pmid">25184912</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1590/abd1806-4841.20142874</pub-id><pub-id pub-id-type="pmcid">PMC4155951</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Birkenfeld</surname><given-names>S</given-names></name><name name-style="western"><surname>Dreiher</surname><given-names>J</given-names></name><name name-style="western"><surname>Weitzman</surname><given-names>D</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>AD</given-names></name></person-group><article-title>Coeliac disease associated with psoriasis</article-title><source>Br J Dermatol</source><year>2009</year><volume>161</volume><fpage>1331</fpage><lpage>1334</lpage><pub-id pub-id-type="pmid">19785615</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2133.2009.09398.x</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Capo</surname><given-names>A</given-names></name><name name-style="western"><surname>Affaitati</surname><given-names>G</given-names></name><name name-style="western"><surname>Giamberardino</surname><given-names>MA</given-names></name><name name-style="western"><surname>Amerio</surname><given-names>P</given-names></name></person-group><article-title>Psoriasis and migraine</article-title><source>J Eur Acad Dermatol Venereol</source><year>2018</year><volume>32</volume><fpage>57</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">28707753</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jdv.14472</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>YM</given-names></name><name name-style="western"><surname>Famenini</surname><given-names>S</given-names></name><name name-style="western"><surname>Wu</surname><given-names>JJ</given-names></name></person-group><article-title>Incidence of Pulmonary Arterial Hypertension in Patients with
Psoriasis: A Retrospective Cohort Study</article-title><source>Perm J</source><year>2017</year><volume>21</volume><pub-id pub-id-type="doi" assigning-authority="pmc">10.7812/TPP/16-073</pub-id><pub-id pub-id-type="pmcid">PMC5499608</pub-id><pub-id pub-id-type="pmid">28678692</pub-id></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>AD</given-names></name><name name-style="western"><surname>Dreiher</surname><given-names>J</given-names></name><name name-style="western"><surname>Shapiro</surname><given-names>Y</given-names></name><name name-style="western"><surname>Vidavsky</surname><given-names>L</given-names></name><name name-style="western"><surname>Vardy</surname><given-names>DA</given-names></name><name name-style="western"><surname>Davidovici</surname><given-names>B</given-names></name><etal/></person-group><article-title>Psoriasis and diabetes: a population-based cross-sectional
study</article-title><source>J Eur Acad Dermatol Venereol</source><year>2008</year><volume>22</volume><fpage>585</fpage><lpage>589</lpage><pub-id pub-id-type="pmid">18331320</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1468-3083.2008.02636.x</pub-id></element-citation></ref><ref id="r23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>AD</given-names></name><name name-style="western"><surname>Weitzman</surname><given-names>D</given-names></name><name name-style="western"><surname>Dreiher</surname><given-names>J</given-names></name></person-group><article-title>Psoriasis and hypertension: a case-control study</article-title><source>Acta Derm Venereol</source><year>2010</year><volume>90</volume><fpage>23</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">20107721</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2340/00015555-0741</pub-id></element-citation></ref><ref id="r24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>BE</given-names></name><name name-style="western"><surname>Martires</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Ho</surname><given-names>RS</given-names></name></person-group><article-title>Psoriasis and the Risk of Depression in the US Population:
National Health and Nutrition Examination Survey 2009-2012</article-title><source>JAMA Dermatol</source><year>2016</year><volume>152</volume><fpage>73</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">26421371</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamadermatol.2015.3605</pub-id></element-citation></ref><ref id="r25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Costa-Silva</surname><given-names>M</given-names></name><name name-style="western"><surname>Vide</surname><given-names>J</given-names></name><name name-style="western"><surname>Lopes</surname><given-names>S</given-names></name><name name-style="western"><surname>Azevedo</surname><given-names>F</given-names></name><name name-style="western"><surname>Magina</surname><given-names>S</given-names></name></person-group><article-title>Psoriasis and comorbidities: general practitioners'
awareness</article-title><source>Acta Dermatovenerol Alp Pannonica Adriat.</source><year>2018</year><volume>27</volume><fpage>5</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">29589638</pub-id></element-citation></ref><ref id="r26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Curc&#243;</surname><given-names>N</given-names></name><name name-style="western"><surname>Barriendos</surname><given-names>N</given-names></name><name name-style="western"><surname>Barahona</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Arteaga</surname><given-names>C</given-names></name><name name-style="western"><surname>Garc&#237;a</surname><given-names>M</given-names></name><name name-style="western"><surname>Yordanov</surname><given-names>S</given-names></name><etal/></person-group><article-title>Factors influencing cardiometabolic risk profile in patients with
psoriasis</article-title><source>Australas J Dermatol</source><year>2018</year><volume>59</volume><fpage>e93</fpage><lpage>e98</lpage><pub-id pub-id-type="pmid">28240341</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ajd.12577</pub-id></element-citation></ref><ref id="r27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dalgard</surname><given-names>FJ</given-names></name><name name-style="western"><surname>Gieler</surname><given-names>U</given-names></name><name name-style="western"><surname>Tomas-Aragones</surname><given-names>L</given-names></name><name name-style="western"><surname>Lien</surname><given-names>L</given-names></name><name name-style="western"><surname>Poot</surname><given-names>F</given-names></name><name name-style="western"><surname>Jemec</surname><given-names>GBE</given-names></name><etal/></person-group><article-title>The psychological burden of skin diseases: a cross-sectional
multicenter study among dermatological out-patients in 13 European
countries</article-title><source>J Invest Dermatol</source><year>2015</year><volume>135</volume><fpage>984</fpage><lpage>991</lpage><pub-id pub-id-type="pmid">25521458</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/jid.2014.530</pub-id><pub-id pub-id-type="pmcid">PMC4378256</pub-id></element-citation></ref><ref id="r28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Damevska</surname><given-names>K</given-names></name><name name-style="western"><surname>Neloska</surname><given-names>L</given-names></name><name name-style="western"><surname>Gocev</surname><given-names>G</given-names></name><name name-style="western"><surname>Mihova</surname><given-names>M</given-names></name></person-group><article-title>Metabolic syndrome in untreated patients with psoriasis:
case-control study</article-title><source>J Dtsch Dermatol Ges</source><year>2013</year><volume>11</volume><fpage>1169</fpage><lpage>1175</lpage><pub-id pub-id-type="pmid">24267013</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ddg.12193</pub-id></element-citation></ref><ref id="r29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dommasch</surname><given-names>ED</given-names></name><name name-style="western"><surname>Li</surname><given-names>T</given-names></name><name name-style="western"><surname>Okereke</surname><given-names>OI</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Qureshi</surname><given-names>AA</given-names></name><name name-style="western"><surname>Cho</surname><given-names>E</given-names></name></person-group><article-title>Risk of depression in women with psoriasis: a cohort
study</article-title><source>Br J Dermatol</source><year>2015</year><volume>173</volume><fpage>975</fpage><lpage>980</lpage><pub-id pub-id-type="pmid">26186277</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bjd.14032</pub-id><pub-id pub-id-type="pmcid">PMC5642997</pub-id></element-citation></ref><ref id="r30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dreiher</surname><given-names>J</given-names></name><name name-style="western"><surname>Weitzman</surname><given-names>D</given-names></name><name name-style="western"><surname>Shapiro</surname><given-names>J</given-names></name><name name-style="western"><surname>Davidovici</surname><given-names>B</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>AD</given-names></name></person-group><article-title>Psoriasis and chronic obstructive pulmonary disease: a
case-control study</article-title><source>Br J Dermatol</source><year>2008</year><volume>159</volume><fpage>956</fpage><lpage>960</lpage><pub-id pub-id-type="pmid">18637897</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2133.2008.08749.x</pub-id></element-citation></ref><ref id="r31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Driessen</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Boezeman</surname><given-names>JB</given-names></name><collab>Van De Kerkhof PC.De Jong EM</collab></person-group><article-title>Cardiovascular risk factors in high-need psoriasis patients and
its implications for biological therapies</article-title><source>J Dermatolog Treat</source><year>2009</year><volume>20</volume><fpage>42</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">18649164</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/09546630802225702</pub-id></element-citation></ref><ref id="r32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Egeberg</surname><given-names>A</given-names></name><name name-style="western"><surname>Khalid</surname><given-names>U</given-names></name><name name-style="western"><surname>Gislason</surname><given-names>GH</given-names></name><name name-style="western"><surname>Mallbris</surname><given-names>L</given-names></name><name name-style="western"><surname>Skov</surname><given-names>L</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>PR</given-names></name></person-group><article-title>Association between depression and risk of atrial fibrillation
and stroke in patients with psoriasis: a Danish nationwide cohort
study</article-title><source>Br J Dermatol</source><year>2015</year><volume>173</volume><fpage>471</fpage><lpage>479</lpage><pub-id pub-id-type="pmid">25781210</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bjd.13778</pub-id></element-citation></ref><ref id="r33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Egeberg</surname><given-names>A</given-names></name><name name-style="western"><surname>Mallbris</surname><given-names>L</given-names></name><name name-style="western"><surname>Hilmar Gislason</surname><given-names>G</given-names></name><name name-style="western"><surname>Skov</surname><given-names>L</given-names></name><name name-style="western"><surname>Riis Hansen</surname><given-names>P</given-names></name></person-group><article-title>Increased risk of migraine in patients with psoriasis: A Danish
nationwide cohort study</article-title><source>J Am Acad Dermatol</source><year>2015</year><volume>73</volume><fpage>829</fpage><lpage>835</lpage><pub-id pub-id-type="pmid">26386630</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaad.2015.08.039</pub-id></element-citation></ref><ref id="r34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eppinga</surname><given-names>H</given-names></name><name name-style="western"><surname>Poortinga</surname><given-names>S</given-names></name><name name-style="western"><surname>Thio</surname><given-names>HB</given-names></name><name name-style="western"><surname>Nijsten</surname><given-names>TEC</given-names></name><name name-style="western"><surname>Nuij</surname><given-names>VJAA</given-names></name><name name-style="western"><surname>van der Woude</surname><given-names>CJ</given-names></name><etal/></person-group><article-title>Prevalence and Phenotype of Concurrent Psoriasis and Inflammatory
Bowel Disease</article-title><source>Inflamm Bowel Dis</source><year>2017</year><volume>23</volume><fpage>1783</fpage><lpage>1789</lpage><pub-id pub-id-type="pmid">28617755</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MIB.0000000000001169</pub-id></element-citation></ref><ref id="r35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feldman</surname><given-names>SR</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shi</surname><given-names>L</given-names></name><name name-style="western"><surname>Tran</surname><given-names>MH</given-names></name></person-group><article-title>Economic and Comorbidity Burden Among Patients with
Moderate-to-Severe Psoriasis</article-title><source>J Manag Care Spec Pharm</source><year>2015</year><volume>21</volume><fpage>874</fpage><lpage>888</lpage><pub-id pub-id-type="pmid">26402388</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18553/jmcp.2015.21.10.874</pub-id><pub-id pub-id-type="pmcid">PMC10397856</pub-id></element-citation></ref><ref id="r36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gisondi</surname><given-names>P</given-names></name><name name-style="western"><surname>Targher</surname><given-names>G</given-names></name><name name-style="western"><surname>Zoppini</surname><given-names>G</given-names></name><name name-style="western"><surname>Girolomoni</surname><given-names>G</given-names></name></person-group><article-title>Non-alcoholic fatty liver disease in patients with chronic plaque
psoriasis</article-title><source>J Hepatol</source><year>2009</year><volume>51</volume><fpage>758</fpage><lpage>764</lpage><pub-id pub-id-type="pmid">19560226</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jhep.2009.04.020</pub-id></element-citation></ref><ref id="r37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goldet</surname><given-names>G</given-names></name><name name-style="western"><surname>Howick</surname><given-names>J</given-names></name></person-group><article-title>Understanding GRADE: an introduction</article-title><source>J J Evid Based Med</source><year>2013</year><volume>6</volume><fpage>50</fpage><lpage>54</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jebm.12018</pub-id><pub-id pub-id-type="pmid">23557528</pub-id></element-citation></ref><ref id="r38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>C</given-names></name><name name-style="western"><surname>Lofland</surname><given-names>JH</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>N</given-names></name><name name-style="western"><surname>Schenkel</surname><given-names>B</given-names></name></person-group><article-title>Increased prevalence of psychiatric disorders and health
care-associated costs among patients with moderate-to-severe
psoriasis</article-title><source>J Drugs Dermatol</source><year>2011</year><volume>10</volume><fpage>843</fpage><lpage>850</lpage><pub-id pub-id-type="pmid">21818505</pub-id></element-citation></ref><ref id="r39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Helmick</surname><given-names>CG</given-names></name><name name-style="western"><surname>Lee-Han</surname><given-names>H</given-names></name><name name-style="western"><surname>Hirsch</surname><given-names>SC</given-names></name><name name-style="western"><surname>Baird</surname><given-names>TL</given-names></name><name name-style="western"><surname>Bartlett</surname><given-names>CL</given-names></name></person-group><article-title>Prevalence of psoriasis among adults in the U.S.: 2003-2006 and
2009-2010 National Health and Nutrition Examination Surveys</article-title><source>Am J Prev Med.</source><year>2014</year><volume>47</volume><fpage>37</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">24746373</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.amepre.2014.02.012</pub-id><pub-id pub-id-type="pmcid">PMC4653077</pub-id></element-citation></ref><ref id="r40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Henseler</surname><given-names>T</given-names></name><name name-style="western"><surname>Christophers</surname><given-names>E</given-names></name></person-group><article-title>Disease concomitance in psoriasis</article-title><source>J Am Acad Dermatol</source><year>1995</year><volume>32</volume><fpage>982</fpage><lpage>986</lpage><pub-id pub-id-type="pmid">7751469</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0190-9622(95)91336-x</pub-id></element-citation></ref><ref id="r41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jadad</surname><given-names>AR</given-names></name><name name-style="western"><surname>Moore</surname><given-names>RA</given-names></name><name name-style="western"><surname>Carroll</surname><given-names>D</given-names></name><name name-style="western"><surname>Jenkinson</surname><given-names>C</given-names></name><name name-style="western"><surname>Reynolds</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Gavaghan</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>Assessing the quality of reports of randomized clinical trials:
is blinding necessary?</article-title><source>Control Clin Trials</source><year>1996</year><volume>17</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">8721797</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0197-2456(95)00134-4</pub-id></element-citation></ref><ref id="r42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jekler</surname><given-names>J</given-names></name><name name-style="western"><surname>Swanbeck</surname><given-names>G</given-names></name></person-group><article-title>One-minute dithranol therapy in psoriasis: a placebo-controlled
paired comparative study</article-title><source>Acta Derm Venereol</source><year>1992</year><volume>72</volume><fpage>449</fpage><lpage>450</lpage><pub-id pub-id-type="pmid">1362841</pub-id></element-citation></ref><ref id="r43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karia</surname><given-names>SB</given-names></name><name name-style="western"><surname>De Sousa</surname><given-names>A</given-names></name><name name-style="western"><surname>Shah</surname><given-names>N</given-names></name><name name-style="western"><surname>Sonavane</surname><given-names>S</given-names></name><name name-style="western"><surname>Bharati</surname><given-names>A</given-names></name></person-group><article-title>Psychiatric morbidity and quality of life in skin diseases: A
comparison of alopecia areata and psoriasis</article-title><source>Ind Psychiatry J</source><year>2015</year><volume>24</volume><fpage>125</fpage><lpage>128</lpage><pub-id pub-id-type="pmid">27212814</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/0972-6748.181724</pub-id><pub-id pub-id-type="pmcid">PMC4866337</pub-id></element-citation></ref><ref id="r44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khalid</surname><given-names>U</given-names></name><name name-style="western"><surname>Ahlehoff</surname><given-names>O</given-names></name><name name-style="western"><surname>Gislason</surname><given-names>GH</given-names></name><name name-style="western"><surname>Skov</surname><given-names>L</given-names></name><name name-style="western"><surname>Torp-Pedersen</surname><given-names>C</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>PR</given-names></name></person-group><article-title>Increased risk of aortic valve stenosis in patients with
psoriasis: a nationwide cohort study</article-title><source>Eur Heart J</source><year>2015</year><volume>36</volume><fpage>2177</fpage><lpage>2183</lpage><pub-id pub-id-type="pmid">26059725</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/eurheartj/ehv185</pub-id></element-citation></ref><ref id="r45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khalid</surname><given-names>U</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>PR</given-names></name><name name-style="western"><surname>Gislason</surname><given-names>GH</given-names></name><name name-style="western"><surname>Lindhardsen</surname><given-names>J</given-names></name><name name-style="western"><surname>Kristensen</surname><given-names>SL</given-names></name><name name-style="western"><surname>Winther</surname><given-names>SA</given-names></name><etal/></person-group><article-title>Psoriasis and new-onset diabetes: a Danish nationwide cohort
study</article-title><source>Diabetes Care</source><year>2013</year><volume>36</volume><fpage>2402</fpage><lpage>2407</lpage><pub-id pub-id-type="pmid">23491525</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/dc12-2330</pub-id><pub-id pub-id-type="pmcid">PMC3714512</pub-id></element-citation></ref><ref id="r46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>CR</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JH</given-names></name></person-group><article-title>An observational study on the obesity and metabolic status of
psoriasis patients</article-title><source>Ann Dermatol</source><year>2013</year><volume>25</volume><fpage>440</fpage><lpage>444</lpage><pub-id pub-id-type="pmid">24371391</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5021/ad.2013.25.4.440</pub-id><pub-id pub-id-type="pmcid">PMC3870212</pub-id></element-citation></ref><ref id="r47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kimball</surname><given-names>AB</given-names></name><name name-style="western"><surname>Wu</surname><given-names>EQ</given-names></name><name name-style="western"><surname>Gu&#233;rin</surname><given-names>A</given-names></name><name name-style="western"><surname>Yu</surname><given-names>AP</given-names></name><name name-style="western"><surname>Tsaneva</surname><given-names>M</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>SR</given-names></name><etal/></person-group><article-title>Risks of developing psychiatric disorders in pediatric patients
with psoriasis</article-title><source>J Am Acad Dermatol</source><year>2012</year><volume>67</volume><fpage>651</fpage><lpage>7.e1-2</lpage><pub-id pub-id-type="pmid">22243764</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaad.2011.11.948</pub-id></element-citation></ref><ref id="r48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>V</given-names></name><name name-style="western"><surname>Mattoo</surname><given-names>SK</given-names></name><name name-style="western"><surname>Handa</surname><given-names>S</given-names></name></person-group><article-title>Psychiatric morbidity in pemphigus and psoriasis: a comparative
study from India</article-title><source>Asian J Psychiatr</source><year>2013</year><volume>6</volume><fpage>151</fpage><lpage>156</lpage><pub-id pub-id-type="pmid">23466113</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajp.2012.10.005</pub-id></element-citation></ref><ref id="r49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kurd</surname><given-names>SK</given-names></name><name name-style="western"><surname>Troxel</surname><given-names>AB</given-names></name><name name-style="western"><surname>Crits-Christoph</surname><given-names>P</given-names></name><name name-style="western"><surname>Gelfand</surname><given-names>JM</given-names></name></person-group><article-title>The risk of depression, anxiety, and suicidality in patients with
psoriasis: a population-based cohort study</article-title><source>Arch Dermatol</source><year>2010</year><volume>146</volume><fpage>891</fpage><lpage>895</lpage><pub-id pub-id-type="pmid">20713823</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/archdermatol.2010.186</pub-id><pub-id pub-id-type="pmcid">PMC2928071</pub-id></element-citation></ref><ref id="r50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lakshmy</surname><given-names>S</given-names></name><name name-style="western"><surname>Balasundaram</surname><given-names>S</given-names></name><name name-style="western"><surname>Sarkar</surname><given-names>S</given-names></name><name name-style="western"><surname>Audhya</surname><given-names>M</given-names></name><name name-style="western"><surname>Subramaniam</surname><given-names>E</given-names></name></person-group><article-title>A Cross-sectional Study of Prevalence and Implications of
Depression and Anxiety in Psoriasis</article-title><source>Indian J Psychol Med</source><year>2015</year><volume>37</volume><fpage>434</fpage><lpage>440</lpage><pub-id pub-id-type="pmid">26702177</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/0253-7176.168587</pub-id><pub-id pub-id-type="pmcid">PMC4676211</pub-id></element-citation></ref><ref id="r51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Madanagobalane</surname><given-names>S</given-names></name><name name-style="western"><surname>Anandan</surname><given-names>S</given-names></name></person-group><article-title>Prevalence of metabolic syndrome in South Indian patients with
psoriasis vulgaris and the relation between disease severity and metabolic
syndrome: a hospital-based case-control study</article-title><source>Indian J Dermatol</source><year>2012</year><volume>57</volume><fpage>353</fpage><lpage>357</lpage><pub-id pub-id-type="pmid">23112353</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/0019-5154.100474</pub-id><pub-id pub-id-type="pmcid">PMC3482796</pub-id></element-citation></ref><ref id="r52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mebazaa</surname><given-names>A</given-names></name><name name-style="western"><surname>El Asmi</surname><given-names>M</given-names></name><name name-style="western"><surname>Zidi</surname><given-names>W</given-names></name><name name-style="western"><surname>Zayani</surname><given-names>Y</given-names></name><name name-style="western"><surname>Cheikh Rouhou</surname><given-names>R</given-names></name><name name-style="western"><surname>El Ounifi</surname><given-names>S</given-names></name><etal/></person-group><article-title>Metabolic syndrome in Tunisian psoriatic patients: prevalence and
determinants</article-title><source>J Eur Acad Dermatol Venereol</source><year>2011</year><volume>25</volume><fpage>705</fpage><lpage>709</lpage><pub-id pub-id-type="pmid">21029207</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1468-3083.2010.03856.x</pub-id></element-citation></ref><ref id="r53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Menegon</surname><given-names>DB</given-names></name><name name-style="western"><surname>Pereira</surname><given-names>AG</given-names></name><name name-style="western"><surname>Camerin</surname><given-names>AC</given-names></name><name name-style="western"><surname>Cestari</surname><given-names>T</given-names></name></person-group><article-title>Psoriasis and comorbidities in a southern Brazilian population: a
case-control study</article-title><source>Int J Dermatol</source><year>2014</year><volume>53</volume><fpage>e518</fpage><lpage>e525</lpage><pub-id pub-id-type="pmid">25070669</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ijd.12186</pub-id></element-citation></ref><ref id="r54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Milcic</surname><given-names>D</given-names></name><name name-style="western"><surname>Jankovic</surname><given-names>S</given-names></name><name name-style="western"><surname>Vesic</surname><given-names>S</given-names></name><name name-style="western"><surname>Milinkovic</surname><given-names>M</given-names></name><name name-style="western"><surname>Marinkovic</surname><given-names>J</given-names></name><name name-style="western"><surname>Cirkovic</surname><given-names>A</given-names></name><etal/></person-group><article-title>Prevalence of metabolic syndrome in patients with psoriasis: a
hospital-based cross-sectional study</article-title><source>An Bras Dermatol</source><year>2017</year><volume>92</volume><fpage>46</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">28225956</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1590/abd1806-4841.20175178</pub-id><pub-id pub-id-type="pmcid">PMC5312178</pub-id></element-citation></ref><ref id="r55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Molina-Leyva</surname><given-names>A</given-names></name><name name-style="western"><surname>Molina-Leyva</surname><given-names>I</given-names></name><name name-style="western"><surname>Almodovar-Real</surname><given-names>A</given-names></name><name name-style="western"><surname>Ruiz-Carrascosa</surname><given-names>JC</given-names></name><name name-style="western"><surname>Naranjo-Sintes</surname><given-names>R5</given-names></name><name name-style="western"><surname>Jimenez-Moleon</surname><given-names>JJ</given-names></name></person-group><article-title>Prevalence and Associated Factors of Erectile Dysfunction in
Patients With Moderate to Severe Psoriasis and Healthy Population: A
Comparative Study Considering Physical and Psychological
Factors</article-title><source>Arch Sex Behav</source><year>2016</year><volume>45</volume><fpage>2047</fpage><lpage>2055</lpage><pub-id pub-id-type="pmid">27270734</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10508-016-0757-8</pub-id></element-citation></ref><ref id="r56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neimann</surname><given-names>AL</given-names></name><name name-style="western"><surname>Shin</surname><given-names>DB</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Margolis</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Troxel</surname><given-names>AB</given-names></name><name name-style="western"><surname>Gelfand</surname><given-names>JM</given-names></name></person-group><article-title>Prevalence of cardiovascular risk factors in patients with
psoriasis</article-title><source>J Am Acad Dermatol</source><year>2006</year><volume>55</volume><fpage>829</fpage><lpage>835</lpage><pub-id pub-id-type="pmid">17052489</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaad.2006.08.040</pub-id></element-citation></ref><ref id="r57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oh</surname><given-names>EH</given-names></name><name name-style="western"><surname>Ro</surname><given-names>YS</given-names></name><name name-style="western"><surname>Kim</surname><given-names>JE</given-names></name></person-group><article-title>Epidemiology and cardiovascular comorbidities in patients with
psoriasis: A Korean nationwide population-based cohort study</article-title><source>J Dermatol</source><year>2017</year><volume>44</volume><fpage>621</fpage><lpage>629</lpage><pub-id pub-id-type="pmid">28191654</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/1346-8138.13761</pub-id></element-citation></ref><ref id="r58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parisi</surname><given-names>R</given-names></name><name name-style="western"><surname>Rutter</surname><given-names>MK</given-names></name><name name-style="western"><surname>Lunt</surname><given-names>M</given-names></name><name name-style="western"><surname>Young</surname><given-names>HS</given-names></name><name name-style="western"><surname>Symmons</surname><given-names>DPM</given-names></name><name name-style="western"><surname>Griffiths</surname><given-names>CEM</given-names></name><etal/></person-group><article-title>Psoriasis and the Risk of Major Cardiovascular Events: Cohort
Study Using the Clinical Practice Research Datalink</article-title><source>J Invest Dermatol</source><year>2015</year><volume>135</volume><fpage>2189</fpage><lpage>2197</lpage><pub-id pub-id-type="pmid">25742120</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/jid.2015.87</pub-id></element-citation></ref><ref id="r59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paschoal</surname><given-names>RS</given-names></name><name name-style="western"><surname>Silva</surname><given-names>DA</given-names></name><name name-style="western"><surname>Cardili</surname><given-names>RN</given-names></name><name name-style="western"><surname>Souza</surname><given-names>CDS</given-names></name></person-group><article-title>Metabolic syndrome, C-reactive protein and cardiovascular risk in
psoriasis patients: a cross-sectional study</article-title><source>An Bras Dermatol</source><year>2018</year><volume>93</volume><fpage>222</fpage><lpage>228</lpage><pub-id pub-id-type="pmid">29723366</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1590/abd1806-4841.20186397</pub-id><pub-id pub-id-type="pmcid">PMC5916394</pub-id></element-citation></ref><ref id="r60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pearce</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Morrison</surname><given-names>AE</given-names></name><name name-style="western"><surname>Higgins</surname><given-names>KB</given-names></name><name name-style="western"><surname>Crane</surname><given-names>MM</given-names></name><name name-style="western"><surname>Balkrishnan</surname><given-names>R</given-names></name><name name-style="western"><surname>Fleischer</surname><given-names>AB Jr</given-names></name><etal/></person-group><article-title>The comorbid state of psoriasis patients in a university
dermatology practice</article-title><source>J Dermatolog Treat</source><year>2005</year><volume>16</volume><fpage>319</fpage><lpage>323</lpage><pub-id pub-id-type="pmid">16428152</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/09546630500335977</pub-id></element-citation></ref><ref id="r61"><label>61</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Phillips</surname><given-names>B</given-names></name></person-group><source>Levels of Evidence and Grades of Recommendation</source><publisher-name>Oxford Centre for Evidence-Based Medicine</publisher-name><year>2001</year><date-in-citation content-type="access-date">2009 mar 01</date-in-citation><comment> Availabre from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cebm.net/2009/06/oxford-centre-evidence-based-medicine-levels-evidence-march-2009">https://www.cebm.net/2009/06/oxford-centre-evidence-based-medicine-levels-evidence-march-2009</ext-link></comment></element-citation></ref><ref id="r62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Picardi</surname><given-names>A</given-names></name><name name-style="western"><surname>Mazzotti</surname><given-names>E</given-names></name><name name-style="western"><surname>Pasquini</surname><given-names>P</given-names></name></person-group><article-title>Prevalence and correlates of suicidal ideation among patients
with skin disease</article-title><source>J Am Acad Dermatol</source><year>2006</year><volume>54</volume><fpage>420</fpage><lpage>426</lpage><pub-id pub-id-type="pmid">16488292</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaad.2005.11.1103</pub-id></element-citation></ref><ref id="r63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pietrzak</surname><given-names>D</given-names></name><name name-style="western"><surname>Pietrzak</surname><given-names>A</given-names></name><name name-style="western"><surname>Krasowska</surname><given-names>D</given-names></name><name name-style="western"><surname>Makara-Studzinska</surname><given-names>M</given-names></name><name name-style="western"><surname>Madej</surname><given-names>A</given-names></name><name name-style="western"><surname>Baranowska</surname><given-names>M</given-names></name><etal/></person-group><article-title>Depressiveness, measured with Beck Depression Inventory, in
patients with psoriasis</article-title><source>J Affect Disord</source><year>2017</year><volume>209</volume><fpage>229</fpage><lpage>234</lpage><pub-id pub-id-type="pmid">27930916</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jad.2016.11.045</pub-id></element-citation></ref><ref id="r64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pompili</surname><given-names>M</given-names></name><name name-style="western"><surname>Innamorati</surname><given-names>M</given-names></name><name name-style="western"><surname>Forte</surname><given-names>A</given-names></name><name name-style="western"><surname>Erbuto</surname><given-names>D</given-names></name><name name-style="western"><surname>Lamis</surname><given-names>DA</given-names></name><name name-style="western"><surname>Narcisi</surname><given-names>A</given-names></name><etal/></person-group><article-title>Psychiatric comorbidity and suicidal ideation in psoriasis,
melanoma and allergic disorders</article-title><source>Int J Psychiatry Clin Pract</source><year>2017</year><volume>21</volume><fpage>209</fpage><lpage>214</lpage><pub-id pub-id-type="pmid">28326880</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/13651501.2017.1301482</pub-id></element-citation></ref><ref id="r65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poot</surname><given-names>F</given-names></name><name name-style="western"><surname>Antoine</surname><given-names>E</given-names></name><name name-style="western"><surname>Gravellier</surname><given-names>M</given-names></name><name name-style="western"><surname>Hirtt</surname><given-names>J</given-names></name><name name-style="western"><surname>Alfani</surname><given-names>S</given-names></name><name name-style="western"><surname>Forchetti</surname><given-names>G</given-names></name><etal/></person-group><article-title>A case-control study on family dysfunction in patients with
alopecia areata, psoriasis and atopic dermatitis</article-title><source>Acta Derm Venereol</source><year>2011</year><volume>91</volume><fpage>415</fpage><lpage>421</lpage><pub-id pub-id-type="pmid">21336474</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2340/00015555-1074</pub-id></element-citation></ref><ref id="r66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prodanovich</surname><given-names>S</given-names></name><name name-style="western"><surname>Kirsner</surname><given-names>RS</given-names></name><name name-style="western"><surname>Kravetz</surname><given-names>JD</given-names></name><name name-style="western"><surname>Ma</surname><given-names>F</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>L</given-names></name><name name-style="western"><surname>Federman</surname><given-names>DG</given-names></name></person-group><article-title>Association of psoriasis with coronary artery, cerebrovascular,
and peripheral vascular diseases and mortality</article-title><source>Arch Dermatol</source><year>2009</year><volume>145</volume><fpage>700</fpage><lpage>703</lpage><pub-id pub-id-type="pmid">19528427</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/archdermatol.2009.94</pub-id></element-citation></ref><ref id="r67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Radtke</surname><given-names>MA</given-names></name><name name-style="western"><surname>Sch&#228;fer</surname><given-names>I</given-names></name><name name-style="western"><surname>Glaeske</surname><given-names>G</given-names></name><name name-style="western"><surname>Jacobi</surname><given-names>A</given-names></name><name name-style="western"><surname>Augustin</surname><given-names>M</given-names></name></person-group><article-title>Prevalence and comorbidities in adults with psoriasis compared to
atopic eczema</article-title><source>J Eur Acad Dermatol Venereol</source><year>2017</year><volume>31</volume><fpage>151</fpage><lpage>157</lpage><pub-id pub-id-type="pmid">27521212</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jdv.13813</pub-id></element-citation></ref><ref id="r68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roberts</surname><given-names>KK</given-names></name><name name-style="western"><surname>Cochet</surname><given-names>AE</given-names></name><name name-style="western"><surname>Lamb</surname><given-names>PB</given-names></name><name name-style="western"><surname>Brown</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Battafarano</surname><given-names>DF</given-names></name><name name-style="western"><surname>Brunt</surname><given-names>EM</given-names></name><etal/></person-group><article-title>The prevalence of NAFLD and NASH among patients with psoriasis in
a tertiary care dermatology and rheumatology clinic</article-title><source>Aliment Pharmacol Ther</source><year>2015</year><volume>41</volume><fpage>293</fpage><lpage>300</lpage><pub-id pub-id-type="pmid">25521607</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/apt.13042</pub-id></element-citation></ref><ref id="r69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salunke</surname><given-names>AS</given-names></name><name name-style="western"><surname>Nagargoje</surname><given-names>MV</given-names></name><name name-style="western"><surname>Belgaumkar</surname><given-names>VA</given-names></name><name name-style="western"><surname>Tolat</surname><given-names>SN</given-names></name><name name-style="western"><surname>Chavan</surname><given-names>RB</given-names></name></person-group><article-title>Association of Metabolic Syndrome in Chronic Plaque Psoriasis
Patients and their Correlation with Disease Severity, Duration and Age: A
Case Control Study from Western Maharashtra</article-title><source>J Clin Diagn Res</source><year>2017</year><volume>11</volume><fpage>WC06</fpage><lpage>WC10</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.7860/JCDR/2017/24390.10348</pub-id><pub-id pub-id-type="pmcid">PMC5620893</pub-id><pub-id pub-id-type="pmid">28969252</pub-id></element-citation></ref><ref id="r70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sampogna</surname><given-names>F</given-names></name><name name-style="western"><surname>Puig</surname><given-names>L</given-names></name><name name-style="western"><surname>Spuls</surname><given-names>P</given-names></name><name name-style="western"><surname>Girolomoni</surname><given-names>G</given-names></name><name name-style="western"><surname>Radtke</surname><given-names>MA</given-names></name><name name-style="western"><surname>Kirby</surname><given-names>B</given-names></name><etal/></person-group><article-title>Prevalence of alexithymia in patients with psoriasis and its
association with disease burden: a multicentre observational
study</article-title><source>Br J Dermatol</source><year>2017</year><volume>176</volume><fpage>1195</fpage><lpage>1203</lpage><pub-id pub-id-type="pmid">27995617</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bjd.15243</pub-id></element-citation></ref><ref id="r71"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sanchez-Carazo</surname><given-names>JL</given-names></name><name name-style="western"><surname>L&#243;pez-Estebaranz</surname><given-names>JL</given-names></name><name name-style="western"><surname>Guisado</surname><given-names>C</given-names></name></person-group><article-title>Comorbidities and health-related quality of life in Spanish
patients with moderate to severe psoriasis: a cross-sectional study (Arizona
study)</article-title><source>J Dermatol</source><year>2014</year><volume>41</volume><fpage>673</fpage><lpage>678</lpage><pub-id pub-id-type="pmid">24942203</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/1346-8138.12465</pub-id></element-citation></ref><ref id="r72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schmitt</surname><given-names>J</given-names></name><name name-style="western"><surname>Ford</surname><given-names>DE</given-names></name></person-group><article-title>Psoriasis is independently associated with psychiatric morbidity
and adverse cardiovascular risk factors, but not with cardiovascular events
in a population-based sample</article-title><source>J Eur Acad Dermatol Venereol</source><year>2010</year><volume>24</volume><fpage>885</fpage><lpage>892</lpage><pub-id pub-id-type="pmid">20015170</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1468-3083.2009.03537.x</pub-id></element-citation></ref><ref id="r73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schwandt</surname><given-names>A</given-names></name><name name-style="western"><surname>Bergis</surname><given-names>D</given-names></name><name name-style="western"><surname>Dapp</surname><given-names>A</given-names></name><name name-style="western"><surname>Ebner</surname><given-names>S</given-names></name><name name-style="western"><surname>Jehle</surname><given-names>PM</given-names></name><name name-style="western"><surname>K&#246;ppen</surname><given-names>S</given-names></name><etal/></person-group><article-title>Psoriasis and Diabetes: A Multicenter Study in 222078 Type 2
Diabetes Patients Reveals High Levels of Depression</article-title><source>J Diabetes Res</source><year>2015</year><volume>2015</volume><fpage>792968</fpage><lpage>792968</lpage><pub-id pub-id-type="pmid">26357664</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2015/792968</pub-id><pub-id pub-id-type="pmcid">PMC4556326</pub-id></element-citation></ref><ref id="r74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shah</surname><given-names>K</given-names></name><name name-style="western"><surname>Mellars</surname><given-names>L</given-names></name><name name-style="western"><surname>Changolkar</surname><given-names>A</given-names></name><name name-style="western"><surname>Feldman</surname><given-names>SR</given-names></name></person-group><article-title>Real-world burden of comorbidities in US patients with
psoriasis</article-title><source>J Am Acad Dermatol</source><year>2017</year><volume>77</volume><fpage>287.e4</fpage><lpage>292.e4</lpage><pub-id pub-id-type="pmid">28623046</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaad.2017.03.037</pub-id></element-citation></ref><ref id="r75"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shapiro</surname><given-names>J</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>AD</given-names></name><name name-style="western"><surname>David</surname><given-names>M</given-names></name><name name-style="western"><surname>Hodak</surname><given-names>E</given-names></name><name name-style="western"><surname>Chodik</surname><given-names>G</given-names></name><name name-style="western"><surname>Viner</surname><given-names>A</given-names></name><etal/></person-group><article-title>The association between psoriasis, diabetes mellitus, and
atherosclerosis in Israel: a case-control study</article-title><source>J Am Acad Dermatol</source><year>2007</year><volume>56</volume><fpage>629</fpage><lpage>634</lpage><pub-id pub-id-type="pmid">17157411</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaad.2006.09.017</pub-id></element-citation></ref><ref id="r76"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sommer</surname><given-names>DM</given-names></name><name name-style="western"><surname>Jenisch</surname><given-names>S</given-names></name><name name-style="western"><surname>Suchan</surname><given-names>M</given-names></name><name name-style="western"><surname>Christophers</surname><given-names>E</given-names></name><name name-style="western"><surname>Weichenthal</surname><given-names>M</given-names></name></person-group><article-title>Increased prevalence of the metabolic syndrome in patients with
moderate to severe psoriasis</article-title><source>Arch Dermatol Res</source><year>2006</year><volume>298</volume><fpage>321</fpage><lpage>328</lpage><pub-id pub-id-type="pmid">17021763</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00403-006-0703-z</pub-id></element-citation></ref><ref id="r77"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsai</surname><given-names>TF</given-names></name><name name-style="western"><surname>Wang</surname><given-names>TS</given-names></name><name name-style="western"><surname>Hung</surname><given-names>ST</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>PI</given-names></name><name name-style="western"><surname>Schenkel</surname><given-names>B</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M</given-names></name><etal/></person-group><article-title>Epidemiology and comorbidities of psoriasis patients in a
national database in Taiwan</article-title><source>J Dermatol Sci</source><year>2011</year><volume>63</volume><fpage>40</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">21543188</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jdermsci.2011.03.002</pub-id></element-citation></ref><ref id="r78"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tseng</surname><given-names>HW</given-names></name><name name-style="western"><surname>Lin</surname><given-names>HS</given-names></name><name name-style="western"><surname>Lam</surname><given-names>HC</given-names></name></person-group><article-title>Co-morbidities in psoriasis: a hospital-based case-control
study</article-title><source>J Eur Acad Dermatol Venereol</source><year>2013</year><volume>27</volume><fpage>1417</fpage><lpage>1425</lpage><pub-id pub-id-type="pmid">23134418</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jdv.12028</pub-id></element-citation></ref><ref id="r79"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsintsadze</surname><given-names>N</given-names></name><name name-style="western"><surname>Beridze</surname><given-names>L</given-names></name><name name-style="western"><surname>Tsintsadze</surname><given-names>N</given-names></name><name name-style="western"><surname>Krichun</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tsivadze</surname><given-names>N</given-names></name><name name-style="western"><surname>Tsintsadze</surname><given-names>M</given-names></name></person-group><article-title>Psychosomatic aspects in patients with dermatologic
diseases</article-title><source>Georgian Med News</source><year>2015</year><volume>243</volume><fpage>70</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">26087735</pub-id></element-citation></ref><ref id="r80"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vanaclocha</surname><given-names>F</given-names></name><name name-style="western"><surname>Crespo-Erchiga</surname><given-names>V</given-names></name><name name-style="western"><surname>Jim&#233;nez-Puya</surname><given-names>R</given-names></name><name name-style="western"><surname>Puig</surname><given-names>L</given-names></name><name name-style="western"><surname>S&#225;nchez-Carazo</surname><given-names>JL</given-names></name><name name-style="western"><surname>Ferr&#225;n</surname><given-names>M</given-names></name><etal/></person-group><article-title>Immune-mediated inflammatory diseases and other comorbidities in
patients with psoriasis: baseline characteristics of patients in the AQUILES
study</article-title><source>Actas Dermosifiliogr</source><year>2015</year><volume>106</volume><fpage>35</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">25091923</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ad.2014.06.003</pub-id></element-citation></ref><ref id="r81"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van der Voort</surname><given-names>EA</given-names></name><name name-style="western"><surname>Koehler</surname><given-names>EM</given-names></name><name name-style="western"><surname>Dowlatshahi</surname><given-names>EA</given-names></name><name name-style="western"><surname>Hofman</surname><given-names>A</given-names></name><name name-style="western"><surname>Stricker</surname><given-names>BH</given-names></name><name name-style="western"><surname>Janssen</surname><given-names>HL</given-names></name><etal/></person-group><article-title>Psoriasis is independently associated with nonalcoholic fatty
liver disease in patients 55 years old or older: Results from a
population-based study</article-title><source>J Am Acad Dermatol</source><year>2014</year><volume>70</volume><fpage>517</fpage><lpage>524</lpage><pub-id pub-id-type="pmid">24373781</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaad.2013.10.044</pub-id></element-citation></ref><ref id="r82"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walter</surname><given-names>R</given-names></name></person-group><article-title>Partial purification and characterization of post-proline
cleaving enzyme: enzymatic inactivation of neurohypophyseal hormones by
kidney preparations of various species</article-title><source>Biochim Biophys Acta</source><year>1976</year><volume>422</volume><fpage>138</fpage><lpage>158</lpage><pub-id pub-id-type="pmid">2300</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0005-2744(76)90015-2</pub-id></element-citation></ref><ref id="r83"><label>83</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name name-style="western"><surname>Wells</surname><given-names>G</given-names></name><name name-style="western"><surname>Shea</surname><given-names>B</given-names></name><name name-style="western"><surname>O'Connell</surname><given-names>D</given-names></name><name name-style="western"><surname>Robertson</surname><given-names>J</given-names></name><name name-style="western"><surname>Peterson</surname><given-names>J</given-names></name><name name-style="western"><surname>Welch</surname><given-names>V</given-names></name><etal/></person-group><source>The Newcastle-Ottawa Scale (NOS) for assessing the quality of
nonrandomised studies in meta-analyses</source><date-in-citation content-type="access-date">2018 nov 01</date-in-citation><comment>Available from: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp">http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp</ext-link></comment></element-citation></ref><ref id="r84"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>X</given-names></name><name name-style="western"><surname>Su</surname><given-names>L</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ding</surname><given-names>Y</given-names></name></person-group><article-title>The Prevalence of Nonalcoholic Fatty Liver Disease and Related
Metabolic Comorbidities Was Associated with Age at Onset of Moderate to
Severe Plaque Psoriasis: A Cross-Sectional Study</article-title><source>PLoS One</source><year>2017</year><volume>12</volume><elocation-id>e0169952</elocation-id><pub-id pub-id-type="pmid">28099469</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0169952</pub-id><pub-id pub-id-type="pmcid">PMC5242531</pub-id></element-citation></ref><ref id="r85"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>YW</given-names></name><name name-style="western"><surname>Keller</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Lin</surname><given-names>HC</given-names></name></person-group><article-title>Medical comorbidity associated with psoriasis in adults: a
population-based study</article-title><source>Br J Dermatol</source><year>2011</year><volume>165</volume><fpage>1037</fpage><lpage>1043</lpage><pub-id pub-id-type="pmid">21711339</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2133.2011.10494.x</pub-id></element-citation></ref><ref id="r86"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yeung</surname><given-names>H</given-names></name><name name-style="western"><surname>Takeshita</surname><given-names>J</given-names></name><name name-style="western"><surname>Mehta</surname><given-names>NN</given-names></name><name name-style="western"><surname>Kimmel</surname><given-names>SE</given-names></name><name name-style="western"><surname>Ogdie</surname><given-names>A</given-names></name><name name-style="western"><surname>Margolis</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>Psoriasis severity and the prevalence of major medical
comorbidity: a population-based study</article-title><source>JAMA Dermatol</source><year>2013</year><volume>149</volume><fpage>1173</fpage><lpage>1179</lpage><pub-id pub-id-type="pmid">23925466</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamadermatol.2013.5015</pub-id><pub-id pub-id-type="pmcid">PMC3800487</pub-id></element-citation></ref><ref id="r87"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yiu</surname><given-names>KH</given-names></name><name name-style="western"><surname>Yeung</surname><given-names>CK</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>CT</given-names></name><name name-style="western"><surname>Chan</surname><given-names>JC</given-names></name><name name-style="western"><surname>Siu</surname><given-names>CW</given-names></name><name name-style="western"><surname>Tam</surname><given-names>S</given-names></name><etal/></person-group><article-title>Prevalence and extent of subclinical atherosclerosis in patients
with psoriasis</article-title><source>J Intern Med</source><year>2013</year><volume>273</volume><fpage>273</fpage><lpage>282</lpage><pub-id pub-id-type="pmid">23003220</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/joim.12002</pub-id></element-citation></ref><ref id="r88"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zander</surname><given-names>N</given-names></name><name name-style="western"><surname>Sch&#228;fer</surname><given-names>I</given-names></name><name name-style="western"><surname>Radtke</surname><given-names>M</given-names></name><name name-style="western"><surname>Jacobi</surname><given-names>A</given-names></name><name name-style="western"><surname>Heigel</surname><given-names>H</given-names></name><name name-style="western"><surname>Augustin</surname><given-names>M</given-names></name></person-group><article-title>Dermatological comorbidity in psoriasis: results from a
large-scale cohort of employees</article-title><source>Arch Dermatol Res</source><year>2017</year><volume>309</volume><fpage>349</fpage><lpage>356</lpage><pub-id pub-id-type="pmid">28405739</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00403-017-1741-4</pub-id></element-citation></ref><ref id="r89"><label>89</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beutner</surname><given-names>K</given-names></name><name name-style="western"><surname>Chakrabarty</surname><given-names>A</given-names></name><name name-style="western"><surname>Lemke</surname><given-names>S</given-names></name><name name-style="western"><surname>Yu</surname><given-names>K</given-names></name></person-group><article-title>An intra-individual randomized safety and efficacy comparison of
clobetasol propionate 0.05% spray and its vehicle in the treatment of plaque
psoriasis</article-title><source>J Drugs Dermatol</source><year>2006</year><volume>5</volume><fpage>357</fpage><lpage>360</lpage><pub-id pub-id-type="pmid">16673804</pub-id></element-citation></ref><ref id="r90"><label>90</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carroll</surname><given-names>CL</given-names></name><name name-style="western"><surname>Feldman</surname><given-names>SR</given-names></name><name name-style="western"><surname>Camacho</surname><given-names>FT</given-names></name><name name-style="western"><surname>Balkrishnan</surname><given-names>R</given-names></name></person-group><article-title>Better medication adherence results in greater improvement in
severity of psoriasis</article-title><source>Br J Dermatol</source><year>2004</year><volume>151</volume><fpage>895</fpage><lpage>897</lpage><pub-id pub-id-type="pmid">15491434</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2133.2004.06174.x</pub-id></element-citation></ref><ref id="r91"><label>91</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carroll</surname><given-names>CL</given-names></name><name name-style="western"><surname>Clarke</surname><given-names>J</given-names></name><name name-style="western"><surname>Camacho</surname><given-names>F</given-names></name><name name-style="western"><surname>Balkrishnan</surname><given-names>R</given-names></name><name name-style="western"><surname>Feldman</surname><given-names>SR</given-names></name></person-group><article-title>Topical tacrolimus ointment combined with 6% salicylic acid gel
for plaque psoriasis treatment</article-title><source>Arch Dermatol</source><year>2005</year><volume>141</volume><fpage>43</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">15655140</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/archderm.141.1.43</pub-id></element-citation></ref><ref id="r92"><label>92</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Decroix</surname><given-names>J</given-names></name><name name-style="western"><surname>Pres</surname><given-names>H</given-names></name><name name-style="western"><surname>Tsankov</surname><given-names>N</given-names></name><name name-style="western"><surname>Poncet</surname><given-names>M</given-names></name><name name-style="western"><surname>Arsonnaud</surname><given-names>S</given-names></name></person-group><article-title>Clobetasol propionate lotion in the treatment of moderate to
severe plaque-type psoriasis</article-title><source>Cutis</source><year>2004</year><volume>74</volume><fpage>201</fpage><lpage>206</lpage><pub-id pub-id-type="pmid">15499763</pub-id></element-citation></ref><ref id="r93"><label>93</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Douglas</surname><given-names>WS</given-names></name><name name-style="western"><surname>Poulin</surname><given-names>Y</given-names></name><name name-style="western"><surname>Decroix</surname><given-names>J</given-names></name><name name-style="western"><surname>Ortonne</surname><given-names>JP</given-names></name><name name-style="western"><surname>Mrowietz</surname><given-names>U</given-names></name><name name-style="western"><surname>Gulliver</surname><given-names>W</given-names></name><etal/></person-group><article-title>A new calcipotriol/betamethasone formulation with rapid onset of
action was superior to monotherapy with betamethasone dipropionate or
calcipotriol in psoriasis vulgaris</article-title><source>Acta Derm Venereol</source><year>2002</year><volume>82</volume><fpage>131</fpage><lpage>135</lpage><pub-id pub-id-type="pmid">12125943</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/00015550252948194</pub-id></element-citation></ref><ref id="r94"><label>94</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dubertret</surname><given-names>L</given-names></name><name name-style="western"><surname>Wallach</surname><given-names>D</given-names></name><name name-style="western"><surname>Souteyrand</surname><given-names>P</given-names></name><name name-style="western"><surname>Perussel</surname><given-names>M</given-names></name><name name-style="western"><surname>Kalis</surname><given-names>B</given-names></name><name name-style="western"><surname>Meynadier</surname><given-names>J</given-names></name><etal/></person-group><article-title>Efficacy and safety of calcipotriol (MC 903) ointment in
psoriasis vulgaris. A randomized, double-blind, right/left comparative,
vehicle-controlled study</article-title><source>J Am Acad Dermatol</source><year>1992</year><volume>27</volume><fpage>983</fpage><lpage>988</lpage><pub-id pub-id-type="pmid">1479106</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0190-9622(92)70299-u</pub-id></element-citation></ref><ref id="r95"><label>95</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feldman</surname><given-names>SR</given-names></name><name name-style="western"><surname>Matheson</surname><given-names>R</given-names></name><name name-style="western"><surname>Bruce</surname><given-names>S</given-names></name><name name-style="western"><surname>Grande</surname><given-names>K</given-names></name><name name-style="western"><surname>Markowitz</surname><given-names>O</given-names></name><name name-style="western"><surname>Kempers</surname><given-names>S</given-names></name><etal/></person-group><article-title>Efficacy and safety of calcipotriene 0.005% foam for the
treatment of plaque-type psoriasis: results of two multicenter, randomized,
double-blind, vehicle-controlled, phase III clinical trials</article-title><source>Am J Clin Dermatol</source><year>2012</year><volume>13</volume><fpage>261</fpage><lpage>271</lpage><pub-id pub-id-type="pmid">22587791</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/11630710-000000000-00000</pub-id></element-citation></ref><ref id="r96"><label>96</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Franz</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Parsell</surname><given-names>DA</given-names></name><name name-style="western"><surname>Myers</surname><given-names>JA</given-names></name><name name-style="western"><surname>Hannigan</surname><given-names>JF</given-names></name></person-group><article-title>Clobetasol propionate foam 0.05%: a novel vehicle with enhanced
delivery</article-title><source>Int J Dermatol</source><year>2000</year><volume>39</volume><fpage>535</fpage><lpage>538</lpage><pub-id pub-id-type="pmid">10940121</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1365-4362.2000.00986-4.x</pub-id></element-citation></ref><ref id="r97"><label>97</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gottlieb</surname><given-names>AB</given-names></name><name name-style="western"><surname>Ford</surname><given-names>RO</given-names></name><name name-style="western"><surname>Spellman</surname><given-names>MC</given-names></name></person-group><article-title>The efficacy and tolerability of clobetasol propionate foam 0.05%
in the treatment of mild to moderate plaque-type psoriasis of nonscalp
regions</article-title><source>J Cutan Med Surg</source><year>2003</year><volume>7</volume><fpage>185</fpage><lpage>192</lpage><pub-id pub-id-type="pmid">12704534</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10227-002-0114-5</pub-id></element-citation></ref><ref id="r98"><label>98</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guenther</surname><given-names>L</given-names></name><name name-style="western"><surname>Van de Kerkhof</surname><given-names>PC</given-names></name><name name-style="western"><surname>Snellman</surname><given-names>E</given-names></name><name name-style="western"><surname>Kragballe</surname><given-names>K</given-names></name><name name-style="western"><surname>Chu</surname><given-names>AC</given-names></name><name name-style="western"><surname>Tegner</surname><given-names>E</given-names></name><etal/></person-group><article-title>Efficacy and safety of a new combination of calcipotriol and
betamethasone dipropionate (once or twice daily) compared to calcipotriol
(twice daily) in the treatment of psoriasis vulgaris: a randomized,
double-blind, vehicle-controlled clinical trial</article-title><source>Br J Dermatol</source><year>2002</year><volume>147</volume><fpage>316</fpage><lpage>323</lpage><pub-id pub-id-type="pmid">12174105</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1365-2133.2002.04967.x</pub-id></element-citation></ref><ref id="r99"><label>99</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Helfrich</surname><given-names>YR</given-names></name><name name-style="western"><surname>Kang</surname><given-names>S</given-names></name><name name-style="western"><surname>Hamilton</surname><given-names>TA</given-names></name><name name-style="western"><surname>Voorhees</surname><given-names>JJ</given-names></name></person-group><article-title>Topical becocalcidiol for the treatment of psoriasis vulgaris: a
randomized, placebo-controlled, double-blind, multicentre
study</article-title><source>Br J Dermatol</source><year>2007</year><volume>157</volume><fpage>369</fpage><lpage>374</lpage><pub-id pub-id-type="pmid">17596167</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2133.2007.08037.x</pub-id></element-citation></ref><ref id="r100"><label>100</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Highton</surname><given-names>A</given-names></name><name name-style="western"><surname>Quell</surname><given-names>J</given-names></name></person-group><article-title>Calcipotriene ointment 0.005% for psoriasis: a safety and
efficacy study. Calcipotriene Study Group</article-title><source>J Am Acad Dermatol</source><year>1995</year><volume>32</volume><fpage>67</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">7822519</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0190-9622(95)90186-8</pub-id></element-citation></ref><ref id="r101"><label>101</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jarratt</surname><given-names>MT</given-names></name><name name-style="western"><surname>Clark</surname><given-names>SD</given-names></name><name name-style="western"><surname>Savin</surname><given-names>RC</given-names></name><name name-style="western"><surname>Swinyer</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Safley</surname><given-names>CF</given-names></name><name name-style="western"><surname>Brodell</surname><given-names>RT</given-names></name><etal/></person-group><article-title>Evaluation of the efficacy and safety of clobetasol propionate
spray in the treatment of plaque-type psoriasis</article-title><source>Cutis</source><year>2006</year><volume>78</volume><fpage>348</fpage><lpage>354</lpage><pub-id pub-id-type="pmid">17186795</pub-id></element-citation></ref><ref id="r102"><label>102</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaufmann</surname><given-names>R</given-names></name><name name-style="western"><surname>Bibby</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Bissonnette</surname><given-names>R</given-names></name><name name-style="western"><surname>Cambazard</surname><given-names>F</given-names></name><name name-style="western"><surname>Chu</surname><given-names>AC</given-names></name><name name-style="western"><surname>Decroix</surname><given-names>J</given-names></name><etal/></person-group><article-title>A New Calcipotriol/Betamethasone Dipropionate Formulation
(Daivobet&lt;sup&gt;TM&lt;/ sup&gt;) Is an Effective Once-Daily Treatment
for Psoriasis vulgaris</article-title><source>Dermatology</source><year>2002</year><volume>205</volume><fpage>389</fpage><lpage>393</lpage><pub-id pub-id-type="pmid">12444337</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000066440</pub-id></element-citation></ref><ref id="r103"><label>103</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kragballe</surname><given-names>K</given-names></name><name name-style="western"><surname>Noerrelund</surname><given-names>KL</given-names></name><name name-style="western"><surname>Lui</surname><given-names>H</given-names></name><name name-style="western"><surname>Ortonne</surname><given-names>JP</given-names></name><name name-style="western"><surname>Wozel</surname><given-names>G</given-names></name><name name-style="western"><surname>Uurasmaa</surname><given-names>T</given-names></name><etal/></person-group><article-title>Efficacy of once-daily treatment regimens with
calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment
in psoriasis vulgaris</article-title><source>Br J Dermatol</source><year>2004</year><volume>150</volume><fpage>1167</fpage><lpage>1173</lpage><pub-id pub-id-type="pmid">15214905</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2133.2004.05986.x</pub-id></element-citation></ref><ref id="r104"><label>104</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kragballe</surname><given-names>K</given-names></name></person-group><article-title>Treatment of psoriasis by the topical application of the novel
cholecalciferol analogue calcipotriol (MC 903)</article-title><source>Arch Dermatol</source><year>1989</year><volume>125</volume><fpage>1647</fpage><lpage>1652</lpage><pub-id pub-id-type="pmid">2531570</pub-id></element-citation></ref><ref id="r105"><label>105</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lane</surname><given-names>AT</given-names></name><name name-style="western"><surname>Wachs</surname><given-names>GN</given-names></name><name name-style="western"><surname>Weston</surname><given-names>WL</given-names></name></person-group><article-title>Once-daily treatment of psoriasis with topical
glucocorticosteroid ointments</article-title><source>J Am Acad Dermatol</source><year>1983</year><volume>8</volume><fpage>523</fpage><lpage>525</lpage><pub-id pub-id-type="pmid">6853785</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0190-9622(83)70059-9</pub-id></element-citation></ref><ref id="r106"><label>106</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Langner</surname><given-names>A</given-names></name><name name-style="western"><surname>Verjans</surname><given-names>H</given-names></name><name name-style="western"><surname>Stap&#243;r</surname><given-names>V</given-names></name><name name-style="western"><surname>Mol</surname><given-names>M</given-names></name><name name-style="western"><surname>Fraczykowska</surname><given-names>M</given-names></name></person-group><article-title>Topical calcitriol in the treatment of chronic plaque psoriasis:
a double-blind study</article-title><source>Br J Dermatol</source><year>1993</year><volume>128</volume><fpage>566</fpage><lpage>571</lpage><pub-id pub-id-type="pmid">8504051</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2133.1993.tb00237.x</pub-id></element-citation></ref><ref id="r107"><label>107</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lebwohl</surname><given-names>M</given-names></name><name name-style="western"><surname>Menter</surname><given-names>A</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>J</given-names></name><name name-style="western"><surname>Clark</surname><given-names>SD</given-names></name><name name-style="western"><surname>Flores</surname><given-names>J</given-names></name><name name-style="western"><surname>Powers</surname><given-names>J</given-names></name><etal/></person-group><article-title>Calcitriol 3 microg/g ointment in the management of mild to
moderate plaque type psoriasis: results from 2 placebo-controlled,
multicenter, randomized double-blind, clinical studies</article-title><source>J Drugs Dermatol</source><year>2007</year><volume>6</volume><fpage>428</fpage><lpage>435</lpage><pub-id pub-id-type="pmid">17668541</pub-id></element-citation></ref><ref id="r108"><label>108</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lebwohl</surname><given-names>M</given-names></name><name name-style="western"><surname>Sherer</surname><given-names>D</given-names></name><name name-style="western"><surname>Washenik</surname><given-names>K</given-names></name><name name-style="western"><surname>Krueger</surname><given-names>GG</given-names></name><name name-style="western"><surname>Menter</surname><given-names>A</given-names></name><name name-style="western"><surname>Koo</surname><given-names>J</given-names></name><etal/></person-group><article-title>A randomized, double-blind, placebo-controlled study of
clobetasol propionate 0.05% foam in the treatment of nonscalp
psoriasis</article-title><source>Int J Dermatol</source><year>2002</year><volume>41</volume><fpage>269</fpage><lpage>274</lpage><pub-id pub-id-type="pmid">12100701</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1365-4362.2002.01431.x</pub-id></element-citation></ref><ref id="r109"><label>109</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olsen</surname><given-names>EA</given-names></name></person-group><article-title>Efficacy and safety of fluticasone propionate 0.005% ointment in
the treatment of psoriasis</article-title><source>Cutis</source><year>1996</year><volume>57</volume><issue>2</issue><supplement>Suppl</supplement><fpage>57</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">8646872</pub-id></element-citation></ref><ref id="r110"><label>110</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Papp</surname><given-names>KA</given-names></name><name name-style="western"><surname>Guenther</surname><given-names>L</given-names></name><name name-style="western"><surname>Boyden</surname><given-names>B</given-names></name><name name-style="western"><surname>Larsen</surname><given-names>FG</given-names></name><name name-style="western"><surname>Harvima</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Guilhou</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>Early onset of action and efficacy of a combination of
calcipotriene and betamethasone dipropionate in the treatment of
psoriasis</article-title><source>J Am Acad Dermatol</source><year>2003</year><volume>48</volume><fpage>48</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">12522370</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1067/mjd.2003.130</pub-id></element-citation></ref><ref id="r111"><label>111</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>P&#232;rez</surname><given-names>A</given-names></name><name name-style="western"><surname>Chen</surname><given-names>TC</given-names></name><name name-style="western"><surname>Turner</surname><given-names>A</given-names></name><name name-style="western"><surname>Raab</surname><given-names>R</given-names></name><name name-style="western"><surname>Bhawan</surname><given-names>J</given-names></name><name name-style="western"><surname>Poche</surname><given-names>P</given-names></name><etal/></person-group><article-title>Efficacy and safety of topical calcitriol (1,25-dihydroxyvitamin
d3) for the treatment of psoriasis</article-title><source>Br J Dermatol</source><year>1996</year><volume>134</volume><fpage>238</fpage><lpage>246</lpage><pub-id pub-id-type="pmid">8746336</pub-id></element-citation></ref><ref id="r112"><label>112</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Queille-Roussel</surname><given-names>C</given-names></name><name name-style="western"><surname>Hoffmann</surname><given-names>V</given-names></name><name name-style="western"><surname>Ganslandt</surname><given-names>C</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>KK</given-names></name></person-group><article-title>Comparison of the antipsoriatic effect and tolerability of
calcipotriol-containing products in the treatment of psoriasis vulgaris
using a modified psoriasis plaque test</article-title><source>Clin Drug Investig</source><year>2012</year><volume>32</volume><fpage>613</fpage><lpage>619</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF03261916</pub-id><pub-id pub-id-type="pmid">22845045</pub-id></element-citation></ref><ref id="r113"><label>113</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saraceno</surname><given-names>R</given-names></name><name name-style="western"><surname>Andreassi</surname><given-names>L</given-names></name><name name-style="western"><surname>Ayala</surname><given-names>F</given-names></name><name name-style="western"><surname>Bongiorno</surname><given-names>MR</given-names></name><name name-style="western"><surname>Giannetti</surname><given-names>A</given-names></name><name name-style="western"><surname>Lisi</surname><given-names>P</given-names></name><etal/></person-group><article-title>Efficacy, safety and quality of life of
calcipotriol/betamethasone dipropionate (Dovobet) versus calcipotriol
(Daivonex) in the treatment of psoriasis vulgaris: a randomized,
multicentre, clinical trial</article-title><source>J Dermatolog Treat</source><year>2007</year><volume>18</volume><fpage>361</fpage><lpage>365</lpage><pub-id pub-id-type="pmid">17934937</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/09546630701646156</pub-id></element-citation></ref><ref id="r114"><label>114</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stein</surname><given-names>LF</given-names></name><name name-style="western"><surname>Sherr</surname><given-names>A</given-names></name><name name-style="western"><surname>Solodkina</surname><given-names>G</given-names></name><name name-style="western"><surname>Gottlieb</surname><given-names>AB</given-names></name><name name-style="western"><surname>Chaudhari</surname><given-names>U</given-names></name></person-group><article-title>Betamethasone valerate foam for treatment of nonscalp
psoriasis</article-title><source>J Cutan Med Surg</source><year>2001</year><volume>5</volume><fpage>303</fpage><lpage>307</lpage><pub-id pub-id-type="pmid">11907840</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10227-001-0006-0</pub-id></element-citation></ref><ref id="r115"><label>115</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van der Velden</surname><given-names>HM1</given-names></name><name name-style="western"><surname>Pasch</surname><given-names>MC</given-names></name><name name-style="western"><surname>van Erp</surname><given-names>PE</given-names></name><name name-style="western"><surname>van Lingen</surname><given-names>RG</given-names></name><name name-style="western"><surname>Otero</surname><given-names>ME</given-names></name><name name-style="western"><surname>de Boervan Huizen</surname><given-names>RT</given-names></name><etal/></person-group><article-title>Treatment of plaque psoriasis with the two-compound product
calcipotriol/betamethasone dipropionate versus both monotherapies: an
immunohistochemical study</article-title><source>J Dermatolog Treat</source><year>2010</year><volume>21</volume><fpage>13</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">20055694</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3109/09546630903214175</pub-id></element-citation></ref><ref id="r116"><label>116</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zonneveld</surname><given-names>IM</given-names></name><name name-style="western"><surname>Rubins</surname><given-names>A</given-names></name><name name-style="western"><surname>Jablonska</surname><given-names>S</given-names></name><name name-style="western"><surname>Dobozy</surname><given-names>A</given-names></name><name name-style="western"><surname>Ruzicka</surname><given-names>T</given-names></name><name name-style="western"><surname>Kind</surname><given-names>P</given-names></name><etal/></person-group><article-title>Topical tacrolimus is not effective in chronic plaque psoriasis.
A pilot study</article-title><source>Arch Dermatol</source><year>1998</year><volume>134</volume><fpage>1101</fpage><lpage>1102</lpage><pub-id pub-id-type="pmid">9762021</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/archderm.134.9.1101</pub-id></element-citation></ref><ref id="r117"><label>117</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tzaneva</surname><given-names>S</given-names></name><name name-style="western"><surname>Geroldinger</surname><given-names>A</given-names></name><name name-style="western"><surname>Trattner</surname><given-names>H</given-names></name><name name-style="western"><surname>Tanew</surname><given-names>A</given-names></name></person-group><article-title>Fumaric acid esters in combination with a 6-week course of
narrowband ultraviolet B provides an accelerated response compared with
fumaric acid esters monotherapy in patients with moderate-to-severe plaque
psoriasis: a randomized prospective clinical study</article-title><source>Br J Dermatol</source><year>2018</year><volume>178</volume><fpage>682</fpage><lpage>688</lpage><pub-id pub-id-type="pmid">29114862</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bjd.16106</pub-id></element-citation></ref><ref id="r118"><label>118</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Hamamy</surname><given-names>HR</given-names></name><name name-style="western"><surname>Al-Mashhadani</surname><given-names>SA</given-names></name><name name-style="western"><surname>Mustafa</surname><given-names>IN</given-names></name></person-group><article-title>Comparative study of the effect of narrowband ultraviolet B
phototherapy plus methotrexate vs. narrowband ultraviolet B alone and
methotrexate alone in the treatment of plaque-type psoriasis</article-title><source>Int J Dermatol</source><year>2014</year><volume>53</volume><fpage>1531</fpage><lpage>1535</lpage><pub-id pub-id-type="pmid">24738793</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ijd.12444</pub-id></element-citation></ref><ref id="r119"><label>119</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lynde</surname><given-names>CW</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>AK</given-names></name><name name-style="western"><surname>Guenther</surname><given-names>L</given-names></name><name name-style="western"><surname>Poulin</surname><given-names>Y</given-names></name><name name-style="western"><surname>Levesque</surname><given-names>A</given-names></name><name name-style="western"><surname>Bissonnette</surname><given-names>R</given-names></name></person-group><article-title>A randomized study comparing the combination of nbUVB and
etanercept to etanercept monotherapy in patients with psoriasis who do not
exhibit an excellent response after 12 weeks of etanercept</article-title><source>J Dermatolog Treat</source><year>2012</year><volume>23</volume><fpage>261</fpage><lpage>267</lpage><pub-id pub-id-type="pmid">21797805</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3109/09546634.2011.607795</pub-id></element-citation></ref><ref id="r120"><label>120</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wolf</surname><given-names>P</given-names></name><name name-style="western"><surname>Hofer</surname><given-names>A</given-names></name><name name-style="western"><surname>Legat</surname><given-names>FJ</given-names></name><name name-style="western"><surname>Bretterklieber</surname><given-names>A</given-names></name><name name-style="western"><surname>Weger</surname><given-names>W</given-names></name><name name-style="western"><surname>Salmhofer</surname><given-names>W</given-names></name><etal/></person-group><article-title>Treatment with 311-nm ultraviolet B accelerates and improves the
clearance of psoriatic lesions in patients treated with
etanercept</article-title><source>Br J Dermatol</source><year>2009</year><volume>160</volume><fpage>186</fpage><lpage>189</lpage><pub-id pub-id-type="pmid">19067710</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2133.2008.08926.x</pub-id></element-citation></ref><ref id="r121"><label>121</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wolf</surname><given-names>P</given-names></name><name name-style="western"><surname>Hofer</surname><given-names>A</given-names></name><name name-style="western"><surname>Weger</surname><given-names>W</given-names></name><name name-style="western"><surname>Posch-Fabian</surname><given-names>T</given-names></name><name name-style="western"><surname>Gruber-Wackernagel</surname><given-names>A</given-names></name><name name-style="western"><surname>Legat</surname><given-names>FJ</given-names></name></person-group><article-title>311 nm ultraviolet B-accelerated response of psoriatic lesions in
adalimumab-treated patients</article-title><source>Photodermatol Photoimmunol Photomed</source><year>2011</year><volume>27</volume><fpage>186</fpage><lpage>189</lpage><pub-id pub-id-type="pmid">21729166</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1600-0781.2011.00594.x</pub-id></element-citation></ref><ref id="r122"><label>122</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takahashi</surname><given-names>H</given-names></name><name name-style="western"><surname>Tsuji</surname><given-names>H</given-names></name><name name-style="western"><surname>Ishida-Yamamoto</surname><given-names>A</given-names></name><name name-style="western"><surname>Iizuka</surname><given-names>H</given-names></name></person-group><article-title>Comparison of clinical effects of psoriasis treatment regimens
among calcipotriol alone, narrowband ultraviolet B phototherapy alone,
combination of calcipotriol and narrowband ultraviolet B phototherapy once a
week, and combination of calcipotriol and narrowband ultraviolet B
phototherapy more than twice a week</article-title><source>J Dermatol</source><year>2013</year><volume>40</volume><fpage>424</fpage><lpage>427</lpage><pub-id pub-id-type="pmid">23414298</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/1346-8138.12102</pub-id></element-citation></ref><ref id="r123"><label>123</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khanna</surname><given-names>N</given-names></name><name name-style="western"><surname>Nazli</surname><given-names>T</given-names></name><name name-style="western"><surname>Siddiqui</surname><given-names>KM</given-names></name><name name-style="western"><surname>Kalaivani</surname><given-names>M</given-names></name><name name-style="western"><surname>Rais-ur-Rahman</surname></name></person-group><article-title>A non-inferiority randomized controlled clinical trial comparing
Unani formulation &amp; psoralen plus ultraviolet A sol in chronic plaque
psoriasis</article-title><source>Indian J Med Res</source><year>2018</year><volume>147</volume><fpage>66</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">29749363</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/ijmr.IJMR_249_16</pub-id><pub-id pub-id-type="pmcid">PMC5967219</pub-id></element-citation></ref><ref id="r124"><label>124</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lozinski</surname><given-names>A</given-names></name><name name-style="western"><surname>Barzilai</surname><given-names>A</given-names></name><name name-style="western"><surname>Pavlotsky</surname><given-names>F</given-names></name></person-group><article-title>Broad-band UVB versus paint PUVA for palmoplantar psoriasis
treatment</article-title><source>J Dermatolog Treat</source><year>2016</year><volume>27</volume><fpage>221</fpage><lpage>223</lpage><pub-id pub-id-type="pmid">26481287</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3109/09546634.2015.1093588</pub-id></element-citation></ref><ref id="r125"><label>125</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dawe</surname><given-names>RS</given-names></name><name name-style="western"><surname>Cameron</surname><given-names>H</given-names></name><name name-style="western"><surname>Yule</surname><given-names>S</given-names></name><name name-style="western"><surname>Man</surname><given-names>I</given-names></name><name name-style="western"><surname>Wainwright</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Ibbotson</surname><given-names>SH</given-names></name><etal/></person-group><article-title>A randomized controlled trial of narrowband ultraviolet B vs
bath-psoralen plus ultraviolet A photochemotherapy for
psoriasis</article-title><source>Br J Dermatol</source><year>2003</year><volume>148</volume><fpage>1194</fpage><lpage>1204</lpage><pub-id pub-id-type="pmid">12828749</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1365-2133.2003.05482.x</pub-id></element-citation></ref><ref id="r126"><label>126</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Snellman</surname><given-names>E</given-names></name><name name-style="western"><surname>Klimenko</surname><given-names>T</given-names></name><name name-style="western"><surname>Rantanen</surname><given-names>T</given-names></name></person-group><article-title>Randomized half-side comparison of narrowband UVB and
trimethylpsoralen bath plus UVA treatments for psoriasis</article-title><source>Acta Derm Venereol</source><year>2004</year><volume>84</volume><fpage>132</fpage><lpage>137</lpage><pub-id pub-id-type="pmid">15206693</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/00015550310022916</pub-id></element-citation></ref><ref id="r127"><label>127</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Markham</surname><given-names>T</given-names></name><name name-style="western"><surname>Rogers</surname><given-names>S</given-names></name><name name-style="western"><surname>Collins</surname><given-names>P</given-names></name></person-group><article-title>Narrowband UV-B (TL-01) phototherapy vs oral 8-methoxypsoralen
psoralen-UV-A for the treatment of chronic plaque psoriasis</article-title><source>Arch Dermatol</source><year>2003</year><volume>139</volume><fpage>325</fpage><lpage>328</lpage><pub-id pub-id-type="pmid">12622624</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/archderm.139.3.325</pub-id></element-citation></ref><ref id="r128"><label>128</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gordon</surname><given-names>PM</given-names></name><name name-style="western"><surname>Diffey</surname><given-names>BL</given-names></name><name name-style="western"><surname>Matthews</surname><given-names>JN</given-names></name><name name-style="western"><surname>Farr</surname><given-names>PM</given-names></name></person-group><article-title>A randomized comparison of narrow-band TL-01 phototherapy and
PUVA photochemotherapy for psoriasis</article-title><source>J Am Acad Dermatol</source><year>1999</year><volume>41</volume><fpage>728</fpage><lpage>732</lpage><pub-id pub-id-type="pmid">10534635</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0190-9622(99)70008-3</pub-id></element-citation></ref><ref id="r129"><label>129</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salem</surname><given-names>SA</given-names></name><name name-style="western"><surname>Barakat</surname><given-names>MA</given-names></name><name name-style="western"><surname>Morcos</surname><given-names>CM</given-names></name></person-group><article-title>Bath psoralen+ultraviolet A photochemotherapy vs. narrow
band-ultraviolet B in psoriasis: a comparison of clinical outcome and effect
on circulating T-helper and T-suppressor/cytotoxic cells</article-title><source>Photodermatol Photoimmunol Photomed</source><year>2010</year><volume>26</volume><fpage>235</fpage><lpage>242</lpage><pub-id pub-id-type="pmid">20831697</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1600-0781.2010.00525.x</pub-id></element-citation></ref><ref id="r130"><label>130</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Green</surname><given-names>C</given-names></name><name name-style="western"><surname>Lakshmipathi</surname><given-names>T</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>BE</given-names></name><name name-style="western"><surname>Ferguson</surname><given-names>J</given-names></name></person-group><article-title>A comparison of the efficacy and relapse rates of narrowband UVB
(TL-01) monotherapy vs. etretinate (re- TL-01) vs. etretinate-PUVA (re-PUVA)
in the treatment of psoriasis patients</article-title><source>Br J Dermatol</source><year>1992</year><volume>127</volume><fpage>5</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">1637696</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2133.1992.tb14815.x</pub-id></element-citation></ref><ref id="r131"><label>131</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ozdemir</surname><given-names>M</given-names></name><name name-style="western"><surname>Engin</surname><given-names>B</given-names></name><name name-style="western"><surname>Baysal</surname><given-names>I</given-names></name><name name-style="western"><surname>Mevlitoglu</surname><given-names>I</given-names></name></person-group><article-title>A randomized comparison of acitretinnarrow-band TL-01
phototherapy and acitretin-psoralen plus ultraviolet A for
psoriasis</article-title><source>Acta Derm Venereol</source><year>2008</year><volume>88</volume><fpage>589</fpage><lpage>593</lpage><pub-id pub-id-type="pmid">19002344</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2340/00015555-0529</pub-id></element-citation></ref><ref id="r132"><label>132</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chauhan</surname><given-names>PS</given-names></name><name name-style="western"><surname>Kaur</surname><given-names>I</given-names></name><name name-style="western"><surname>Dogra</surname><given-names>S</given-names></name><name name-style="western"><surname>De</surname><given-names>D</given-names></name><name name-style="western"><surname>Kanwar</surname><given-names>AJ</given-names></name></person-group><article-title>Narrowband ultraviolet B versus psoralen plus ultraviolet A
therapy for severe plaque psoriasis: an Indian perspective</article-title><source>Clin Exp Dermatol</source><year>2011</year><volume>36</volume><fpage>169</fpage><lpage>173</lpage><pub-id pub-id-type="pmid">20545955</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2230.2010.03874.x</pub-id></element-citation></ref><ref id="r133"><label>133</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dayal</surname><given-names>S</given-names></name><name name-style="western"><surname>Mayanka</surname></name><name name-style="western"><surname>Jain</surname><given-names>VK</given-names></name></person-group><article-title>Comparative evaluation of NBUVB phototherapy and PUVA
photochemotherapy in chronic plaque psoriasis</article-title><source>Indian J Dermatol Venereol Leprol</source><year>2010</year><volume>76</volume><fpage>533</fpage><lpage>537</lpage><pub-id pub-id-type="pmid">20826993</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/0378-6323.69081</pub-id></element-citation></ref><ref id="r134"><label>134</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sezer</surname><given-names>E</given-names></name><name name-style="western"><surname>Erbil</surname><given-names>AH</given-names></name><name name-style="western"><surname>Kurumlu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Tastan</surname><given-names>HB</given-names></name><name name-style="western"><surname>Etikan</surname><given-names>I</given-names></name></person-group><article-title>Comparison of the efficacy of local narrowband ultraviolet B
(NB-UVB) phototherapy versus psoralen plus ultraviolet A (PUVA) paint for
palmoplantar psoriasis</article-title><source>J Dermatol</source><year>2007</year><volume>34</volume><fpage>435</fpage><lpage>440</lpage><pub-id pub-id-type="pmid">17584319</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1346-8138.2007.00306.x</pub-id></element-citation></ref><ref id="r135"><label>135</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Warren</surname><given-names>RB</given-names></name><name name-style="western"><surname>Mrowietz</surname><given-names>U</given-names></name><name name-style="western"><surname>von Kiedrowski</surname><given-names>R</given-names></name><name name-style="western"><surname>Niesmann</surname><given-names>J</given-names></name><name name-style="western"><surname>Wilsmann-Theis</surname><given-names>D</given-names></name><name name-style="western"><surname>Ghoreschi</surname><given-names>K</given-names></name><etal/></person-group><article-title>An intensified dosing schedule of subcutaneous methotrexate in
patients with moderate to severe plaque-type psoriasis (METOP): a 52 week,
multicentre, randomised, double-blind, placebo-controlled, phase 3
trial</article-title><source>Lancet</source><year>2017</year><volume>389</volume><fpage>528</fpage><lpage>537</lpage><pub-id pub-id-type="pmid">28012564</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(16)32127-4</pub-id></element-citation></ref><ref id="r136"><label>136</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reich</surname><given-names>K</given-names></name><name name-style="western"><surname>Signorovitch</surname><given-names>J</given-names></name><name name-style="western"><surname>Ramakrishnan</surname><given-names>K</given-names></name><name name-style="western"><surname>Yu</surname><given-names>AP</given-names></name><name name-style="western"><surname>Wu</surname><given-names>EQ</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>SR</given-names></name><etal/></person-group><article-title>Benefit-risk analysis of adalimumab versus methotrexate and
placebo in the treatment of moderate to severe psoriasis: comparison of
adverse event-free response days in the CHAMPION trial</article-title><source>J Am Acad Dermatol</source><year>2010</year><volume>63</volume><fpage>1011</fpage><lpage>1018</lpage><pub-id pub-id-type="pmid">20933301</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaad.2009.12.029</pub-id></element-citation></ref><ref id="r137"><label>137</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saurat</surname><given-names>JH</given-names></name><name name-style="western"><surname>Stingl</surname><given-names>G</given-names></name><name name-style="western"><surname>Dubertret</surname><given-names>L</given-names></name><name name-style="western"><surname>Papp</surname><given-names>K</given-names></name><name name-style="western"><surname>Langley</surname><given-names>RG</given-names></name><name name-style="western"><surname>Ortonne</surname><given-names>JP</given-names></name><etal/></person-group><article-title>Efficacy and safety results from the randomized controlled
comparative study of adalimumab vs. methotrexate vs. placebo in patients
with psoriasis (CHAMPION)</article-title><source>Br J Dermatol</source><year>2008</year><volume>158</volume><fpage>558</fpage><lpage>566</lpage><pub-id pub-id-type="pmid">18047523</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2133.2007.08315.x</pub-id></element-citation></ref><ref id="r138"><label>138</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dogra</surname><given-names>S</given-names></name><name name-style="western"><surname>Jain</surname><given-names>A</given-names></name><name name-style="western"><surname>Kanwar</surname><given-names>AJ</given-names></name></person-group><article-title>Efficacy and safety of acitretin in three fixed doses of 25, 35
and 50 mg in adult patients with severe plaque type psoriasis: a randomized,
double blind, parallel group, dose ranging study</article-title><source>J Eur Acad Dermatol Venereol</source><year>2013</year><volume>27</volume><fpage>e305</fpage><lpage>e311</lpage><pub-id pub-id-type="pmid">22816881</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1468-3083.2012.04644.x</pub-id></element-citation></ref><ref id="r139"><label>139</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gupta</surname><given-names>AK</given-names></name><name name-style="western"><surname>Goldfarb</surname><given-names>MT</given-names></name><name name-style="western"><surname>Ellis</surname><given-names>CN</given-names></name><name name-style="western"><surname>Voorhees</surname><given-names>JJ</given-names></name></person-group><article-title>Side-effect profile of acitretin therapy in
psoriasis</article-title><source>J Am Acad Dermatol</source><year>1989</year><volume>20</volume><fpage>1088</fpage><lpage>1093</lpage><pub-id pub-id-type="pmid">2526824</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0190-9622(89)70138-9</pub-id></element-citation></ref><ref id="r140"><label>140</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Colombo</surname><given-names>D</given-names></name><name name-style="western"><surname>Cassano</surname><given-names>N</given-names></name><name name-style="western"><surname>Altomare</surname><given-names>G</given-names></name><name name-style="western"><surname>Giannetti</surname><given-names>A</given-names></name><name name-style="western"><surname>Vena</surname><given-names>GA</given-names></name></person-group><article-title>Psoriasis relapse evaluation with week-end cyclosporine A
treatment: results of a randomized, double-blind, multicenter
study</article-title><source>Int J Immunopathol Pharmacol</source><year>2010</year><volume>23</volume><fpage>1143</fpage><lpage>1152</lpage><pub-id pub-id-type="pmid">21244763</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/039463201002300418</pub-id></element-citation></ref><ref id="r141"><label>141</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Laburte</surname><given-names>C</given-names></name><name name-style="western"><surname>Grossman</surname><given-names>R</given-names></name><name name-style="western"><surname>Abi-Rached</surname><given-names>J</given-names></name><name name-style="western"><surname>Abeywickrama</surname><given-names>KH</given-names></name><name name-style="western"><surname>Dubertret</surname><given-names>L</given-names></name></person-group><article-title>Efficacy and safety of oral cyclosporin A (CyA; Sandimmun) for
long-term treatment of chronic severe plaque psoriasis</article-title><source>Br J Dermatol</source><year>1994</year><volume>130</volume><fpage>366</fpage><lpage>375</lpage><pub-id pub-id-type="pmid">8148280</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2133.1994.tb02935.x</pub-id></element-citation></ref><ref id="r142"><label>142</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Christophers</surname><given-names>E</given-names></name><name name-style="western"><surname>Mrowietz</surname><given-names>U</given-names></name><name name-style="western"><surname>Henneicke</surname><given-names>HH</given-names></name><name name-style="western"><surname>F&#228;rber</surname><given-names>L</given-names></name><name name-style="western"><surname>Welzel</surname><given-names>D</given-names></name></person-group><article-title>Cyclosporine in psoriasis: a multicenter dose-finding study in
severe plaque psoriasis</article-title><source>J Am Acad Dermatol</source><year>1992</year><volume>26</volume><fpage>86</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">1732342</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0190-9622(92)70012-5</pub-id></element-citation></ref><ref id="r143"><label>143</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Asahina</surname><given-names>A</given-names></name><name name-style="western"><surname>Nakagawa</surname><given-names>H</given-names></name><name name-style="western"><surname>Etoh</surname><given-names>T</given-names></name><name name-style="western"><surname>Ohtsuki</surname><given-names>M</given-names></name><collab>Adalimumab M04-688 Study Group</collab></person-group><article-title>Adalimumab in Japanese patients with moderate to severe chronic
plaque psoriasis: Efficacy and safety results from a Phase II/III randomized
controlled study</article-title><source>J Dermatol</source><year>2010</year><volume>37</volume><fpage>299</fpage><lpage>310</lpage><pub-id pub-id-type="pmid">20507398</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1346-8138.2009.00748.x</pub-id></element-citation></ref><ref id="r144"><label>144</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bagel</surname><given-names>J</given-names></name><name name-style="western"><surname>Lynde</surname><given-names>C</given-names></name><name name-style="western"><surname>Tyring</surname><given-names>S</given-names></name><name name-style="western"><surname>Kricorian</surname><given-names>G</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Klekotka</surname><given-names>P</given-names></name></person-group><article-title>Moderate to severe plaque psoriasis with scalp involvement: a
randomized, double-blind, placebo-controlled study of
etanercept</article-title><source>J Am Acad Dermatol</source><year>2012</year><volume>67</volume><fpage>86</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">22014541</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaad.2011.07.034</pub-id></element-citation></ref><ref id="r145"><label>145</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cai</surname><given-names>L</given-names></name><name name-style="western"><surname>Gu</surname><given-names>J</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>J</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>M</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G</given-names></name><name name-style="western"><surname>Xi</surname><given-names>LY</given-names></name><etal/></person-group><article-title>Efficacy and safety of adalimumab in Chinese patients with
moderate-to-severe plaque psoriasis: results from a phase 3, randomized,
placebo-controlled, double-blind study</article-title><source>J Eur Acad Dermatol Venereol</source><year>2017</year><volume>31</volume><fpage>89</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">27504914</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jdv.13746</pub-id><pub-id pub-id-type="pmcid">PMC5215651</pub-id></element-citation></ref><ref id="r146"><label>146</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chaudhari</surname><given-names>U</given-names></name><name name-style="western"><surname>Romano</surname><given-names>P</given-names></name><name name-style="western"><surname>Mulcahy</surname><given-names>LD</given-names></name><name name-style="western"><surname>Dooley</surname><given-names>LT</given-names></name><name name-style="western"><surname>Baker</surname><given-names>DG</given-names></name><name name-style="western"><surname>Gottlieb</surname><given-names>AB</given-names></name></person-group><article-title>Efficacy and safety of infliximab monotherapy for plaque-type
psoriasis: a randomised trial</article-title><source>Lancet</source><year>2001</year><volume>357</volume><fpage>1842</fpage><lpage>1847</lpage><pub-id pub-id-type="pmid">11410193</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0140-6736(00)04954-0</pub-id></element-citation></ref><ref id="r147"><label>147</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feldman</surname><given-names>SR</given-names></name><name name-style="western"><surname>Gottlieb</surname><given-names>AB</given-names></name><name name-style="western"><surname>Bala</surname><given-names>M</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Eisenberg</surname><given-names>D</given-names></name><name name-style="western"><surname>Guzzo</surname><given-names>C</given-names></name><etal/></person-group><article-title>Infliximab improves health-related quality of life in the
presence of comorbidities among patients with moderate-to-severe
psoriasis</article-title><source>Br J Dermatol</source><year>2008</year><volume>159</volume><fpage>704</fpage><lpage>710</lpage><pub-id pub-id-type="pmid">18627375</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2133.2008.08727.x</pub-id></element-citation></ref><ref id="r148"><label>148</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feldman</surname><given-names>SR</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>KB</given-names></name><name name-style="western"><surname>Bala</surname><given-names>M</given-names></name><name name-style="western"><surname>Evans</surname><given-names>R</given-names></name><name name-style="western"><surname>Li</surname><given-names>S</given-names></name><name name-style="western"><surname>Dooley</surname><given-names>LT</given-names></name><etal/></person-group><article-title>Infliximab treatment results in significant improvement in the
quality of life of patients with severe psoriasis: a double-blind
placebo-controlled trial</article-title><source>Br J Dermatol</source><year>2005</year><volume>152</volume><fpage>954</fpage><lpage>960</lpage><pub-id pub-id-type="pmid">15888152</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2133.2005.06510.x</pub-id></element-citation></ref><ref id="r149"><label>149</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feldman</surname><given-names>SR</given-names></name><name name-style="western"><surname>Kimball</surname><given-names>AB</given-names></name><name name-style="western"><surname>Krueger</surname><given-names>GG</given-names></name><name name-style="western"><surname>Woolley</surname><given-names>JM</given-names></name><name name-style="western"><surname>Lalla</surname><given-names>D</given-names></name><name name-style="western"><surname>Jahreis</surname><given-names>A</given-names></name></person-group><article-title>Etanercept improves the health-related quality of life of
patients with psoriasis: Results of a phase III randomized clinical
trial</article-title><source>J Am Acad Dermatol</source><year>2005</year><volume>53</volume><fpage>887</fpage><lpage>889</lpage><pub-id pub-id-type="pmid">16243150</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaad.2005.06.053</pub-id></element-citation></ref><ref id="r150"><label>150</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gordon</surname><given-names>KB</given-names></name><name name-style="western"><surname>Langley</surname><given-names>RG</given-names></name><name name-style="western"><surname>Leonardi</surname><given-names>C</given-names></name><name name-style="western"><surname>Toth</surname><given-names>D</given-names></name><name name-style="western"><surname>Menter</surname><given-names>MA</given-names></name><name name-style="western"><surname>Kang</surname><given-names>S</given-names></name><etal/></person-group><article-title>Clinical response to adalimumab treatment in patients with
moderate to severe psoriasis: Double-blind, randomized controlled trial and
open-label extension study</article-title><source>J Am Acad Dermatol</source><year>2006</year><volume>55</volume><fpage>598</fpage><lpage>606</lpage><pub-id pub-id-type="pmid">17010738</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaad.2006.05.027</pub-id></element-citation></ref><ref id="r151"><label>151</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gottlieb</surname><given-names>AB</given-names></name><name name-style="western"><surname>Leonardi</surname><given-names>C</given-names></name><name name-style="western"><surname>Kerdel</surname><given-names>F</given-names></name><name name-style="western"><surname>Mehlis</surname><given-names>S</given-names></name><name name-style="western"><surname>Olds</surname><given-names>M</given-names></name><name name-style="western"><surname>Williams</surname><given-names>DA</given-names></name></person-group><article-title>Efficacy and safety of briakinumab vs. etanercept and placebo in
patients with moderate to severe chronic plaque psoriasis</article-title><source>Br J Dermatol</source><year>2011</year><volume>165</volume><fpage>652</fpage><lpage>660</lpage><pub-id pub-id-type="pmid">21574983</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2133.2011.10418.x</pub-id></element-citation></ref><ref id="r152"><label>152</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gottlieb</surname><given-names>AB</given-names></name><name name-style="western"><surname>Matheson</surname><given-names>RT</given-names></name><name name-style="western"><surname>Lowe</surname><given-names>N</given-names></name><name name-style="western"><surname>Krueger</surname><given-names>GG</given-names></name><name name-style="western"><surname>Kang</surname><given-names>S</given-names></name><name name-style="western"><surname>Goffe</surname><given-names>BS</given-names></name><etal/></person-group><article-title>A randomized trial of etanercept as monotherapy for
psoriasis</article-title><source>Arch Dermatol</source><year>2003</year><month>12</month><volume>139</volume><issue>12</issue><fpage>1627</fpage><lpage>1632</lpage><pub-id pub-id-type="pmid">14676082</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/archderm.139.12.1627</pub-id></element-citation></ref><ref id="r153"><label>153</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gottlieb</surname><given-names>AB</given-names></name><name name-style="western"><surname>Chaudhari</surname><given-names>U</given-names></name><name name-style="western"><surname>Mulcahy</surname><given-names>LD</given-names></name><name name-style="western"><surname>Li</surname><given-names>S</given-names></name><name name-style="western"><surname>Dooley</surname><given-names>LT</given-names></name><name name-style="western"><surname>Baker</surname><given-names>DG</given-names></name></person-group><article-title>Infliximab monotherapy provides rapid and sustained benefit for
plaque-type psoriasis</article-title><source>J Am Acad Dermatol</source><year>2003</year><volume>48</volume><fpage>829</fpage><lpage>835</lpage><pub-id pub-id-type="pmid">12789171</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1067/mjd.2003.307</pub-id></element-citation></ref><ref id="r154"><label>154</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guenther</surname><given-names>L</given-names></name><name name-style="western"><surname>Han</surname><given-names>C</given-names></name><name name-style="western"><surname>Szapary</surname><given-names>P</given-names></name><name name-style="western"><surname>Schenkel</surname><given-names>B</given-names></name><name name-style="western"><surname>Poulin</surname><given-names>Y</given-names></name><name name-style="western"><surname>Bourcier</surname><given-names>M</given-names></name><etal/></person-group><article-title>Impact of ustekinumab on health-related quality of life and
sexual difficulties associated with psoriasis: results from two phase III
clinical trials</article-title><source>J Eur Acad Dermatol Venereol</source><year>2011</year><month>7</month><volume>25</volume><issue>7</issue><fpage>851</fpage><lpage>857</lpage><pub-id pub-id-type="pmid">21521375</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1468-3083.2011.04082.x</pub-id></element-citation></ref><ref id="r155"><label>155</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van de Kerkhof</surname><given-names>PC</given-names></name><name name-style="western"><surname>Segaert</surname><given-names>S</given-names></name><name name-style="western"><surname>Lahfa</surname><given-names>M</given-names></name><name name-style="western"><surname>Luger</surname><given-names>TA</given-names></name><name name-style="western"><surname>Karolyi</surname><given-names>Z</given-names></name><name name-style="western"><surname>Kaszuba</surname><given-names>A</given-names></name><etal/></person-group><article-title>Once weekly administration of etanercept 50 mg is efficacious and
well tolerated in patients with moderate-to-severe plaque psoriasis: a
randomized controlled trial with open-label extension</article-title><source>Br J Dermatol</source><year>2008</year><volume>159</volume><fpage>1177</fpage><lpage>1185</lpage><pub-id pub-id-type="pmid">18673365</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2133.2008.08771.x</pub-id></element-citation></ref><ref id="r156"><label>156</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kimball</surname><given-names>AB</given-names></name><name name-style="western"><surname>Papp</surname><given-names>KA</given-names></name><name name-style="western"><surname>Wasfi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chan</surname><given-names>D</given-names></name><name name-style="western"><surname>Bissonnette</surname><given-names>R</given-names></name><name name-style="western"><surname>Sofen</surname><given-names>H</given-names></name><etal/></person-group><article-title>Long-term efficacy of ustekinumab in patients with
moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1
study</article-title><source>J Eur Acad Dermatol Venereol</source><year>2013</year><volume>27</volume><fpage>1535</fpage><lpage>1545</lpage><pub-id pub-id-type="pmid">23279003</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jdv.12046</pub-id></element-citation></ref><ref id="r157"><label>157</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kimball</surname><given-names>AB</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>KB</given-names></name><name name-style="western"><surname>Fakharzadeh</surname><given-names>S</given-names></name><name name-style="western"><surname>Yeilding</surname><given-names>N</given-names></name><name name-style="western"><surname>Szapary</surname><given-names>PO</given-names></name><name name-style="western"><surname>Schenkel</surname><given-names>B</given-names></name><etal/></person-group><article-title>Long-term efficacy of ustekinumab in patients with
moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to
3 years</article-title><source>Br J Dermatol</source><year>2012</year><volume>166</volume><fpage>861</fpage><lpage>872</lpage><pub-id pub-id-type="pmid">22356258</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2133.2012.10901.x</pub-id></element-citation></ref><ref id="r158"><label>158</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krueger</surname><given-names>GG</given-names></name><name name-style="western"><surname>Langley</surname><given-names>RG</given-names></name><name name-style="western"><surname>Finlay</surname><given-names>AY</given-names></name><name name-style="western"><surname>Griffiths</surname><given-names>CE</given-names></name><name name-style="western"><surname>Woolley</surname><given-names>JM</given-names></name><name name-style="western"><surname>Lalla</surname><given-names>D</given-names></name><etal/></person-group><article-title>Patient-reported outcomes of psoriasis improvement with
etanercept therapy: results of a randomized phase III trial</article-title><source>Br J Dermatol</source><year>2005</year><volume>153</volume><fpage>1192</fpage><lpage>1199</lpage><pub-id pub-id-type="pmid">16307657</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2133.2005.06948.x</pub-id></element-citation></ref><ref id="r159"><label>159</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Langley</surname><given-names>RG</given-names></name><name name-style="western"><surname>Elewski</surname><given-names>BE</given-names></name><name name-style="western"><surname>Lebwohl</surname><given-names>M</given-names></name><name name-style="western"><surname>Reich</surname><given-names>K</given-names></name><name name-style="western"><surname>Griffiths</surname><given-names>CE</given-names></name><name name-style="western"><surname>Papp</surname><given-names>K</given-names></name><etal/></person-group><article-title>Secukinumab in Plaque Psoriasis - Results of Two Phase 3
Trials</article-title><source>N Engl J Med</source><year>2014</year><volume>371</volume><fpage>326</fpage><lpage>338</lpage><pub-id pub-id-type="pmid">25007392</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1314258</pub-id></element-citation></ref><ref id="r160"><label>160</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Langley</surname><given-names>RG</given-names></name><name name-style="western"><surname>Feldman</surname><given-names>SR</given-names></name><name name-style="western"><surname>Han</surname><given-names>C</given-names></name><name name-style="western"><surname>Schenkel</surname><given-names>B</given-names></name><name name-style="western"><surname>Szapary</surname><given-names>P</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>MC</given-names></name><etal/></person-group><article-title>Ustekinumab significantly improves symptoms of anxiety,
depression, and skin-related quality of life in patients with
moderate-to-severe psoriasis: Results from a randomized, double-blind,
placebo-controlled phase III trial</article-title><source>J Am Acad Dermatol</source><year>2010</year><volume>63</volume><fpage>457</fpage><lpage>465</lpage><pub-id pub-id-type="pmid">20462664</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaad.2009.09.014</pub-id></element-citation></ref><ref id="r161"><label>161</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leonardi</surname><given-names>CL</given-names></name><name name-style="western"><surname>Kimball</surname><given-names>AB</given-names></name><name name-style="western"><surname>Papp</surname><given-names>KA</given-names></name><name name-style="western"><surname>Yeilding</surname><given-names>N</given-names></name><name name-style="western"><surname>Guzzo</surname><given-names>C</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Efficacy and safety of ustekinumab, a human interleukin-12/23
monoclonal antibody, in patients with psoriasis: 76-week results from a
randomised, double-blind, placebo-controlled trial (PHOENIX
1)</article-title><source>Lancet</source><year>2008</year><volume>371</volume><fpage>1665</fpage><lpage>1674</lpage><pub-id pub-id-type="pmid">18486739</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(08)60725-4</pub-id></element-citation></ref><ref id="r162"><label>162</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leonardi</surname><given-names>CL</given-names></name><name name-style="western"><surname>Powers</surname><given-names>JL</given-names></name><name name-style="western"><surname>Matheson</surname><given-names>RT</given-names></name><name name-style="western"><surname>Goffe</surname><given-names>BS</given-names></name><name name-style="western"><surname>Zitnik</surname><given-names>R</given-names></name><name name-style="western"><surname>Wang</surname><given-names>A</given-names></name><etal/></person-group><article-title>Etanercept as monotherapy in patients with
psoriasis</article-title><source>N Engl J Med</source><year>2003</year><volume>349</volume><fpage>2014</fpage><lpage>2022</lpage><pub-id pub-id-type="pmid">14627786</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa030409</pub-id></element-citation></ref><ref id="r163"><label>163</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lebwohl</surname><given-names>M</given-names></name><name name-style="western"><surname>Papp</surname><given-names>K</given-names></name><name name-style="western"><surname>Han</surname><given-names>C</given-names></name><name name-style="western"><surname>Schenkel</surname><given-names>B</given-names></name><name name-style="western"><surname>Yeilding</surname><given-names>N</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Ustekinumab improves health-related quality of life in patients
with moderate-to-severe psoriasis: results from the PHOENIX 1
trial</article-title><source>Br J Dermatol</source><year>2010</year><volume>162</volume><fpage>137</fpage><lpage>146</lpage><pub-id pub-id-type="pmid">19903183</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2133.2009.09491.x</pub-id></element-citation></ref><ref id="r164"><label>164</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Menter</surname><given-names>A</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>KB</given-names></name><name name-style="western"><surname>Leonardi</surname><given-names>CL</given-names></name><name name-style="western"><surname>Gu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Goldblum</surname><given-names>OM</given-names></name></person-group><article-title>Efficacy and safety of adalimumab across subgroups of patients
with moderate to severe psoriasis</article-title><source>J Am Acad Dermatol</source><year>2010</year><volume>63</volume><fpage>448</fpage><lpage>456</lpage><pub-id pub-id-type="pmid">20605254</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaad.2009.09.040</pub-id></element-citation></ref><ref id="r165"><label>165</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Menter</surname><given-names>A</given-names></name><name name-style="western"><surname>Tyring</surname><given-names>SK</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>K</given-names></name><name name-style="western"><surname>Kimball</surname><given-names>AB</given-names></name><name name-style="western"><surname>Leonardi</surname><given-names>CL</given-names></name><name name-style="western"><surname>Langley</surname><given-names>RG</given-names></name><etal/></person-group><article-title>Adalimumab therapy for moderate to severe psoriasis: A
randomized, controlled phase III trial</article-title><source>J Am Acad Dermatol</source><year>2008</year><volume>58</volume><fpage>106</fpage><lpage>115</lpage><pub-id pub-id-type="pmid">17936411</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaad.2007.09.010</pub-id></element-citation></ref><ref id="r166"><label>166</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakagawa</surname><given-names>H</given-names></name><name name-style="western"><surname>Schenkel</surname><given-names>B</given-names></name><name name-style="western"><surname>Kato</surname><given-names>M</given-names></name><name name-style="western"><surname>Kato</surname><given-names>T</given-names></name><name name-style="western"><surname>Igarashi</surname><given-names>A</given-names></name><collab>Japanese Ustekinumab Study Group</collab></person-group><article-title>Impact of ustekinumab on health-related quality of life in
Japanese patients with moderate-to-severe plaque psoriasis: Results from a
randomized, double-blind, placebo-controlled phase 2/3 trial</article-title><source>J Dermatol</source><year>2012</year><volume>39</volume><fpage>761</fpage><lpage>769</lpage><pub-id pub-id-type="pmid">22409383</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1346-8138.2012.01521.x</pub-id></element-citation></ref><ref id="r167"><label>167</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Papp</surname><given-names>KA</given-names></name><name name-style="western"><surname>Tyring</surname><given-names>S</given-names></name><name name-style="western"><surname>Lahfa</surname><given-names>M</given-names></name><name name-style="western"><surname>Prinz</surname><given-names>J</given-names></name><name name-style="western"><surname>Griffiths</surname><given-names>CE</given-names></name><name name-style="western"><surname>Nakanishi</surname><given-names>AM</given-names></name><etal/></person-group><article-title>A global phase III randomized controlled trial of etanercept in
psoriasis: safety, efficacy, and effect of dose reduction</article-title><source>Br J Dermatol</source><year>2005</year><volume>152</volume><fpage>1304</fpage><lpage>1312</lpage><pub-id pub-id-type="pmid">15948997</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2133.2005.06688.x</pub-id></element-citation></ref><ref id="r168"><label>168</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reich</surname><given-names>K</given-names></name><name name-style="western"><surname>Nestle</surname><given-names>FO</given-names></name><name name-style="western"><surname>Papp</surname><given-names>K</given-names></name><name name-style="western"><surname>Ortonne</surname><given-names>JP</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Bala</surname><given-names>M</given-names></name><etal/></person-group><article-title>Improvement in quality of life with infliximab induction and
maintenance therapy in patients with moderate-to-severe psoriasis: a
randomized controlled trial</article-title><source>Br J Dermatol</source><year>2006</year><volume>154</volume><fpage>1161</fpage><lpage>1168</lpage><pub-id pub-id-type="pmid">16704649</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2133.2006.07237.x</pub-id></element-citation></ref><ref id="r169"><label>169</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reich</surname><given-names>K</given-names></name><name name-style="western"><surname>Schenkel</surname><given-names>B</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>N</given-names></name><name name-style="western"><surname>Szapary</surname><given-names>P</given-names></name><name name-style="western"><surname>Augustin</surname><given-names>M</given-names></name><name name-style="western"><surname>Bourcier</surname><given-names>M</given-names></name><etal/></person-group><article-title>Ustekinumab decreases work limitations, improves work
productivity, and reduces work days missed in patients with
moderate-to-severe psoriasis: results from PHOENIX 2</article-title><source>J Dermatolog Treat</source><year>2011</year><volume>22</volume><fpage>337</fpage><lpage>347</lpage><pub-id pub-id-type="pmid">21034290</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3109/09546634.2010.499931</pub-id></element-citation></ref><ref id="r170"><label>170</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Revicki</surname><given-names>D</given-names></name><name name-style="western"><surname>Willian</surname><given-names>MK</given-names></name><name name-style="western"><surname>Saurat</surname><given-names>JH</given-names></name><name name-style="western"><surname>Papp</surname><given-names>KA</given-names></name><name name-style="western"><surname>Ortonne</surname><given-names>JP</given-names></name><name name-style="western"><surname>Sexton</surname><given-names>C</given-names></name><etal/></person-group><article-title>Impact of adalimumab treatment on health-related quality of life
and other patient-reported outcomes: results from a 16-week randomized
controlled trial in patients with moderate to severe plaque
psoriasis</article-title><source>Br J Dermatol</source><year>2008</year><volume>158</volume><fpage>549</fpage><lpage>557</lpage><pub-id pub-id-type="pmid">18047521</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2133.2007.08236.x</pub-id></element-citation></ref><ref id="r171"><label>171</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Revicki</surname><given-names>DA</given-names></name><name name-style="western"><surname>Menter</surname><given-names>A</given-names></name><name name-style="western"><surname>Feldman</surname><given-names>S</given-names></name><name name-style="western"><surname>Kimel</surname><given-names>M</given-names></name><name name-style="western"><surname>Harnam</surname><given-names>N</given-names></name><name name-style="western"><surname>Willian</surname><given-names>MK</given-names></name></person-group><article-title>Adalimumab improves health-related quality of life in patients
with moderate to severe plaque psoriasis compared with the United States
general population norms: Results from a randomized, controlled Phase III
study</article-title><source>Health Qual Life Outcomes</source><year>2008</year><volume>6</volume><fpage>75</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">18831744</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1477-7525-6-75</pub-id><pub-id pub-id-type="pmcid">PMC2579425</pub-id></element-citation></ref><ref id="r172"><label>172</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Revicki</surname><given-names>DA</given-names></name><name name-style="western"><surname>Willian</surname><given-names>MK</given-names></name><name name-style="western"><surname>Menter</surname><given-names>A</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>KB</given-names></name><name name-style="western"><surname>Kimball</surname><given-names>AB</given-names></name><name name-style="western"><surname>Leonardi</surname><given-names>CL</given-names></name><etal/></person-group><article-title>Impact of adalimumab treatment on patient-reported outcomes:
results from a Phase III clinical trial in patients with moderate to severe
plaque psoriasis</article-title><source>J Dermatolog Treat</source><year>2007</year><volume>18</volume><fpage>341</fpage><lpage>350</lpage><pub-id pub-id-type="pmid">18058494</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/09546630701646172</pub-id></element-citation></ref><ref id="r173"><label>173</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Strober</surname><given-names>BE</given-names></name><name name-style="western"><surname>Crowley</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Yamauchi</surname><given-names>PS</given-names></name><name name-style="western"><surname>Olds</surname><given-names>M</given-names></name><name name-style="western"><surname>Williams</surname><given-names>DA</given-names></name></person-group><article-title>Efficacy and safety results from a phase III, randomized
controlled trial comparing the safety and efficacy of briakinumab with
etanercept and placebo in patients with moderate to severe chronic plaque
psoriasis</article-title><source>Br J Dermatol</source><year>2011</year><volume>165</volume><fpage>661</fpage><lpage>668</lpage><pub-id pub-id-type="pmid">21574984</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2133.2011.10419.x</pub-id></element-citation></ref><ref id="r174"><label>174</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Langley</surname><given-names>RG</given-names></name><name name-style="western"><surname>Lebwohl</surname><given-names>M</given-names></name><name name-style="western"><surname>Krueger</surname><given-names>GG</given-names></name><name name-style="western"><surname>Szapary</surname><given-names>PO</given-names></name><name name-style="western"><surname>Wasfi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chan</surname><given-names>D</given-names></name><etal/></person-group><article-title>Long-term efficacy and safety of ustekinumab, with and without
dosing adjustment, in patients with moderate-to-severe psoriasis: results
from the PHOENIX 2 study through 5 years of follow-up</article-title><source>Br J Dermatol</source><year>2015</year><volume>172</volume><fpage>1371</fpage><lpage>1383</lpage><pub-id pub-id-type="pmid">25307931</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bjd.13469</pub-id></element-citation></ref><ref id="r175"><label>175</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Papp</surname><given-names>KA</given-names></name><name name-style="western"><surname>Langley</surname><given-names>RG</given-names></name><name name-style="western"><surname>Lebwohl</surname><given-names>M</given-names></name><name name-style="western"><surname>Krueger</surname><given-names>GG</given-names></name><name name-style="western"><surname>Szapary</surname><given-names>P</given-names></name><name name-style="western"><surname>Yeilding</surname><given-names>N</given-names></name><etal/></person-group><article-title>Efficacy and safety of ustekinumab, a human interleukin-12/23
monoclonal antibody, in patients with psoriasis: 52-week results from a
randomised, double-blind, placebo-controlled trial (PHOENIX
2)</article-title><source>Lancet</source><year>2008</year><volume>371</volume><fpage>1675</fpage><lpage>1684</lpage><pub-id pub-id-type="pmid">18486740</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(08)60726-6</pub-id></element-citation></ref><ref id="r176"><label>176</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Igarashi</surname><given-names>A</given-names></name><name name-style="western"><surname>Kato</surname><given-names>T</given-names></name><name name-style="western"><surname>Kato</surname><given-names>M</given-names></name><name name-style="western"><surname>Song</surname><given-names>M</given-names></name><name name-style="western"><surname>Nakagawa</surname><given-names>H</given-names></name><collab>Japanese Ustekinumab Study Group</collab></person-group><article-title>Efficacy and safety of ustekinumab in Japanese patients with
moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3
clinical trial</article-title><source>J Dermatol</source><year>2012</year><volume>39</volume><fpage>242</fpage><lpage>252</lpage><pub-id pub-id-type="pmid">21955098</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1346-8138.2011.01347.x</pub-id></element-citation></ref><ref id="r177"><label>177</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsai TF Ho</surname><given-names>JC</given-names></name><name name-style="western"><surname>Song</surname><given-names>M</given-names></name><name name-style="western"><surname>Szapary</surname><given-names>P</given-names></name><name name-style="western"><surname>Guzzo</surname><given-names>C</given-names></name><name name-style="western"><surname>Shen</surname><given-names>YK</given-names></name><etal/></person-group><article-title>Efficacy and safety of ustekinumab for the treatment of
moderate-to-severe psoriasis: A phase III, randomized, placebo-controlled
trial in Taiwanese and Korean patients (PEARL)</article-title><source>J Dermatol Sci</source><year>2011</year><volume>63</volume><fpage>154</fpage><lpage>163</lpage><pub-id pub-id-type="pmid">21741220</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jdermsci.2011.05.005</pub-id></element-citation></ref><ref id="r178"><label>178</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ohtsuki</surname><given-names>M</given-names></name><name name-style="western"><surname>Kubo</surname><given-names>H</given-names></name><name name-style="western"><surname>Morishima</surname><given-names>H</given-names></name><name name-style="western"><surname>Goto</surname><given-names>R</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>R</given-names></name><name name-style="western"><surname>Nakagawa</surname><given-names>H</given-names></name></person-group><article-title>Guselkumab, an anti-interleukin-23 monoclonal antibody, for the
treatment of moderate to severe plaque-type psoriasis in Japanese patients:
Efficacy and safety results from a phase 3, randomized, double-blind,
placebo-controlled study</article-title><source>J Dermatol</source><year>2018</year><volume>45</volume><fpage>1053</fpage><lpage>1062</lpage><pub-id pub-id-type="pmid">29905383</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/1346-8138.14504</pub-id><pub-id pub-id-type="pmcid">PMC6175099</pub-id></element-citation></ref><ref id="r179"><label>179</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blauvelt</surname><given-names>A</given-names></name><name name-style="western"><surname>Papp</surname><given-names>KA</given-names></name><name name-style="western"><surname>Griffiths</surname><given-names>CE</given-names></name><name name-style="western"><surname>Randazzo</surname><given-names>B</given-names></name><name name-style="western"><surname>Wasfi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shen</surname><given-names>YK</given-names></name><etal/></person-group><article-title>Efficacy and safety of guselkumab, an anti-interleukin-23
monoclonal antibody, compared with adalimumab for the continuous treatment
of patients with moderate to severe psoriasis: Results from the phase III,
double-blinded, placebo- and active comparator-controlled VOYAGE 1
trial</article-title><source>J Am Acad Dermatol</source><year>2017</year><volume>76</volume><fpage>405</fpage><lpage>417</lpage><pub-id pub-id-type="pmid">28057360</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaad.2016.11.041</pub-id></element-citation></ref><ref id="r180"><label>180</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blauvelt</surname><given-names>A</given-names></name><name name-style="western"><surname>Gooderham</surname><given-names>M</given-names></name><name name-style="western"><surname>Iversen</surname><given-names>L</given-names></name><name name-style="western"><surname>Ball</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Agada</surname><given-names>NO</given-names></name><etal/></person-group><article-title>Efficacy and safety of ixekizumab for the treatment of
moderate-to-severe plaque psoriasis: Results through 108 weeks of a
randomized, controlled phase 3 clinical trial (UNCOVER-3)</article-title><source>J Am Acad Dermatol</source><year>2017</year><volume>77</volume><fpage>855</fpage><lpage>862</lpage><pub-id pub-id-type="pmid">28917383</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaad.2017.06.153</pub-id></element-citation></ref><ref id="r181"><label>181</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leonardi</surname><given-names>C</given-names></name><name name-style="western"><surname>Maari</surname><given-names>C</given-names></name><name name-style="western"><surname>Philipp</surname><given-names>S</given-names></name><name name-style="western"><surname>Goldblum</surname><given-names>O</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Burkhardt</surname><given-names>N</given-names></name><etal/></person-group><article-title>Maintenance of skin clearance with ixekizumab treatment of
psoriasis: Three-year results from the UNCOVER-3 study</article-title><source>J Am Acad Dermatol</source><year>2018</year><volume>79</volume><fpage>824</fpage><lpage>830.e2</lpage><pub-id pub-id-type="pmid">29803904</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaad.2018.05.032</pub-id></element-citation></ref><ref id="r182"><label>182</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bissonnette</surname><given-names>R</given-names></name><name name-style="western"><surname>Luger</surname><given-names>T</given-names></name><name name-style="western"><surname>Tha&#231;i</surname><given-names>D</given-names></name><name name-style="western"><surname>Toth</surname><given-names>D</given-names></name><name name-style="western"><surname>Messina</surname><given-names>I</given-names></name><name name-style="western"><surname>You</surname><given-names>R</given-names></name><etal/></person-group><article-title>Secukinumab sustains good efficacy and favourable safety in
moderate-to-severe psoriasis after up to 3 years of treatment: results from
a double-blind extension study</article-title><source>Br J Dermatol</source><year>2017</year><volume>177</volume><fpage>1033</fpage><lpage>1042</lpage><pub-id pub-id-type="pmid">28580579</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bjd.15706</pub-id></element-citation></ref><ref id="r183"><label>183</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Griffiths</surname><given-names>CE</given-names></name><name name-style="western"><surname>Strober</surname><given-names>BE</given-names></name><name name-style="western"><surname>van de Kerkhof</surname><given-names>P</given-names></name><name name-style="western"><surname>Ho</surname><given-names>V</given-names></name><name name-style="western"><surname>Fidelus-Gort</surname><given-names>R</given-names></name><name name-style="western"><surname>Yeilding</surname><given-names>N</given-names></name><etal/></person-group><article-title>Comparison of ustekinumab and etanercept for moderate-to-severe
psoriasis</article-title><source>N Engl J Med</source><year>2010</year><volume>362</volume><fpage>118</fpage><lpage>128</lpage><pub-id pub-id-type="pmid">20071701</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa0810652</pub-id></element-citation></ref><ref id="r184"><label>184</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lebwohl</surname><given-names>M</given-names></name><name name-style="western"><surname>Strober</surname><given-names>B</given-names></name><name name-style="western"><surname>Menter</surname><given-names>A</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>K</given-names></name><name name-style="western"><surname>Weglowska</surname><given-names>J</given-names></name><name name-style="western"><surname>Puig</surname><given-names>L</given-names></name><etal/></person-group><article-title>Phase 3 Studies Comparing Brodalumab with Ustekinumab in
Psoriasis</article-title><source>N Engl J Med.</source><year>2015</year><volume>373</volume><fpage>1318</fpage><lpage>1328</lpage><pub-id pub-id-type="pmid">26422722</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1503824</pub-id></element-citation></ref><ref id="r185"><label>185</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Griffiths</surname><given-names>CE</given-names></name><name name-style="western"><surname>Reich</surname><given-names>K</given-names></name><name name-style="western"><surname>Lebwohl</surname><given-names>M</given-names></name><name name-style="western"><surname>van de Kerkhof</surname><given-names>P</given-names></name><name name-style="western"><surname>Paul</surname><given-names>C</given-names></name><name name-style="western"><surname>Menter</surname><given-names>A</given-names></name><etal/></person-group><article-title>Comparison of ixekizumab with etanercept or placebo in
moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two
phase 3 randomised trials</article-title><source>Lancet</source><year>2015</year><volume>386</volume><fpage>541</fpage><lpage>551</lpage><pub-id pub-id-type="pmid">26072109</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(15)60125-8</pub-id></element-citation></ref><ref id="r186"><label>186</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barker</surname><given-names>J</given-names></name><name name-style="western"><surname>Hoffmann</surname><given-names>M</given-names></name><name name-style="western"><surname>Wozel</surname><given-names>G</given-names></name><name name-style="western"><surname>Ortonne</surname><given-names>JP</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>H</given-names></name><name name-style="western"><surname>van Hoogstraten</surname><given-names>H</given-names></name><etal/></person-group><article-title>Efficacy and safety of infliximab vs. methotrexate in patients
with moderate-to-severe plaque psoriasis: results of an open-label,
active-controlled, randomized trial (RESTORE1)</article-title><source>Br J Dermatol</source><year>2011</year><volume>165</volume><fpage>1109</fpage><lpage>1117</lpage><pub-id pub-id-type="pmid">21910713</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2133.2011.10615.x</pub-id></element-citation></ref><ref id="r187"><label>187</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>JH</given-names></name><name name-style="western"><surname>Youn</surname><given-names>JI</given-names></name><name name-style="western"><surname>Kim</surname><given-names>TY</given-names></name><name name-style="western"><surname>Choi</surname><given-names>JH</given-names></name><name name-style="western"><surname>Park</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Choe</surname><given-names>YB</given-names></name></person-group><article-title>A multicenter, randomized, open-label pilot trial assessing the
efficacy and safety of etanercept 50 mg twice weekly followed by etanercept
25 mg twice weekly, the combination of etanercept 25 mg twice weekly and
acitretin, and acitretin alone in patients with moderate to severe
psoriasis</article-title><source>BMC Dermatol</source><year>2016</year><volume>16</volume><fpage>11</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">27455955</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12895-016-0048-z</pub-id><pub-id pub-id-type="pmcid">PMC4960797</pub-id></element-citation></ref><ref id="r188"><label>188</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gottlieb</surname><given-names>AB</given-names></name><name name-style="western"><surname>Lacour</surname><given-names>JP</given-names></name><name name-style="western"><surname>Korman</surname><given-names>N</given-names></name><name name-style="western"><surname>Wilhelm</surname><given-names>S</given-names></name><name name-style="western"><surname>Dutronc</surname><given-names>Y</given-names></name><name name-style="western"><surname>Schacht</surname><given-names>A</given-names></name><etal/></person-group><article-title>Treatment outcomes with ixekizumab in patients with
moderate-to-severe psoriasis who have or have not received prior biological
therapies: an integrated analysis of two Phase III randomized
studies</article-title><source>J Eur Acad Dermatol Venereol</source><year>2017</year><volume>31</volume><fpage>679</fpage><lpage>685</lpage><pub-id pub-id-type="pmid">27696577</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jdv.13990</pub-id><pub-id pub-id-type="pmcid">PMC5412924</pub-id></element-citation></ref><ref id="r189"><label>189</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van L&#252;mig</surname><given-names>PP</given-names></name><name name-style="western"><surname>Lecluse</surname><given-names>LL</given-names></name><name name-style="western"><surname>Driessen</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Spuls</surname><given-names>PI</given-names></name><name name-style="western"><surname>Boezeman</surname><given-names>JB</given-names></name><name name-style="western"><surname>van de Kerkhof</surname><given-names>PC</given-names></name><etal/></person-group><article-title>Switching from etanercept to adalimumab is effective and safe:
results in 30 patients with psoriasis with primary failure, secondary
failure or intolerance to etanercept</article-title><source>Br J Dermatol</source><year>2010</year><volume>163</volume><fpage>838</fpage><lpage>846</lpage><pub-id pub-id-type="pmid">20649798</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2133.2010.09950.x</pub-id></element-citation></ref><ref id="r190"><label>190</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van L&#252;mig</surname><given-names>PP</given-names></name><name name-style="western"><surname>van de Kerkhof</surname><given-names>PC</given-names></name><name name-style="western"><surname>Boezeman</surname><given-names>JB</given-names></name><name name-style="western"><surname>Driessen</surname><given-names>RJ</given-names></name><name name-style="western"><surname>de Jong</surname><given-names>EM</given-names></name></person-group><article-title>Adalimumab therapy for psoriasis in real-world practice:
efficacy, safety and results in biologic-na&#239;ve vs. non-na&#239;ve
patients</article-title><source>J Eur Acad Dermatol Venereol</source><year>2013</year><volume>27</volume><fpage>593</fpage><lpage>600</lpage><pub-id pub-id-type="pmid">22416818</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1468-3083.2012.04496.x</pub-id></element-citation></ref><ref id="r191"><label>191</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ortonne</surname><given-names>JP</given-names></name><name name-style="western"><surname>Chimenti</surname><given-names>S</given-names></name><name name-style="western"><surname>Reich</surname><given-names>K</given-names></name><name name-style="western"><surname>Gniadecki</surname><given-names>R</given-names></name><name name-style="western"><surname>Spr&#248;gel</surname><given-names>P</given-names></name><name name-style="western"><surname>Unnebrink</surname><given-names>K</given-names></name><etal/></person-group><article-title>Efficacy and safety of adalimumab in patients with psoriasis
previously treated with anti-tumour necrosis factor agents: subanalysis of
BELIEVE</article-title><source>J Eur Acad Dermatol Venereol</source><year>2011</year><volume>25</volume><fpage>1012</fpage><lpage>1020</lpage><pub-id pub-id-type="pmid">21214631</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1468-3083.2010.03944.x</pub-id></element-citation></ref><ref id="r192"><label>192</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mazzotta</surname><given-names>A</given-names></name><name name-style="western"><surname>Esposito</surname><given-names>M</given-names></name><name name-style="western"><surname>Costanzo</surname><given-names>A</given-names></name><name name-style="western"><surname>Chimenti</surname><given-names>S</given-names></name></person-group><article-title>Efficacy and safety of etanercept in psoriasis after switching
from other treatments: an observational study</article-title><source>Am J Clin Dermatol</source><year>2009</year><volume>10</volume><fpage>319</fpage><lpage>324</lpage><pub-id pub-id-type="pmid">19658444</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/11310770-000000000-00000</pub-id></element-citation></ref><ref id="r193"><label>193</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>An</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>D</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Teng</surname><given-names>X</given-names></name><name name-style="western"><surname>Gao</surname><given-names>X</given-names></name><etal/></person-group><article-title>The acitretin and methotrexate combination therapy for psoriasis
vulgaris achieves higher effectiveness and less liver
fibrosis</article-title><source>Pharmacol Res</source><year>2017</year><volume>121</volume><fpage>158</fpage><lpage>168</lpage><pub-id pub-id-type="pmid">28414177</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.phrs.2017.04.014</pub-id></element-citation></ref><ref id="r194"><label>194</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Asawanonda</surname><given-names>P</given-names></name><name name-style="western"><surname>Nateetongrungsak</surname><given-names>Y</given-names></name></person-group><article-title>Methotrexate plus narrowband UVB phototherapy versus narrowband
UVB phototherapy alone in the treatment of plaque-type psoriasis: a
randomized, placebo-controlled study</article-title><source>J Am Acad Dermatol</source><year>2006</year><volume>54</volume><fpage>1013</fpage><lpage>1018</lpage><pub-id pub-id-type="pmid">16713455</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaad.2006.01.004</pub-id></element-citation></ref><ref id="r195"><label>195</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aydin</surname><given-names>F</given-names></name><name name-style="western"><surname>Canturk</surname><given-names>T</given-names></name><name name-style="western"><surname>Senturk</surname><given-names>N</given-names></name><name name-style="western"><surname>Turanli</surname><given-names>AY</given-names></name></person-group><article-title>Methotrexate and ciclosporin combination for the treatment of
severe psoriasis</article-title><source>Clin Exp Dermatol</source><year>2006</year><volume>31</volume><fpage>520</fpage><lpage>524</lpage><pub-id pub-id-type="pmid">16716153</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2230.2006.02153.x</pub-id></element-citation></ref><ref id="r196"><label>196</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Calzavara-Pinton</surname><given-names>PG</given-names></name><name name-style="western"><surname>Sala</surname><given-names>R</given-names></name><name name-style="western"><surname>Arisi</surname><given-names>M</given-names></name><name name-style="western"><surname>Rossi</surname><given-names>MT</given-names></name><name name-style="western"><surname>Venturini</surname><given-names>M</given-names></name><name name-style="western"><surname>Ortel</surname><given-names>B</given-names></name></person-group><article-title>Synergism between narrowband ultraviolet B phototherapy and
etanercept for the treatment of plaque-type psoriasis</article-title><source>Br J Dermatol</source><year>2013</year><volume>169</volume><fpage>130</fpage><lpage>136</lpage><pub-id pub-id-type="pmid">23834117</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bjd.12277</pub-id></element-citation></ref><ref id="r197"><label>197</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gambichler</surname><given-names>T</given-names></name><name name-style="western"><surname>Tigges</surname><given-names>C</given-names></name><name name-style="western"><surname>Scola</surname><given-names>N</given-names></name><name name-style="western"><surname>Weber</surname><given-names>J</given-names></name><name name-style="western"><surname>Skrygan</surname><given-names>M</given-names></name><name name-style="western"><surname>Bechara</surname><given-names>FG</given-names></name><etal/></person-group><article-title>Etanercept plus narrowband ultraviolet B phototherapy of
psoriasis is more effective than etanercept monotherapy at 6
weeks</article-title><source>Br J Dermatol</source><year>2011</year><volume>164</volume><fpage>1383</fpage><lpage>1386</lpage><pub-id pub-id-type="pmid">21466532</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2133.2011.10358.x</pub-id></element-citation></ref><ref id="r198"><label>198</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gisondi</surname><given-names>P</given-names></name><name name-style="western"><surname>Del Giglio</surname><given-names>M</given-names></name><name name-style="western"><surname>Cotena</surname><given-names>C</given-names></name><name name-style="western"><surname>Girolomoni</surname><given-names>G</given-names></name></person-group><article-title>Combining etanercept and acitretin in the therapy of chronic
plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded
pilot trial</article-title><source>Br J Dermatol</source><year>2008</year><volume>158</volume><fpage>1345</fpage><lpage>1349</lpage><pub-id pub-id-type="pmid">18410408</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2133.2008.08564.x</pub-id></element-citation></ref><ref id="r199"><label>199</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gottlieb</surname><given-names>AB</given-names></name><name name-style="western"><surname>Langley</surname><given-names>RG</given-names></name><name name-style="western"><surname>Strober</surname><given-names>BE</given-names></name><name name-style="western"><surname>Papp</surname><given-names>KA</given-names></name><name name-style="western"><surname>Klekotka</surname><given-names>P</given-names></name><name name-style="western"><surname>Creamer</surname><given-names>K</given-names></name><etal/></person-group><article-title>A randomized, double-blind, placebo-controlled study to evaluate
the addition of methotrexate to etanercept in patients with moderate to
severe plaque psoriasis</article-title><source>Br J Dermatol</source><year>2012</year><volume>167</volume><fpage>649</fpage><lpage>657</lpage><pub-id pub-id-type="pmid">22533447</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2133.2012.11015.x</pub-id><pub-id pub-id-type="pmcid">PMC3504074</pub-id></element-citation></ref><ref id="r200"><label>200</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iest</surname><given-names>J</given-names></name><name name-style="western"><surname>Boer</surname><given-names>J</given-names></name></person-group><article-title>Combined treatment of psoriasis with acitretin and UVB
phototherapy compared with acitretin alone and UVB alone</article-title><source>Br J Dermatol</source><year>1989</year><volume>120</volume><fpage>665</fpage><lpage>670</lpage><pub-id pub-id-type="pmid">2527051</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2133.1989.tb01354.x</pub-id></element-citation></ref><ref id="r201"><label>201</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lowe</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Prystowsky</surname><given-names>JH</given-names></name><name name-style="western"><surname>Bourget</surname><given-names>T</given-names></name><name name-style="western"><surname>Edelstein</surname><given-names>J</given-names></name><name name-style="western"><surname>Nychay</surname><given-names>S</given-names></name><name name-style="western"><surname>Armstrong</surname><given-names>R</given-names></name></person-group><article-title>Acitretin plus UVB therapy for psoriasis. Comparisons with
placebo plus UVB and acitretin alone</article-title><source>J Am Acad Dermatol</source><year>1991</year><volume>24</volume><fpage>591</fpage><lpage>594</lpage><pub-id pub-id-type="pmid">1827799</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0190-9622(91)70089-k</pub-id></element-citation></ref><ref id="r202"><label>202</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mahajan</surname><given-names>R</given-names></name><name name-style="western"><surname>Kaur</surname><given-names>I</given-names></name><name name-style="western"><surname>Kanwar</surname><given-names>AJ</given-names></name></person-group><article-title>Methotrexate/narrowband UVB phototherapy combination vs.
narrowband UVB phototherapy in the treatment of chronic plaque-type
psoriasis--a randomized single-blinded placebo-controlled
study</article-title><source>J Eur Acad Dermatol Venereol</source><year>2010</year><volume>24</volume><fpage>595</fpage><lpage>600</lpage><pub-id pub-id-type="pmid">20015056</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1468-3083.2009.03486.x</pub-id></element-citation></ref><ref id="r203"><label>203</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mohanan</surname><given-names>S</given-names></name><name name-style="western"><surname>Ramassamy</surname><given-names>S</given-names></name><name name-style="western"><surname>Chandrashekar</surname><given-names>L</given-names></name><name name-style="western"><surname>Thappa</surname><given-names>DM</given-names></name></person-group><article-title>A retrospective analysis of combination methotrexate-cyclosporine
therapy in moderate-severe psoriasis</article-title><source>J Dermatolog Treat</source><year>2014</year><volume>25</volume><fpage>50</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">23469768</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3109/09546634.2013.782094</pub-id></element-citation></ref><ref id="r204"><label>204</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Papp</surname><given-names>KA</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>KB</given-names></name><name name-style="western"><surname>Langley</surname><given-names>RG</given-names></name><name name-style="western"><surname>Lebwohl</surname><given-names>MG</given-names></name><name name-style="western"><surname>Gottlieb</surname><given-names>AB</given-names></name><name name-style="western"><surname>Rastogi</surname><given-names>S</given-names></name><etal/></person-group><article-title>Impact of previous biologic use on the efficacy and safety of
brodalumab and ustekinumab in patients with moderate-to-severe plaque
psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2
and AMAGINE-3</article-title><source>Br J Dermatol</source><year>2018</year><volume>179</volume><fpage>320</fpage><lpage>328</lpage><pub-id pub-id-type="pmid">29488226</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bjd.16464</pub-id></element-citation></ref><ref id="r205"><label>205</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>KK</given-names></name><name name-style="western"><surname>Wu</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Koo</surname><given-names>J</given-names></name></person-group><article-title>A randomized, "head-to-head" pilot study comparing the effects of
etanercept monotherapy vs. etanercept and narrowband ultraviolet B (NB-UVB)
phototherapy in obese psoriasis patients</article-title><source>J Eur Acad Dermatol Venereol</source><year>2013</year><volume>27</volume><fpage>899</fpage><lpage>906</lpage><pub-id pub-id-type="pmid">22702846</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1468-3083.2012.04611.x</pub-id></element-citation></ref><ref id="r206"><label>206</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tanew</surname><given-names>A</given-names></name><name name-style="western"><surname>Guggenbichler</surname><given-names>A</given-names></name><name name-style="western"><surname>H&#246;nigsmann</surname><given-names>H</given-names></name><name name-style="western"><surname>Geiger</surname><given-names>JM</given-names></name><name name-style="western"><surname>Fritsch</surname><given-names>P</given-names></name></person-group><article-title>Photochemotherapy for severe psoriasis without or in combination
with acitretin: a randomized, double-blind comparison study</article-title><source>J Am Acad Dermatol</source><year>1991</year><volume>25</volume><fpage>682</fpage><lpage>684</lpage><pub-id pub-id-type="pmid">1838750</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0190-9622(91)70253-x</pub-id></element-citation></ref><ref id="r207"><label>207</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wolf</surname><given-names>P</given-names></name><name name-style="western"><surname>Weger</surname><given-names>W</given-names></name><name name-style="western"><surname>Legat</surname><given-names>FJ</given-names></name><name name-style="western"><surname>Posch-Fabian</surname><given-names>T</given-names></name><name name-style="western"><surname>Gruber-Wackernagel</surname><given-names>A</given-names></name><name name-style="western"><surname>Inzinger</surname><given-names>M</given-names></name><name name-style="western"><surname>Salmhofer</surname><given-names>W</given-names></name><etal/></person-group><article-title>Treatment with 311-nm ultraviolet B enhanced response of
psoriatic lesions in ustekinumab-treated patients: a randomized
intraindividual trial</article-title><source>Br J Dermatol</source><year>2012</year><volume>166</volume><fpage>147</fpage><lpage>153</lpage><pub-id pub-id-type="pmid">21910714</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2133.2011.10616.x</pub-id></element-citation></ref><ref id="r208"><label>208</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zachariae</surname><given-names>C</given-names></name><name name-style="western"><surname>M&#248;rk</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Reunala</surname><given-names>T</given-names></name><name name-style="western"><surname>Lorentzen</surname><given-names>H</given-names></name><name name-style="western"><surname>Falk</surname><given-names>E</given-names></name><name name-style="western"><surname>Karvonen</surname><given-names>SL</given-names></name><etal/></person-group><article-title>The Combination of Etanercept and Methotrexate Increases the
Effectiveness of Treatment in Active Psoriasis Despite Inadequate Effect of
Methotrexate Therapy</article-title><source>Acta Derm Venereol</source><year>2008</year><volume>88</volume><fpage>495</fpage><lpage>501</lpage><pub-id pub-id-type="pmid">18779890</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2340/00015555-0511</pub-id></element-citation></ref><ref id="r209"><label>209</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abrouk</surname><given-names>M</given-names></name><name name-style="western"><surname>Beroukhim</surname><given-names>K</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>TH</given-names></name><name name-style="western"><surname>Farahnik</surname><given-names>B</given-names></name><name name-style="western"><surname>Singh</surname><given-names>R</given-names></name><etal/></person-group><article-title>Considerations on biologic agents in psoriasis with the new
pregnancy lactation labeling rule</article-title><source>Int J Womens Dermatol</source><year>2016</year><volume>2</volume><fpage>62</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">28492009</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijwd.2016.02.001</pub-id><pub-id pub-id-type="pmcid">PMC5412117</pub-id></element-citation></ref><ref id="r210"><label>210</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bae</surname><given-names>YS</given-names></name><name name-style="western"><surname>Van Voorhees</surname><given-names>AS</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>S</given-names></name><name name-style="western"><surname>Korman</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Lebwohl</surname><given-names>MG</given-names></name><name name-style="western"><surname>Young</surname><given-names>M</given-names></name><etal/></person-group><article-title>Review of treatment options for psoriasis in pregnant or
lactating women: from the Medical Board of the National Psoriasis
Foundation</article-title><source>J Am Acad Dermatol</source><year>2012</year><volume>67</volume><fpage>459</fpage><lpage>477</lpage><pub-id pub-id-type="pmid">22018758</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaad.2011.07.039</pub-id></element-citation></ref><ref id="r211"><label>211</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bangsgaard</surname><given-names>N</given-names></name><name name-style="western"><surname>R&#248;rbye</surname><given-names>C</given-names></name><name name-style="western"><surname>Skov</surname><given-names>L</given-names></name></person-group><article-title>Treating Psoriasis During Pregnancy: Safety and Efficacy of
Treatments</article-title><source>Am J Clin Dermatol</source><year>2015</year><volume>16</volume><fpage>389</fpage><lpage>398</lpage><pub-id pub-id-type="pmid">26149091</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40257-015-0137-5</pub-id></element-citation></ref><ref id="r212"><label>212</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bar Oz</surname><given-names>B</given-names></name><name name-style="western"><surname>Hackman</surname><given-names>R</given-names></name><name name-style="western"><surname>Einarson</surname><given-names>T</given-names></name><name name-style="western"><surname>Koren</surname><given-names>G</given-names></name></person-group><article-title>Pregnancy outcome after cyclosporine therapy during pregnancy: a
meta-analysis</article-title><source>Transplantation</source><year>2001</year><volume>71</volume><fpage>1051</fpage><lpage>1055</lpage><pub-id pub-id-type="pmid">11374400</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00007890-200104270-00006</pub-id></element-citation></ref><ref id="r213"><label>213</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berthelsen</surname><given-names>BG</given-names></name><name name-style="western"><surname>Fjelds&#248;e-Nielsen</surname><given-names>H</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>CT</given-names></name><name name-style="western"><surname>Hellmuth</surname><given-names>E</given-names></name></person-group><article-title>Etanercept concentrations in maternal serum, umbilical cord
serum, breast milk and child serum during breastfeeding</article-title><source>Rheumatology (Oxford)</source><year>2010</year><volume>49</volume><fpage>2225</fpage><lpage>2227</lpage><pub-id pub-id-type="pmid">20581374</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/rheumatology/keq185</pub-id></element-citation></ref><ref id="r214"><label>214</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brown</surname><given-names>SM</given-names></name><name name-style="western"><surname>Aljefri</surname><given-names>K</given-names></name><name name-style="western"><surname>Waas</surname><given-names>R</given-names></name><name name-style="western"><surname>Hampton</surname><given-names>P</given-names></name></person-group><article-title>Systemic medications used in treatment of common dermatological
conditions: safety profile with respect to pregnancy, breast feeding and
content in seminal fluid</article-title><source>J Dermatolog Treat</source><year>2018</year><volume>13</volume><fpage>1</fpage><lpage>17</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/09546634.2016.1202402</pub-id><pub-id pub-id-type="pmid">28092212</pub-id></element-citation></ref><ref id="r215"><label>215</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carman</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Accortt</surname><given-names>NA</given-names></name><name name-style="western"><surname>Anthony</surname><given-names>MS</given-names></name><name name-style="western"><surname>Iles</surname><given-names>J</given-names></name><name name-style="western"><surname>Enger</surname><given-names>C</given-names></name></person-group><article-title>Pregnancy and infant outcomes including major congenital
malformations among women with chronic inflammatory arthritis or psoriasis,
with and without etanercept use</article-title><source>Pharmacoepidemiol Drug Saf</source><year>2017</year><volume>26</volume><fpage>1109</fpage><lpage>1118</lpage><pub-id pub-id-type="pmid">28758274</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/pds.4261</pub-id></element-citation></ref><ref id="r216"><label>216</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chi</surname><given-names>CC</given-names></name><name name-style="western"><surname>Mayon-White</surname><given-names>RT</given-names></name><name name-style="western"><surname>Wojnarowska</surname><given-names>FT</given-names></name></person-group><article-title>Safety of topical corticosteroids in pregnancy: a
population-based cohort study</article-title><source>J Invest Dermatol</source><year>2011</year><volume>131</volume><fpage>884</fpage><lpage>891</lpage><pub-id pub-id-type="pmid">21191410</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/jid.2010.392</pub-id></element-citation></ref><ref id="r217"><label>217</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clowse</surname><given-names>ME</given-names></name><name name-style="western"><surname>Feldman</surname><given-names>SR</given-names></name><name name-style="western"><surname>Isaacs</surname><given-names>JD</given-names></name><name name-style="western"><surname>Kimball</surname><given-names>AB</given-names></name><name name-style="western"><surname>Strand</surname><given-names>V</given-names></name><name name-style="western"><surname>Warren</surname><given-names>RB</given-names></name><etal/></person-group><article-title>Pregnancy Outcomes in the Tofacitinib Safety Databases for
Rheumatoid Arthritis and Psoriasis</article-title><source>Drug Saf</source><year>2016</year><volume>39</volume><fpage>755</fpage><lpage>762</lpage><pub-id pub-id-type="pmid">27282428</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40264-016-0431-z</pub-id><pub-id pub-id-type="pmcid">PMC4933738</pub-id></element-citation></ref><ref id="r218"><label>218</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>El-Saie</surname><given-names>LT</given-names></name><name name-style="western"><surname>Rabie</surname><given-names>AR</given-names></name><name name-style="western"><surname>Kamel</surname><given-names>MI</given-names></name><name name-style="western"><surname>Seddeik</surname><given-names>AK</given-names></name><name name-style="western"><surname>Elsaie</surname><given-names>ML</given-names></name></person-group><article-title>Effect of narrowband ultraviolet B phototherapy on serum folic
acid levels in patients with psoriasis</article-title><source>Lasers Med Sci</source><year>2011</year><volume>26</volume><fpage>481</fpage><lpage>485</lpage><pub-id pub-id-type="pmid">21344249</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10103-011-0895-0</pub-id></element-citation></ref><ref id="r219"><label>219</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feldkamp</surname><given-names>M</given-names></name><name name-style="western"><surname>Carey</surname><given-names>JC</given-names></name></person-group><article-title>Clinical teratology counseling and consultation case report: low
dose methotrexate exposure in the early weeks of pregnancy</article-title><source>Teratology</source><year>1993</year><volume>47</volume><fpage>533</fpage><lpage>539</lpage><pub-id pub-id-type="pmid">8367826</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/tera.1420470605</pub-id></element-citation></ref><ref id="r220"><label>220</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Franssen</surname><given-names>ME</given-names></name><name name-style="western"><surname>van der Wilt</surname><given-names>GJ</given-names></name><name name-style="western"><surname>de Jong</surname><given-names>PC</given-names></name><name name-style="western"><surname>Bos</surname><given-names>RP</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>WP</given-names></name></person-group><article-title>A retrospective study of the teratogenicity of dermatological
coal tar products</article-title><source>Acta Derm Venereol</source><year>1999</year><volume>79</volume><fpage>390</fpage><lpage>391</lpage><pub-id pub-id-type="pmid">10494722</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/000155599750010373</pub-id></element-citation></ref><ref id="r221"><label>221</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fritzsche</surname><given-names>J</given-names></name><name name-style="western"><surname>Pilch</surname><given-names>A</given-names></name><name name-style="western"><surname>Mury</surname><given-names>D</given-names></name><name name-style="western"><surname>Schaefer</surname><given-names>C</given-names></name><name name-style="western"><surname>Weber-Schoendorfer</surname><given-names>C</given-names></name></person-group><article-title>Infliximab and adalimumab use during
breastfeeding</article-title><source>J Clin Gastroenterol</source><year>2012</year><volume>46</volume><fpage>718</fpage><lpage>719</lpage><pub-id pub-id-type="pmid">22858514</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MCG.0b013e31825f2807</pub-id></element-citation></ref><ref id="r222"><label>222</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghanem</surname><given-names>ME</given-names></name><name name-style="western"><surname>El-Baghdadi</surname><given-names>LA</given-names></name><name name-style="western"><surname>Badawy</surname><given-names>AM</given-names></name><name name-style="western"><surname>Bakr</surname><given-names>MA</given-names></name><name name-style="western"><surname>Sobhe</surname><given-names>MA</given-names></name><name name-style="western"><surname>Ghoneim</surname><given-names>MA</given-names></name></person-group><article-title>Pregnancy outcome after renal allograft transplantation: 15 years
experience</article-title><source>Eur J Obstet Gynecol Reprod Biol</source><year>2005</year><volume>121</volume><fpage>178</fpage><lpage>181</lpage><pub-id pub-id-type="pmid">16009483</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejogrb.2004.11.035</pub-id></element-citation></ref><ref id="r223"><label>223</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goldberg</surname><given-names>LD</given-names></name></person-group><article-title>Transmission of a vitamin-D metabolite in breast
milk</article-title><source>Lancet</source><year>1972</year><volume>2</volume><fpage>1258</fpage><lpage>1259</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0140-6736(72)92319-7</pub-id><pub-id pub-id-type="pmid">4117755</pub-id></element-citation></ref><ref id="r224"><label>224</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guillonneau</surname><given-names>M</given-names></name><name name-style="western"><surname>Jacqz-Aigrain</surname><given-names>E</given-names></name></person-group><article-title>Teratogenic effects of vitamin A and its
derivates</article-title><source>Arch Pediatr</source><year>1997</year><volume>4</volume><fpage>867</fpage><lpage>874</lpage><pub-id pub-id-type="pmid">9345570</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0929-693x(97)88158-4</pub-id></element-citation></ref><ref id="r225"><label>225</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gunnarskog</surname><given-names>JG</given-names></name><name name-style="western"><surname>K&#228;ll&#233;n</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Lindel&#246;f</surname><given-names>BG</given-names></name><name name-style="western"><surname>Sigurgeirsson</surname><given-names>B</given-names></name></person-group><article-title>Psoralen photochemotherapy (PUVA) and pregnancy</article-title><source>Arch Dermatol</source><year>1993</year><volume>129</volume><fpage>320</fpage><lpage>323</lpage><pub-id pub-id-type="pmid">7772086</pub-id></element-citation></ref><ref id="r226"><label>226</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hale</surname><given-names>EK</given-names></name><name name-style="western"><surname>Pomeranz</surname><given-names>MK</given-names></name></person-group><article-title>Dermatologic agents during pregnancy and lactation: an update and
clinical review</article-title><source>Int J Dermatol</source><year>2002</year><volume>41</volume><fpage>197</fpage><lpage>203</lpage><pub-id pub-id-type="pmid">12031026</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1365-4362.2002.01464.x</pub-id></element-citation></ref><ref id="r227"><label>227</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoffman</surname><given-names>MB</given-names></name><name name-style="western"><surname>Farhangian</surname><given-names>M</given-names></name><name name-style="western"><surname>Feldman</surname><given-names>SR</given-names></name></person-group><article-title>Psoriasis during pregnancy: characteristics and important
management recommendations</article-title><source>Expert Rev Clin Immunol</source><year>2015</year><volume>11</volume><fpage>709</fpage><lpage>720</lpage><pub-id pub-id-type="pmid">25873365</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1586/1744666X.2015.1037742</pub-id></element-citation></ref><ref id="r228"><label>228</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johansen</surname><given-names>CB</given-names></name><name name-style="western"><surname>Jimenez-Solem</surname><given-names>E</given-names></name><name name-style="western"><surname>Haerskjold</surname><given-names>A</given-names></name><name name-style="western"><surname>Sand</surname><given-names>FL</given-names></name><name name-style="western"><surname>Thomsen</surname><given-names>SF</given-names></name></person-group><article-title>The Use and Safety of TNF Inhibitors during Pregnancy in Women
with Psoriasis: A Review</article-title><source>Int J Mol Sci</source><year>2018</year><volume>19</volume><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms19051349</pub-id><pub-id pub-id-type="pmcid">PMC5983707</pub-id><pub-id pub-id-type="pmid">29751529</pub-id></element-citation></ref><ref id="r229"><label>229</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johns</surname><given-names>DG</given-names></name><name name-style="western"><surname>Rutherford</surname><given-names>LD</given-names></name><name name-style="western"><surname>Leighton</surname><given-names>PC</given-names></name><name name-style="western"><surname>Vogel</surname><given-names>CL</given-names></name></person-group><article-title>Secretion of methotrexate into human milk</article-title><source>Am J Obstet Gynecol</source><year>1972</year><month>4</month><day>01</day><volume>112</volume><fpage>978</fpage><lpage>980</lpage><pub-id pub-id-type="pmid">5042796</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0002-9378(72)90824-1</pub-id></element-citation></ref><ref id="r230"><label>230</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kane</surname><given-names>S</given-names></name><name name-style="western"><surname>Ford</surname><given-names>J</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>R</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>C</given-names></name></person-group><article-title>Absence of infliximab in infants and breast milk from nursing
mothers receiving therapy for Crohn's disease before and after
delivery</article-title><source>J Clin Gastroenterol</source><year>2009</year><volume>43</volume><fpage>613</fpage><lpage>616</lpage><pub-id pub-id-type="pmid">19142167</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MCG.0b013e31817f9367</pub-id></element-citation></ref><ref id="r231"><label>231</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kozlowski</surname><given-names>RD</given-names></name><name name-style="western"><surname>Steinbrunner</surname><given-names>JV</given-names></name><name name-style="western"><surname>MacKenzie</surname><given-names>AH</given-names></name><name name-style="western"><surname>Clough</surname><given-names>JD</given-names></name><name name-style="western"><surname>Wilke</surname><given-names>WS</given-names></name><name name-style="western"><surname>Segal</surname><given-names>AM</given-names></name></person-group><article-title>Outcome of first-trimester exposure to low-dose methotrexate in
eight patients with rheumatic disease</article-title><source>Am J Med</source><year>1990</year><volume>88</volume><fpage>589</fpage><lpage>592</lpage><pub-id pub-id-type="pmid">2189302</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0002-9343(90)90522-f</pub-id></element-citation></ref><ref id="r232"><label>232</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kurizky</surname><given-names>PS</given-names></name><name name-style="western"><surname>Ferreira Cde</surname><given-names>C</given-names></name><name name-style="western"><surname>Nogueira</surname><given-names>LS</given-names></name><name name-style="western"><surname>Mota</surname><given-names>LM</given-names></name></person-group><article-title>Treatment of psoriasis and psoriatic arthritis during pregnancy
and breastfeeding</article-title><source>An Bras Dermatol</source><year>2015</year><volume>90</volume><fpage>367</fpage><lpage>375</lpage><pub-id pub-id-type="pmid">26131868</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1590/abd1806-4841.20153113</pub-id><pub-id pub-id-type="pmcid">PMC4516109</pub-id></element-citation></ref><ref id="r233"><label>233</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lamarque</surname><given-names>V</given-names></name><name name-style="western"><surname>Leleu</surname><given-names>MF</given-names></name><name name-style="western"><surname>Monka</surname><given-names>C</given-names></name><name name-style="western"><surname>Krupp</surname><given-names>P</given-names></name></person-group><article-title>Analysis of 629 pregnancy outcomes in transplant recipients
treated with Sandimmun</article-title><source>Transplant Proc</source><year>1997</year><month>8</month><volume>29</volume><issue>5</issue><fpage>2480</fpage><lpage>2480</lpage><pub-id pub-id-type="pmid">9270819</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0041-1345(97)00458-2</pub-id></element-citation></ref><ref id="r234"><label>234</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murase</surname><given-names>JE</given-names></name><name name-style="western"><surname>Heller</surname><given-names>MM</given-names></name><name name-style="western"><surname>Butler</surname><given-names>DC</given-names></name></person-group><article-title>Safety of dermatologic medications in pregnancy and lactation:
Part I. Pregnancy</article-title><source>J Am Acad Dermatol</source><year>2014</year><volume>70</volume><fpage>401.e1</fpage><lpage>401.e14</lpage><pub-id pub-id-type="pmid">24528911</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaad.2013.09.010</pub-id></element-citation></ref><ref id="r235"><label>235</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murashima</surname><given-names>A</given-names></name><name name-style="western"><surname>Watanabe</surname><given-names>N</given-names></name><name name-style="western"><surname>Ozawa</surname><given-names>N</given-names></name><name name-style="western"><surname>Saito</surname><given-names>H</given-names></name><name name-style="western"><surname>Yamaguchi</surname><given-names>K</given-names></name></person-group><article-title>Etanercept during pregnancy and lactation in a patient with
rheumatoid arthritis: drug levels in maternal serum, cord blood, breast milk
and the infant's serum</article-title><source>Ann Rheum Dis</source><year>2009</year><volume>68</volume><fpage>1793</fpage><lpage>1794</lpage><pub-id pub-id-type="pmid">19822717</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/ard.2008.105924</pub-id></element-citation></ref><ref id="r236"><label>236</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nguyen</surname><given-names>C</given-names></name><name name-style="western"><surname>Duhl</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Escallon</surname><given-names>CS</given-names></name><name name-style="western"><surname>Blakemore</surname><given-names>KJ</given-names></name></person-group><article-title>Multiple anomalies in a fetus exposed to low-dose methotrexate in
the first trimester</article-title><source>Obstet Gynecol</source><year>2002</year><volume>99</volume><fpage>599</fpage><lpage>602</lpage><pub-id pub-id-type="pmid">12039119</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0029-7844(01)01607-6</pub-id></element-citation></ref><ref id="r237"><label>237</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nyberg</surname><given-names>G</given-names></name><name name-style="western"><surname>Haljam&#228;e</surname><given-names>U</given-names></name><name name-style="western"><surname>Frisenette-Fich</surname><given-names>C</given-names></name><name name-style="western"><surname>Wennergren</surname><given-names>M</given-names></name><name name-style="western"><surname>Kjellmer</surname><given-names>I</given-names></name></person-group><article-title>Breast-feeding during treatment with cyclosporine</article-title><source>Transplantation</source><year>1998</year><volume>65</volume><fpage>253</fpage><lpage>255</lpage><pub-id pub-id-type="pmid">9458024</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00007890-199801270-00019</pub-id></element-citation></ref><ref id="r238"><label>238</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paziana</surname><given-names>K</given-names></name><name name-style="western"><surname>Del Monaco</surname><given-names>M</given-names></name><name name-style="western"><surname>Cardonick</surname><given-names>E</given-names></name><name name-style="western"><surname>Moritz</surname><given-names>M</given-names></name><name name-style="western"><surname>Keller</surname><given-names>M</given-names></name><name name-style="western"><surname>Smith</surname><given-names>B</given-names></name><etal/></person-group><article-title>Ciclosporin use during pregnancy</article-title><source>Drug Saf</source><year>2013</year><volume>36</volume><fpage>279</fpage><lpage>294</lpage><pub-id pub-id-type="pmid">23516008</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40264-013-0034-x</pub-id></element-citation></ref><ref id="r239"><label>239</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rademaker</surname><given-names>M</given-names></name><name name-style="western"><surname>Agnew</surname><given-names>K</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>M</given-names></name><name name-style="western"><surname>Armour</surname><given-names>K</given-names></name><name name-style="western"><surname>Baker</surname><given-names>C</given-names></name><name name-style="western"><surname>Foley</surname><given-names>P</given-names></name><etal/></person-group><article-title>Psoriasis in those planning a family, pregnant or breast-feeding.
The Australasian Psoriasis Collaboration</article-title><source>Australas J Dermatol</source><year>2018</year><volume>59</volume><fpage>86</fpage><lpage>100</lpage><pub-id pub-id-type="pmid">28543445</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ajd.12641</pub-id></element-citation></ref><ref id="r240"><label>240</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rollman</surname><given-names>O</given-names></name><name name-style="western"><surname>Pihl-Lundin</surname><given-names>I</given-names></name></person-group><article-title>Acitretin excretion into human breast milk</article-title><source>Acta Derm Venereol</source><year>1990</year><volume>70</volume><fpage>487</fpage><lpage>490</lpage><pub-id pub-id-type="pmid">1981420</pub-id></element-citation></ref><ref id="r241"><label>241</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ruiz</surname><given-names>V</given-names></name><name name-style="western"><surname>Manubens</surname><given-names>E</given-names></name><name name-style="western"><surname>Puig</surname><given-names>L</given-names></name></person-group><article-title>Psoriasis in pregnancy: a review (II)</article-title><source>Actas Dermosifiliogr</source><year>2014</year><volume>105</volume><fpage>813</fpage><lpage>821</lpage><pub-id pub-id-type="pmid">24314892</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ad.2013.06.005</pub-id></element-citation></ref><ref id="r242"><label>242</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Schaefer</surname><given-names>C</given-names></name><name name-style="western"><surname>Peters</surname><given-names>P</given-names></name><name name-style="western"><surname>Miller</surname><given-names>RK</given-names></name></person-group><source>Drugs during pregnancy and lactation: treatment options and risk
assessment</source><year>2014</year><edition>3rd ed</edition><publisher-loc>Cambridge</publisher-loc><publisher-name>Academic Press</publisher-name></element-citation></ref><ref id="r243"><label>243</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scheepers</surname><given-names>PT</given-names></name><name name-style="western"><surname>van Houtum</surname><given-names>JL</given-names></name><name name-style="western"><surname>Anzion</surname><given-names>RB</given-names></name><name name-style="western"><surname>Harder</surname><given-names>R</given-names></name><name name-style="western"><surname>Bos</surname><given-names>RP</given-names></name><name name-style="western"><surname>van der Valk</surname><given-names>PG</given-names></name></person-group><article-title>Uptake of pyrene in a breast-fed child of a mother treated with
coal tar</article-title><source>Pediatr Dermatol</source><year>2009</year><volume>26</volume><fpage>184</fpage><lpage>187</lpage><pub-id pub-id-type="pmid">19419468</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1525-1470.2009.00880.x</pub-id></element-citation></ref><ref id="r244"><label>244</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Stefano</surname><given-names>P</given-names></name><name name-style="western"><surname>Bongo</surname><given-names>IG</given-names></name><name name-style="western"><surname>Borgna-Pignatti</surname><given-names>C</given-names></name><name name-style="western"><surname>Severi</surname><given-names>F</given-names></name></person-group><article-title>Factitious hypertension with mineralocorticoid excess in an
infant</article-title><source>Helv Paediatr Acta</source><year>1983</year><volume>38</volume><fpage>185</fpage><lpage>189</lpage><pub-id pub-id-type="pmid">6874387</pub-id></element-citation></ref><ref id="r245"><label>245</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stengel</surname><given-names>JZ</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>HL</given-names></name></person-group><article-title>Is infliximab safe to use while breastfeeding?</article-title><source>World J Gastroenterol</source><year>2008</year><volume>14</volume><fpage>3085</fpage><lpage>3087</lpage><pub-id pub-id-type="pmid">18494064</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3748/wjg.14.3085</pub-id><pub-id pub-id-type="pmcid">PMC2712180</pub-id></element-citation></ref><ref id="r246"><label>246</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stern</surname><given-names>RS</given-names></name><name name-style="western"><surname>Lange</surname><given-names>R</given-names></name></person-group><article-title>Outcomes of pregnancies among women and partners of men with a
history of exposure to methoxsalen photochemotherapy (PUVA) for the
treatment of psoriasis</article-title><source>Arch Dermatol</source><year>1991</year><volume>127</volume><fpage>347</fpage><lpage>350</lpage><pub-id pub-id-type="pmid">1998364</pub-id></element-citation></ref><ref id="r247"><label>247</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vena</surname><given-names>GA</given-names></name><name name-style="western"><surname>Cassano</surname><given-names>N</given-names></name><name name-style="western"><surname>Bellia</surname><given-names>G</given-names></name><name name-style="western"><surname>Colombo</surname><given-names>D</given-names></name></person-group><article-title>Psoriasis in pregnancy: challenges and solutions</article-title><source>Psoriasis (Auckl)</source><year>2015</year><volume>5</volume><fpage>83</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">29387585</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/PTT.S82975</pub-id><pub-id pub-id-type="pmcid">PMC5683115</pub-id></element-citation></ref><ref id="r248"><label>248</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vun</surname><given-names>YY</given-names></name><name name-style="western"><surname>Jones</surname><given-names>B</given-names></name><name name-style="western"><surname>Al-Mudhaffer</surname><given-names>M</given-names></name><name name-style="western"><surname>Egan</surname><given-names>C</given-names></name></person-group><article-title>Generalized pustular psoriasis of pregnancy treated with
narrowband UVB and topical steroids</article-title><source>J Am Acad Dermatol</source><year>2006</year><volume>54</volume><issue>Suppl</issue><fpage>S28</fpage><lpage>S30</lpage><pub-id pub-id-type="pmid">16427987</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaad.2005.04.041</pub-id></element-citation></ref><ref id="r249"><label>249</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Warren</surname><given-names>RB</given-names></name><name name-style="western"><surname>Reich</surname><given-names>K</given-names></name><name name-style="western"><surname>Langley</surname><given-names>RG</given-names></name><name name-style="western"><surname>Strober</surname><given-names>B</given-names></name><name name-style="western"><surname>Gladman</surname><given-names>D</given-names></name><name name-style="western"><surname>Deodhar</surname><given-names>A</given-names></name><etal/></person-group><article-title>Secukinumab in pregnancy: outcomes in psoriasis, psoriatic
arthritis and ankylosing spondylitis from the global safety
database</article-title><source>Br J Dermatol</source><year>2018</year><volume>179</volume><fpage>1205</fpage><lpage>1207</lpage><pub-id pub-id-type="pmid">29927479</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bjd.16901</pub-id></element-citation></ref><ref id="r250"><label>250</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Westermann</surname><given-names>L</given-names></name><name name-style="western"><surname>H&#252;gel</surname><given-names>R</given-names></name><name name-style="western"><surname>Meier</surname><given-names>M</given-names></name><name name-style="western"><surname>Weichenthal</surname><given-names>M</given-names></name><name name-style="western"><surname>Zillikens</surname><given-names>D</given-names></name><name name-style="western"><surname>Gl&#228;ser</surname><given-names>R</given-names></name><etal/></person-group><article-title>Glucocorticosteroid-resistant pemphigoid gestationis: successful
treatment with adjuvant immunoadsorption</article-title><source>J Dermatol</source><year>2012</year><volume>39</volume><fpage>168</fpage><lpage>171</lpage><pub-id pub-id-type="pmid">22379622</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1346-8138.2011.01376.x</pub-id></element-citation></ref><ref id="r251"><label>251</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yiu</surname><given-names>ZZ</given-names></name><name name-style="western"><surname>Warren</surname><given-names>RB</given-names></name><name name-style="western"><surname>Mrowietz</surname><given-names>U</given-names></name><name name-style="western"><surname>Griffiths</surname><given-names>CE</given-names></name></person-group><article-title>Safety of conventional systemic therapies for psoriasis on
reproductive potential and outcomes</article-title><source>J Dermatolog Treat</source><year>2015</year><volume>26</volume><fpage>329</fpage><lpage>334</lpage><pub-id pub-id-type="pmid">25424052</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3109/09546634.2014.991673</pub-id></element-citation></ref><ref id="r252"><label>252</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tillack</surname><given-names>C</given-names></name><name name-style="western"><surname>Ehmann</surname><given-names>LM</given-names></name><name name-style="western"><surname>Friedrich</surname><given-names>M</given-names></name><name name-style="western"><surname>Laubender</surname><given-names>RP</given-names></name><name name-style="western"><surname>Papay</surname><given-names>P</given-names></name><name name-style="western"><surname>Vogelsang</surname><given-names>H</given-names></name><etal/></person-group><article-title>Anti-TNF antibody-induced psoriasiform skin lesions in patients
with inflammatory bowel disease are characterised by
interferon-&#947;-expressing Th1 cells and IL-17A/ IL-22-expressing Th17
cells and respond to anti-IL-12/IL-23 antibody treatment</article-title><source>Gut</source><year>2014</year><volume>63</volume><fpage>567</fpage><lpage>577</lpage><pub-id pub-id-type="pmid">23468464</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/gutjnl-2012-302853</pub-id></element-citation></ref><ref id="r253"><label>253</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guerra</surname><given-names>I</given-names></name><name name-style="western"><surname>Algaba</surname><given-names>A</given-names></name><name name-style="western"><surname>P&#233;rez-Calle</surname><given-names>JL</given-names></name><name name-style="western"><surname>Chaparro</surname><given-names>M</given-names></name><name name-style="western"><surname>Mar&#237;n-Jim&#233;nez</surname><given-names>I</given-names></name><name name-style="western"><surname>Garc&#237;a-Castellanos</surname><given-names>R</given-names></name><etal/></person-group><article-title>Induction of psoriasis with anti-TNF agents in patients with
inflammatory bowel disease: a report of 21 cases</article-title><source>J Crohns Colitis</source><year>2012</year><volume>6</volume><fpage>518</fpage><lpage>523</lpage><pub-id pub-id-type="pmid">22398059</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.crohns.2011.10.007</pub-id></element-citation></ref><ref id="r254"><label>254</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Darrigade</surname><given-names>AS</given-names></name><name name-style="western"><surname>Milpied</surname><given-names>B</given-names></name><name name-style="western"><surname>Truchetet</surname><given-names>ME</given-names></name><name name-style="western"><surname>Schaeverbeke</surname><given-names>T</given-names></name><name name-style="western"><surname>Laharie</surname><given-names>D</given-names></name><name name-style="western"><surname>Zerbib</surname><given-names>F</given-names></name><etal/></person-group><article-title>Pattern and Severity of Psoriasiform Eruptions in Patients with
Inflammatory Bowel Diseases, Arthritis or Skin Inflammatory Disorders
Treated with TNF-alpha Inhibitors</article-title><source>Acta Derm Venereol</source><year>2017</year><volume>97</volume><fpage>731</fpage><lpage>734</lpage><pub-id pub-id-type="pmid">28218339</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2340/00015555-2636</pub-id></element-citation></ref><ref id="r255"><label>255</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kirthi Jeyarajah</surname><given-names>S</given-names></name><name name-style="western"><surname>Tobin</surname><given-names>AM</given-names></name><name name-style="western"><surname>Hussey</surname><given-names>M</given-names></name><name name-style="western"><surname>Scaldaferri</surname><given-names>F</given-names></name><name name-style="western"><surname>McNamara</surname><given-names>D</given-names></name></person-group><article-title>Anti-TNF&#945; antibody-induced psoriasiform skin lesions in
patients with inflammatory bowel disease: an Irish Cohort
Study</article-title><source>QJM</source><year>2017</year><volume>110</volume><fpage>379</fpage><lpage>382</lpage><pub-id pub-id-type="pmid">28069913</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/qjmed/hcx003</pub-id></element-citation></ref><ref id="r256"><label>256</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guerra</surname><given-names>I1</given-names></name><name name-style="western"><surname>P&#233;rez-Jeldres</surname><given-names>T</given-names></name><name name-style="western"><surname>Iborra</surname><given-names>M</given-names></name><name name-style="western"><surname>Algaba</surname><given-names>A</given-names></name><name name-style="western"><surname>Monfort</surname><given-names>D</given-names></name><name name-style="western"><surname>Calvet</surname><given-names>X</given-names></name><etal/></person-group><article-title>Incidence, Clinical Characteristics, and Management of Psoriasis
Induced by Anti-TNF Therapy in Patients with Inflammatory Bowel Disease: A
Nationwide Cohort Study</article-title><source>Inflamm Bowel Dis</source><year>2016</year><volume>22</volume><fpage>894</fpage><lpage>901</lpage><pub-id pub-id-type="pmid">26933750</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MIB.0000000000000757</pub-id></element-citation></ref><ref id="r257"><label>257</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Afshar</surname><given-names>M</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>AD</given-names></name><name name-style="western"><surname>Gallo</surname><given-names>RL</given-names></name><name name-style="western"><surname>Hata</surname><given-names>TR</given-names></name></person-group><article-title>Induction and exacerbation of psoriasis with Interferon-alpha
therapy for hepatitis C: a review and analysis of 36 cases</article-title><source>J Eur Acad Dermatol Venereol</source><year>2013</year><volume>27</volume><fpage>771</fpage><lpage>778</lpage><pub-id pub-id-type="pmid">22671985</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1468-3083.2012.04582.x</pub-id><pub-id pub-id-type="pmcid">PMC3443510</pub-id></element-citation></ref><ref id="r258"><label>258</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lamba</surname><given-names>G</given-names></name><name name-style="western"><surname>Palaniswamy</surname><given-names>C</given-names></name><name name-style="western"><surname>Singh</surname><given-names>T</given-names></name><name name-style="western"><surname>Shah</surname><given-names>D</given-names></name><name name-style="western"><surname>Lal</surname><given-names>S</given-names></name><name name-style="western"><surname>Vinnakota</surname><given-names>R</given-names></name></person-group><article-title>Psoriasis induced by losartan therapy: a case report and review
of the literature</article-title><source>Am J Ther</source><year>2011</year><volume>18</volume><fpage>e78</fpage><lpage>e80</lpage><pub-id pub-id-type="pmid">20027103</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MJT.0b013e3181c6c0c2</pub-id></element-citation></ref><ref id="r259"><label>259</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Katoulis</surname><given-names>AC</given-names></name><name name-style="western"><surname>Bozi</surname><given-names>E</given-names></name><name name-style="western"><surname>Kanelleas</surname><given-names>A</given-names></name><name name-style="western"><surname>Makris</surname><given-names>M</given-names></name><name name-style="western"><surname>Alevizou</surname><given-names>A</given-names></name><name name-style="western"><surname>Panagiotides</surname><given-names>I</given-names></name><etal/></person-group><article-title>Psoriasiform fixed drug eruption caused by
nimesulide</article-title><source>Clin Exp Dermatol</source><year>2009</year><volume>34</volume><fpage>e360</fpage><lpage>e361</lpage><pub-id pub-id-type="pmid">19486051</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2230.2009.03315.x</pub-id></element-citation></ref><ref id="r260"><label>260</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clark</surname><given-names>DW</given-names></name><name name-style="western"><surname>Coulter</surname><given-names>DM</given-names></name></person-group><article-title>Psoriasis associated with rofecoxib</article-title><source>Arch Dermatol</source><year>2003</year><volume>139</volume><fpage>1223</fpage><lpage>1223</lpage><pub-id pub-id-type="pmid">12975177</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/archderm.139.9.1223</pub-id></element-citation></ref><ref id="r261"><label>261</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>S</given-names></name><name name-style="western"><surname>Han</surname><given-names>J</given-names></name><name name-style="western"><surname>Qureshi</surname><given-names>AA</given-names></name></person-group><article-title>Use of aspirin, non-steroidal anti-inflammatory drugs, and
acetaminophen (paracetamol), and risk of psoriasis and psoriatic arthritis:
a cohort study</article-title><source>Acta Derm Venereol</source><year>2015</year><volume>95</volume><fpage>217</fpage><lpage>223</lpage><pub-id pub-id-type="pmid">24691893</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2340/00015555-1855</pub-id><pub-id pub-id-type="pmcid">PMC4183729</pub-id></element-citation></ref><ref id="r262"><label>262</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brauchli</surname><given-names>YB</given-names></name><name name-style="western"><surname>Jick</surname><given-names>SS</given-names></name><name name-style="western"><surname>Curtin</surname><given-names>F</given-names></name><name name-style="western"><surname>Meier</surname><given-names>CR</given-names></name></person-group><article-title>Association between beta-blockers, other antihypertensive drugs
and psoriasis: population-based case-control study</article-title><source>Br J Dermatol</source><year>2008</year><volume>158</volume><fpage>1299</fpage><lpage>1307</lpage><pub-id pub-id-type="pmid">18410416</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2133.2008.08563.x</pub-id></element-citation></ref><ref id="r263"><label>263</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arntzen</surname><given-names>N</given-names></name><name name-style="western"><surname>Kavli</surname><given-names>G</given-names></name><name name-style="western"><surname>Volden</surname><given-names>G</given-names></name></person-group><article-title>Psoriasis provoked by beta-blocking agents</article-title><source>Acta Derm Venereol</source><year>1984</year><volume>64</volume><fpage>346</fpage><lpage>348</lpage><pub-id pub-id-type="pmid">6209897</pub-id></element-citation></ref><ref id="r264"><label>264</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brauchli</surname><given-names>YB</given-names></name><name name-style="western"><surname>Jick</surname><given-names>SS</given-names></name><name name-style="western"><surname>Curtin</surname><given-names>F</given-names></name><name name-style="western"><surname>Meier</surname><given-names>CR</given-names></name></person-group><article-title>Lithium, antipsychotics, and risk of psoriasis</article-title><source>J Clin Psychopharmacol</source><year>2009</year><volume>29</volume><fpage>134</fpage><lpage>140</lpage><pub-id pub-id-type="pmid">19512974</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/JCP.0b013e31819a4b7c</pub-id></element-citation></ref><ref id="r265"><label>265</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>HH</given-names></name><name name-style="western"><surname>Wing</surname><given-names>Y</given-names></name><name name-style="western"><surname>Su</surname><given-names>R</given-names></name><name name-style="western"><surname>Van Krevel</surname><given-names>C</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S</given-names></name></person-group><article-title>A control study of the cutaneous side effects of chronic lithium
therapy</article-title><source>J Affect Disord</source><year>2000</year><volume>57</volume><fpage>107</fpage><lpage>113</lpage><pub-id pub-id-type="pmid">10708822</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0165-0327(99)00064-6</pub-id></element-citation></ref><ref id="r266"><label>266</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gilleaudeau</surname><given-names>P</given-names></name><name name-style="western"><surname>Vallat</surname><given-names>VP</given-names></name><name name-style="western"><surname>Carter</surname><given-names>DM</given-names></name><name name-style="western"><surname>Gottlieb</surname><given-names>AB</given-names></name></person-group><article-title>Angiotensin-converting enzyme inhibitors as possible exacerbating
drugs in psoriasis</article-title><source>J Am Acad Dermatol</source><year>1993</year><volume>28</volume><fpage>490</fpage><lpage>492</lpage><pub-id pub-id-type="pmid">8267693</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0190-9622(08)81761-6</pub-id></element-citation></ref><ref id="r267"><label>267</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coulter</surname><given-names>DM</given-names></name><name name-style="western"><surname>Pillans</surname><given-names>PI</given-names></name></person-group><article-title>Angiotensin-converting enzyme inhibitors and
psoriasis</article-title><source>N Z Med J</source><year>1993</year><volume>106</volume><fpage>392</fpage><lpage>393</lpage><pub-id pub-id-type="pmid">8396227</pub-id></element-citation></ref><ref id="r268"><label>268</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vestey</surname><given-names>JP</given-names></name><name name-style="western"><surname>Savin</surname><given-names>JA</given-names></name></person-group><article-title>Psoriasis worsened by antimalarial prophylaxis</article-title><source>J Infect</source><year>1992</year><volume>24</volume><fpage>211</fpage><lpage>212</lpage><pub-id pub-id-type="pmid">1569312</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0163-4453(92)93058-x</pub-id></element-citation></ref><ref id="r269"><label>269</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mallett</surname><given-names>R</given-names></name><name name-style="western"><surname>Pye</surname><given-names>R</given-names></name></person-group><article-title>Risks and benefits of prophylactic antimalarial
drugs</article-title><source>BMJ</source><year>1989</year><volume>299</volume><fpage>1400</fpage><lpage>1400</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.299.6712.1400-a</pub-id><pub-id pub-id-type="pmcid">PMC1838225</pub-id><pub-id pub-id-type="pmid">2513979</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>